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ABSTRACT 
 
Scaffold proteins facilitate many aspects of intracellular signaling. These 
proteins can regulate two or more proteins in the same pathway, or coordinate 
signaling from multiple pathways. Scaffold proteins are therefore key control 
points for the flux of signaling and play essential roles in biological systems.  There 
are four possible mechanisms by which scaffold proteins achieve activation and 
propagate signaling: 1) rigid protein binding between two or more proteins to co-
localize binding partners, 2) ligand-induced activation such as may result from a 
conformational change, 3) disorder-to-order transition where the scaffold protein 
folds as a result of a protein-protein interaction, and 4) dynamic processes such as 
phosphorylation. The scaffold protein NF-κB essential modulator (NEMO) 
functions via ligand-induced activation and serves as the key control point for 
 vii 
canonical NF-κB signaling. The work described in this thesis investigates the role 
of a previously uncharacterized domain within NEMO that is required for 
function, which we term the Intervening Domain (IVD). Bioinformatic analysis 
reveals a high level of sequence conservation across species within this domain. 
Conformational changes following ligand binding are observed for NEMO and 
these changes require conserved sequences in the IVD. Additionally, a functional 
IVD is shown to increase the binding affinity of NEMO for IKKβ, enhance the 
thermal stability of NEMO, and is required to propagate NF-κB signaling in cells. 
A fluorescence-based assay is also developed to characterize the formation of a 
complex composed of NEMO, a zinc ion, and IκBα. A separate fluorescence-based 
assay is developed to measure IKK activity and is used to determine that NEMO 
alone or in the presence of linear tetraubiquitin does not enhance the rate of IKKβ 
phosphorylation of an IκBα-derived peptide. Furthermore, a number of organic 
small molecules and macrocycles are screened against the NEMO-IKKβ 
interaction. One small molecule was validated as an inhibitor and its biophysical 
properties and inhibition kinetics are described in this thesis. These analyses 
represent the first characterization of a highly conserved domain required for the 
function of the key control point in NF-κB signaling. The IVD domain of NEMO 
 viii 
could be targeted for development of an allosteric effector for therapeutic 
discovery. 
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Chapter 1: Scaffold Proteins in Eukaryotic Signaling 
1.1 Scaffold Proteins Provide Key Control Points for Intracellular Signaling 
Signaling scaffold proteins are defined as molecules that bind two or more 
proteins1, and facilitate the temporal, spatial, orientational, and contextual 
interactions between proteins involved in intracellular signaling. Classical 
scaffolds do not possess enzymatic activity; for the purpose of this dissertation, 
non-classical scaffold proteins that are catalysts (e.g., ATPases) are not discussed. 
Scaffold proteins may regulate two or more proteins of the same pathway, or 
coordinate signaling between different pathways2. The most basic function of 
scaffolds is to provide a binding platform to spatially and temporally co-localize 
kinases and/or phosphatases with their substrates, thereby directing and 
regulating phosphorylation events within signal transduction pathways3,4 in 
either a positive or negative fashion. This spatial and temporal coordination 
affords greater specificity for pathway components, decreasing the likelihood of 
non-specific interactions and off-pathway effects5. Scaffolds can play a more 
active role than simple co-localization, however, for example by allosterically 
regulating the activity of their binding partners6. In some cases such as the yeast 
scaffold protein Ste5, scaffolds exert complex allosteric control to regulate the 
interactions between signaling components7. Because of their ubiquity and ability 
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to facilitate complex signaling events, scaffold proteins have been used in 
directed evolution to engineer signaling outcomes or efficiently generate desired 
products7.  
Scaffold proteins typically possess a modular domain structure. Each 
domain acts as a functional unit to impart a specific protein binding site or 
oligomerization interface, to contribute one or more overall scaffold protein 
roles. These domain modules can vary widely in both sequence and function. 
Scaffold proteins are found in all domains of life, such as YopM in bacteria and 
RACK1 in both prokaryotes and eukaryotes8,9. However, based on their 
substantial heterogeneity, it is likely that scaffold proteins evolved convergently. 
For instance, it is unlikely that the scaffold protein POSH, a multi-SH3 domain-
containing protein, shares common ancestry with PSD-90, which is comprised of 
multiple PDZ domains. SH3 domains bind to proline and hydrophobic amino 
acids, whereas PDZ domains recognize short motifs at the C-termini of target 
proteins and are structurally distinct. Even MAPK scaffolds that organize the 
highly conserved set of MAPK cascade components into functional modules do 
not possess sequence similarity: Ste5, KSR, JIP, and β-arrestin family members all 
interact with MAPK proteins but are highly dissimilar10. This heterogeneity 
suggests that scaffolds have emerged several times independently during the 
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course of evolution. Another indication of convergent evolution is in the number 
of scaffolds identified in certain organisms. In primitive, unicellular eukaryotes 
and higher plants, the number of scaffold proteins is quite low11,12. Ste5 is the 
major MAPK scaffold protein in yeast, but is unrelated by sequence to the dozen 
or so MAPK scaffolds in mammals. Similarly, multi-PDZ domain proteins are 
abundant in animals but are rarely found in lower eukaryotes, fungi, or plants13. 
In contrast, tyrosine kinases likely evolved once during evolution due to their 
common sequence motifs and coincident emergence with multicellular 
organisms12,14,15. 
Scaffold proteins belong to many different and substantially distinct 
families. The most well-characterized scaffold families are the MAPK-
participating scaffolds include the Kinase Suppressor of Ras (KSR) family16, JNK-
interacting protein (JIP) family17, β-arrestins18, and Ste519. In addition to these 
well-known families, there are several examples of other similarly important but 
less often noted families. The following discussion is designed to illustrate the 
vast diversity in scaffold proteins, and highlight a few examples in lesser-known 
signaling pathways. Paxillins are scaffold proteins for adhesion of cells to the 
extracellular matrix and for focal adhesion of non-striated cells20. The Grb2-
associated binder (Gab) family has been shown to play a central role in multiple 
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major signaling pathways through its Pleckstrin homology (PH) domain and 
binding sites for SH2 and SH3 domains21. The membrane-associated guanylate 
kinase (MAGUK) family contains PDZ (Psd-95 [Post Synaptic Density Protein], 
DlgA [Drosophila Disc Large Tumor Suppressor] and ZO1 [Zonula Occludens-1 
Protein]), SH3 (Src Homology 3), and GUK domains, and participate in diverse 
processes including tissue development, cell-cell communication, and cell 
polarity control22. The Homer family of scaffolds contains an Ena/VASP 
homology 1 (EVH1) domain, coiled-coils, and leucine zippers, and maintains 
architecture in the post-synaptic density23. Notably, the MAGUK family contains 
PSD-95, a key scaffold at the post-synaptic density; this scaffold works alongside 
Homer proteins in a similar capacity, yet shares little sequence similarity, 
reinforcing the concept that scaffold proteins evolved convergently. A-kinase 
anchoring proteins (AKAPs) are structurally diverse scaffold proteins that 
typically bind protein kinase A (PKA) to localize it within the cell or to bring the 
kinase into close proximity to other proteins24. WD-repeat proteins typically have 
a circularized beta-propeller structure, but are involved in highly diverse 
functions including signal transduction and apoptosis25. The scaffold protein 
discussed herein does not belong to any of these classical families, but shares 
some domain structure similarity with the Homer family by the presence of both 
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coiled-coil domains and leucine zippers. 
 
1.2 Mechanisms for Scaffold Activation and Function 
Despite lack of sequence similarity and domain structure across scaffold 
proteins in general, two basic strategies are used for protein recognition and 
binding, and four strategies are used for activation of function. Some scaffolds 
bind one or more loops using a rigid protein structure, where these loops fit into 
a substantial but often shallow binding concavity on the surface of the scaffold 
protein. An example is the interaction of Adnectin binding to epidermal growth 
factor receptor (EGFR), where one loop of Adnectin fits into a flat pocket on 
EGFR26. The second strategy is by the interaction of surface-exposed side chains 
of secondary structure elements to form either hydrogen-bond networks or 
hydrophobic channels for structure; for example, a heterotetrameric coiled-coil of 
α-helices or leucine zippers27–29. The former strategy is more common for PPIs, 
the latter for oligomerization. These binding modes are illustrated in Figure 1; 
Fig. 1A illustrates a flat loop fitting into a shallow pocket26, and Fig. 1B is an 
example of a leucine zipper where two α-helices come together forming a 
hydrophobic channel29.  
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To explore scaffold protein function beyond simple protein binding or 
requirement for signal propagation, recent studies analyzed four distinct scaffold 
protein activation mechanisms linked to downstream function. Specifically, these 
mechanisms may be accomplished by rigid protein binding, ligand-based 
activation, disorder-order transition, or dynamic processes such as pH change or 
phosphorylation (Figure 2). Often these strategies may be used in conjunction 
with each other. 
  
 
Figure 1: Strategies for scaffold protein recognition and binding. A: Fitting of loops into a 
substantial binding concavity. EGF (gray) contains a pocket for a loop of Adnectin (light blue) 
to bind between structure denoted as red space fill and dark blue loops. B: an example of a 
model leucine zipper creates a hydrophobic channel that facilitates PPIs. 
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Rigid protein binding (Figure 2A) is the classically accepted mechanism 
for scaffold activation30. Src-homology-2 and -3 (SH2 and SH3) domains comprise 
50-100 amino acids that fold independently and recognize binding motifs ~5-10 
residues in length31. PDZ domains bind to four C-terminal residues of a protein 
chain, and in some instances can bind internal recognition sequences32. Helical 
 
Figure 2: Mechanisms for scaffold activation. A: Rigid protein binding. EBP50 (pink) binds to 
integral membrane proteins through PDZ domains and cytoskeletal proteins through its EB 
domain to promote cytoskeletal formation. B: Ligand-based activation. NEMO and IKKβ are 
activated by membrane tethering by poly-ubiquitination, which enhances IKKβ binding and 
promotes NEMO-mediated complex activation. C: Disorder-to-order transition. Intrinsically 
disordered regions in Kv gated channels (small circles) bind PSD-95 weakly to promote ease-of-
encounter complex formation once all complex components are available. D: Dynamic processes 
including phosphorylation. ZAP-70 phosphorylates LAT, which promotes Grb2 binding and 
subsequent activation. 
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repeats, including the Armadillo, HEAT, Ankyrin, and tetratricopeptide, are 
especially suited to bind longer linear motifs. These domains are bundles of 
repeated α-helices that are extended and conformationally rigid to create 
extensive surfaces for PPIs. They are commonly seen in proteins involved in 
translocation or sequestration events, such as in the nuclear transport shuttles, 
importins, that are comprised of Armadillo repeats33, or Inhibitor of κB proteins 
that are comprised of Ankyrin repeats34. A simple exemplary role for rigid 
protein binding in scaffold activation is the assembly of signaling components 
for cytoskeletal formation. Co-immunoprecipitation assays demonstrated that 
NHERF1/EBP50 binds to integral membrane proteins via PDZ domains, and to 
actin filaments via an EB domain (ERM-binding domain, another such rigid 
protein binding domain), to link the cytoskeleton to the plasma membrane5 
(Figure 2A). Rigid protein binding, however, cannot account for the regulation of 
pathway branching and other complex signaling regulation events30. 
In ligand-based activation (Figure 2B), binding of a protein partner to the 
scaffold induces a conformational change or other allosteric regulation event to 
promote activity of a downstream molecule. In one example, crystallographic 
analysis and kinetics of phosphorylation show how KSR undergoes an allosteric 
transition upon B-Raf (BRAF) binding to stimulate phosphorylation of the 
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downstream signaling molecule MAPKK35. In another, homodimerization of 
AHNAK as determined by crystallography reveals a pocket for binding to a 
peptide thought to be important for downstream complex formation; however, 
the biological function of the complex has yet to be determined32. 
Disorder-to-order transition (Figure 2C) is a mechanism for scaffold 
proteins to achieve a multitude of functions with the same disordered domain.  
Here, high-specificity but low-affinity interactions are favored. For example, 
disorder-to-order transition is employed in ease of encounter complex formation 
in voltage-gated potassium channels: the disordered binding interface promotes 
weak non-specific interactions to keep binding partners such as PSD-95 in an 
encounter complex until subsequent spatial rearrangements result in the proper 
orientation for specific binding (Figure 2C). This type of intricate, step-wise 
complex formation is hypothesized to be a more general mechanism for large 
macromolecular complex formation, as opposed to rigid docking of several 
proteins into one complex36. Disorder-to-order transition may also achieve 
binding-site overlap. For example, co-immunoprecipitation was used to show 
that a 15-residue intrinsically disordered loop in glycogen synthase kinase 3β 
(GSK-3β) binds to frequently rearranged in activated T-cells (FRAT) in one 
context, and axin in another2. 
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Dynamic processes that lead to scaffold activation (Figure 2D) include pH 
changes and phosphorylation events, among others. A pH-induced 
conformational change is observed by NMR in the scaffold protein IscU that is 
hypothesized to play an important physiological role in activation of iron-sulfur 
cluster biosynthesis37. The disordered protein linker for activation of T cells 
(LAT) is phosphorylated in a remote site by ZAP-70 to change the overall 
ensemble of conformational states. This equilibrium shift achieves an activated 
state that then modulates the accessibility of other phosphorylated sites to the 
binding partner Grb2 and promotes signaling activity38 (Figure 2D). Dynamic 
processes such as conformational change can also affect simple rigid protein 
binding, as in the case of NHERF1. Here, a head-to-tail conformation masks 
NHERF1 association with PDZ domain-specific ligands PTEN and β-catenin. 
Association of the EB domain of NHERF1 with ezrin releases this auto-inhibitory 
state, allowing the scaffold to become activated and bind PDZ domain-specific 
ligands39.  
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The above four mechanisms of scaffold activation are summarized in 
Table 1. However, this description would be incomplete if it neglected to discuss 
one of the most well-characterized scaffold proteins, Ste5. This protein organizes 
the yeast mating mitogen-activated protein kinase (MAPK) pathway. A model of 
auto-inhibition was generated by truncation mapping and a partial crystal 
structure. Here, a conformational change acts as a gate to present the binding 
surface for Fus3 to propagate a mating-specific signal upon α-factor binding40. 
Additionally, RING domain of Ste5 has been shown to undergo a major 
conformational transition upon Ste4/Ste18 binding, from a stable molten globule 
to a folded, more globular structure41. Four phosphorylation sites on Ste5 have 
been shown to regulate a switch-like dissociation of Fus3 that is necessary to 
Table 1: Summary of activation mechanisms, with noted examples, key 
domains, and relevant pathways. 
Activation Mechanism Examples Key Domain(s) Pathways 
Rigid protein binding EBP50 
Grb2 
Importin 
PDZ 
SH2 
Armadillo 
Cytoskeletal 
T cell activation 
Nuclear transport 
Ligand-based activation NEMO 
KSR 
AHNAK 
CCa, ZFb 
CC-SAMc 
PDZ 
NF-κB 
MAPK 
Differentiation 
Disorder-to-order Kv channel 
GSK-3β 
IDd 
ID 
Axon potential 
Multiple 
Dynamic processes IscU 
LAT 
NifU-like 
Transmembrane 
Fe-S biosynthesis 
T cell activation 
aCC, coiled-coil; bZF, zinc finger; cCC-SAM, coiled-coil sterile α-motif; dID, 
intrinsically disordered. 
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generate the switch-like mating response19. Therefore, Ste5 has been shown to 
exhibit the four above described scaffold protein activation mechanisms: ligand-
based activation by α-factor binding, rigid binding of Fus3, disorder-to-order 
transition, and dynamic activation by phosphorylation. As exemplified by the 
most well studied scaffold protein, it is possible that most scaffold proteins 
employ multiple, if not all, such strategies. Widespread scaffold protein 
characterization would directly address this hypothesis. 
 
1.3 NEMO as a Scaffold Protein and its Role in the NF-κB Pathway 
 The Nuclear Factor κB (NF-κB) pathway is a multi-component pathway 
that regulates the expression of hundreds of genes that are involved in diverse 
and key cellular and organismal processes, including cell proliferation, cell 
survival, the cellular stress response, innate immunity, and inflammation42. The 
NF-κB family contains five transcription factors that function as either homo- or 
heterodimers: NF-κB1, NF-κB2, RelA, RelB, and c-Rel43,44. These NF-κB proteins 
are typically sequestered in the cytoplasm by an Inhibitor κB (IκB) protein 
characterized by containing multiple Ankyrin repeat domains. There are 
multiple isoforms of IκB proteins: IκBα, IκBβ, IκBδ, IκBε, Bcl3, IκBζ, and 
IκBNS44,45. These IκB proteins are phosphorylated by IκB kinase α (IKKα) in the 
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non-canonical pathway, or IKKβ in the canonical pathway, which are 
homologous members of the IKK complex46. Phosphorylated IκB is degraded by 
the proteasome, which frees the previously sequestered NF-κB subunits to 
translocate into the nucleus. An essential regulatory element in the canonical 
pathway in the IKK complex is the scaffold protein IKKγ, or NF-κB Essential 
Modulator (NEMO). Upon pathway stimulation by tumor necrosis factor (TNF) 
α or other intercellular signaling molecules targeting TNF-receptor I, the IL-1R 
receptor, or TLRs47, the IKK complex becomes poly-ubiquitinated and associates 
with effector proteins bound to the activating receptor. It is currently believed 
that there are three distinct mechanisms for activation of the IKK complex. One 
mechanism involves an E2/E3 ligase complex attaching linked ubiquitin chains 
onto the kinase Receptor Interacting Protein 1 (RIP1), which bind directly to 
NEMO and thereby recruit the IKK complex together with the kinase TAK1 into 
association with RIP1. TAK1 then phosphorylates IKKβ to activate the kinase. It 
has also been shown that IKKβ may be activated via trans-autophosphorylation, 
though in this activation mechanism TAK1 phosphorylation is the primary 
manner of IKKβ activation48,49. A second mechanism by which signaling can be 
activated is triggered by linear ubiquitin chain assembly complex (LUBAC) 
association with the TNFR1 receptor50–52. LUBAC can then directly link ubiquitin 
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chains to NEMO, which enables trans-autophosphorylation of IKKβ for complex 
activation53. A third mechanism for canonical NF-κB activation is dependent 
upon association of effector proteins with the IL-1R and TLR receptors. Ubc13 
and TRAF6 proteins as part of an E2/E3 ligase complex are recruited to these 
receptors where they conjugate K63-linked ubiquitin chains to IRAK1 that is also 
associated with the receptors48,54. Similar to the first mechanism, binding of TAK1 
and the IKK complex to the ubiquitin chains initiates phosphorylation of IKKβ to 
activate the complex48. Notably, GSK-3β has been shown to phosphorylate 
serines 8, 17, 31, and 43 within the disordered N-terminus of NEMO, which is 
hypothesized to be important for ordered canonical NF-κB signaling in each of 
the above activation cases55–57. These activation mechanisms classify NEMO in 
the first and fourth categories of scaffold activation as described above: ligand-
based activation by poly-ubiquitin binding, and dynamic activation by 
phosphorylation events. Non-canonical NF-κB activation does not require 
NEMO, and is associated with organism development47, which is not discussed 
in this thesis. 
Within the IKK complex, NEMO binds IKKβ, an otherwise pleiotropic 
transducer58. They form a heterotetrameric complex involving a region close to 
the NEMO N-terminus encompassing residues 44-111 and a region close to the 
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IKKβ C-terminus encompassing residues 701-74528. IKKα may also bind NEMO 
in a similar functional complex46,47, but has been shown to only function in 
canonical NF-κB signaling in IKKβ knockout models59,60. The minimal NEMO 
binding motif on IKKβ (NEMO-Binding Domain, NBD) comprises 11 residues 
(735-745)28,61, though full binding affinity requires up to 45 residues28. NEMO 
dimerization is required for IKK activation62, but phosphorylation of NEMO on 
S68 and within the IKKβ NBD disrupts the heterotetrameric complex, which may 
prove to be a negative feedback mechanism45. An additional negative feedback 
mechanism was postulated recently for residues 112-150, that the authors 
propose maintains NEMO in an autoinhibitory state prior to poly-ubiquitin (>4) 
binding63. In that work, the authors showed that inclusion of residues 112-150 
prevents linear di-ubiquitin from binding to NEMO, despite ubiquitination 
occurring C-terminal to this region. Additionally, they argue that their SAXS 
model is too compact for NEMO to be fully extended (320 Å), and is likely in a 
conformation where the 112-150 region is folded back and in contact with the 
ubiquitin binding site.  
The C-terminal zinc finger of NEMO, encompassing 25 residues from 
position 395 to 419, binds the Inhibitor of κB proteins; see Figure 3. The IκB 
protein most commonly studied in conjunction with NEMO is IκBα. A key 
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function of NEMO is therefore to direct IKKβ to phosphorylate IκBα58. This 
occurs on IκBα S32 and S36; IkBβ is phosphorylated on S19 and S2345. 
Phosphorylated IκBα is then released from the complex and is K48-linked 
polyubiquitinated by the E3 ubiquitin ligase SCF/βTRCP, releases the 
sequestered NF-κB subunits, and is degraded in the 26S proteasome45,64. The 
released NF-κB subunits are then free to translocate to the nucleus, and activate 
NF-κB responsive genes that regulate inflammation and other biological 
outcomes. This pathway is diagrammed in Figure 4. 
 
 
Figure 3: Schematic domain map of NEMO (domains in blue) with binding sites of major 
partners IKKβ and IκBα boxed in black, and sites of covalent modification boxed in orange.  
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Additional binding partners have been reported for NEMO that affect NF-
κB signaling. Poly ADP-ribose polymerase 1 (PARP1) and protein inhibitor of 
activated STAT γ (PIASγ) bind within the N-terminal 120 residues of NEMO, 
and activate the IKK complex in response to DNA damage65. Ataxia-
telangiectasia mutated (ATM) is activated following DNA damage, which leads 
to binding and phosphorylation of NEMO at S85. NEMO is then mono-
 
Figure 4: Schematic cartoon representation of canonical NF-κB signaling. Receptor representative of 
any receptor for listed stimuli. Solid lines denote single step in signaling. Dashed lines denote 
ultimate fates of components of IκBα:p50:p65 complex. 
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ubiquitinated, and ATM-NEMO-Ub binds IKKβ to lead to IKK complex 
activation and induction of NK-kB signaling66. P53-induced death domain 
(PIDD) also activates NEMO in response to DNA damage, but the mechanism of 
activation is unknown67. Viral FLICE-like inhibitory protein (v-FLIP), a human 
herpes virus 8 protein, has been shown to bind between residues 150 and 272 of 
NEMO to activate the IKK complex in an Hsp90-dependent manner68. 
Interestingly, the chaperone Hsp90 has been shown to be physically associated 
with NEMO in a colonic malignant cell line, and contributes strongly to NF-κB 
signaling via this NEMO interaction. It is hypothesized that Hsp90 regulates the 
folding of NEMO and the IKK complex in another general regulation mechanism 
of canonical NF-κB signaling69.  
NEMO is essential for propagation of canonical NF-κB signaling. Several 
NEMO knockout studies have been performed that associate NEMO with a 
variety of diseases and therefore provide evidence for the essentiality of NEMO. 
Knockout of NEMO in a mouse model caused uncontrolled liver apoptosis 
arising from the absence of NF-κB-mediated proliferation signals, which led to 
fatal liver damage70. Thyroid-selective knockout of NEMO in a different mouse 
model led to the development of underweight mice with short lifespans71. 
Osteoporosis was induced following a knockout of NEMO in osteoclast and 
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myeloid progenitors in another mouse model72. Mice with a NEMO knockout in 
the pancreas developed caerulein pancreatitis73. In humans, because the NF-κB 
pathway is responsible for proliferation and differentiation outcomes, it has been 
shown to be significantly upregulated in certain cancers74–77.  
NEMO mutations abolishing its ability to dimerize have been shown to 
block NF-κB signaling78,79. An in-frame deletion mutation that eliminates residues 
Q134-R256 leads to Incontinentia Pigmenti (IP), likely through a lack of linear 
ubiquitination. IP is a genetic disease of the skin, hair, teeth and central nervous 
system80. The truncation mutation E391X in patients with inflammatory skin and 
intestinal disease in addition to ectodermal dysplasia with immunodeficiency 
(EDA-ID), has been correlated with abolition of the interaction with A20, a 
putative suppressor of NF-κB activity. EDA-ID is a group of conditions in which 
there is abnormal development of the skin, hair, nails, teeth, or sweat glands81. 
Even point mutations in NEMO are sufficient to bring about immune 
impairment diseases42,82.  
Because NEMO is an essential component of such an impactful pathway 
in human biology, there exists a strong therapeutic motive in studying and 
targeting this protein. A small-molecule inhibitor of the NEMO-Ubiquitin 
interaction was developed that selectively inhibits NF-κB activation in response 
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to TNFα, but not IL-1β, stimulation. This small molecule was shown to 
selectively kill lymphoma cells that were addicted to NF-κB signaling, providing 
strong evidence that NEMO is a potentially useful therapeutic target83. A 
different small-molecule inhibitor of the NEMO-IKKβ interaction was shown to 
inhibit cellular NF-κB signaling, and was computationally docked into the X-ray 
crystal structure of the NEMO-IKKβ binding interface84. However, no 
mechanistic studies were performed, so the precise target of the small molecule is 
unknown. A cell-permeant version of the NBD 11-mer peptide has been shown 
to disrupt the NEMO/IKKβ complex in vivo, and causes a specific biological 
outcome that attenuates activation of NF-κB but does not affect basal NF-κB 
function85,86. Quite surprisingly, the NBD peptide has been shown to prevent 
memory loss in a mouse model of Alzheimer’s disease, a function with which 
NF-κB had not previously been directly linked87. The NBD peptide has also been 
shown to attenuate tumor proliferation and prolonged mouse survival in a 
malignant glioma mouse line88. A synthetic loop replacement version of the NBD, 
in which a conserved hydrogen bond was replaced with a covalent hydrocarbon 
bridge to enhance rigidity, has been shown to be 10-fold more potent in blocking 
NEMO-mediated NF-κB signaling than wild-type NBD peptide89, and may prove 
to be a worthwhile strategy for further optimizing the NBD peptide for 
 
 
 
 
21 
 
 
Figure 5: Domain map of NEMO and select complexes. The existing crystal structures of 
individual NEMO domains. NEMO in beige; IKKβ in red (PDB 3BRV); linear di-ubiquitin in 
orange (PDB 2ZVO); red spheres represent structurally uncharacterized regions. HLX2 from 
PDB 3CL3; ZF from PDB 2JVX.  
 
therapeutic use. IKKβ knockout in a mouse model mimicked NEMO-knockout, 
but the fatal liver damage occurred at a later stage in embryonic development90. 
Notably, IKKβ inhibition through salicylate and its derivatives has been 
established but studied in models of vascular disorders and metabolic 
syndrome91 in addition to immunomodulatory capacities92,93. These attempts to 
inhibit NF-κB signaling through IKKβ have not been shown to modulate NEMO-
based NF-κB disease states. 
  
1.4 Current State of Biochemical and Biophysical Characterization of NEMO 
 The full-length X-ray crystal structure of NEMO has yet to be determined, 
but a number of atomic resolution structures exist of individual domains (Figure 
5). These include the X-ray crystallographic structure of IKKβ binding site in 
complex with a 45-mer of IKKβ in a 2:2 stoichiometry28, the CC2 domain in 
complex with the viral FLICE inhibitory protein94 (vFLIP), the CC2-LZ domain in 
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complex with DARPin95, the ubiquitin binding domain96,97, and an NMR structure 
of the zinc-bound zinc finger98. These encompass the entirety of NEMO except 
for the first 44 residues, the 85 residues from 111 to 195, and the 48 residues from 
345 to 393. Each of these structures, save the zinc finger, shows NEMO in an 
alpha-helical parallel dimer conformation. Many other oligomerization states of 
NEMO have been reported, including monomer99–103, dimer28,78,94–97,99–105, trimer78,99–
102, tetramer79,104, and pentamer102. It is not known whether oligomeric states other 
than dimer are biologically relevant or exist as stable species; for instance, full-
length NEMO is unlikely to exist as a trimer or pentamer given AUC and 
analytical gel filtration results from more recent studies103,104. 
Some of the challenge in studying NEMO biophysically has been 
attributed to the high aggregation, insolubility, and poor expression levels of the 
protein grown in E. coli. Due to these factors, determining oligomerization states 
has been complicated, and likely explains the variety of reported oligomerization 
states in literature. Up to seven of the cysteines outside of the NEMO zinc finger 
were mutated to alanine to avoid formation of unproductive disulfide bonds. 
Using this 7xAla construct, named for 7 Cys-to-Ala mutations, we determined 
NEMO to be a constitutive noncovalent dimer via analytical gel filtration and 
SDS-PAGE103. In NEMO-reconstituted cells, treatment with H2O2 to induce 
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oxidative stress formed covalent disulfide-linked dimers with wild-type NEMO 
and 5xAla NEMO, containing Cys54 and Cys347, but not 7xAla, with these two 
cysteines additionally mutated to alanines99. This demonstrated that Cys54 and 
Cys347 were sufficient for mediating interchain disulfide bonding. Most 
importantly, the 7xAla construct was shown to have an indistinguishable 
binding affinity for IKKβ(701-745) and ability to propagate TNFα-induced NF-κB 
signaling as compared to wild type NEMO103. For these reasons, 5xAla and 7xAla 
are used interchangeably throughout this thesis to serve as “wild-type” NEMO. 
IκBα was shown by gel filtration to bind directly to the zinc finger of 
NEMO, encompassing residues 384-419; this is in addition to demonstrating that 
NEMO, IKKβ, and IκBα form a three-member heterologous complex that is 
stable enough for co-immunoprecipitation58. Perhaps most relevant to this thesis, 
Catici et al. (2015) demonstrated a conformational change undergone by NEMO 
in response to binding of IKKβ, IκBα, and both IKKβ and IκBα peptides by 
monitoring of intrinsic fluorescence and ANS dye binding. The conformational 
changes occur on the order of seconds, and the magnitude of the signal change is 
increased by polyubiquitin binding with a direct positive correlation to Ub chain 
length. Also importantly, the study demonstrated that IκBα binds to NEMO 
cooperatively at a ratio of 2:2106. From these studies, NEMO is emerging as a 
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dynamic regulator of the function or outcome of several components of a major 
signaling pathway, despite no apparent enzymatic activity. 
As was discussed above, NEMO binds IKKα and IKKβ at the N-terminus, 
minimally requiring residues 47-80 of NEMO61,62,107. The affinity of NEMO 
binding to IKKβ(701-745) in a 2:2 stoichiometry has been measured to be 2.2 ± 0.8 
nM in a fluorescence anisotropy assay103, and similar values have been 
determined using surface plasmon resonance (D. Petrescu, unpublished). The 
binding affinity of NEMO for full-length IKKβ has not been reported. The 
binding interface has been tested via alanine-scanning mutagenesis along the 
NBD of IKKβ, and analyzed using computational hot-spot mapping108. These 
analyses have determined the location of a strong binding energy hot spot, 
specifically W739, W741, and L742, in addition to distal hot spots at L708/V709 
and L719/I723. The top hot spot contains residues that are not only bulky but also 
reasonably close in space, forming a triangle with maximum dimensions of 6.6 x 
5.5 x 3.6 Å. This may be a sufficiently large and hydrophobic pocket for a small 
molecule to bind, but may not be sufficient to allow design of a potent inhibitor; 
according to Kozakov et al., a site is druggable if two strong hot spots have a 
center-to-center distance of less than 8 Å109. Because the major hot spot is farther 
away than 8 Å from the distal hot spots in NEMO, this protein-protein 
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interaction site may be difficult to target with more conventional drug-like 
molecules.  
1.5 Overview of Thesis 
In this thesis, I discuss the role of a previously uncharacterized domain, 
termed the IVD, within NEMO that is required for its function. Bioinformatic 
analysis illustrates a high level of sequence conservation across species within 
the IVD. Conformational dynamics and structural information have been 
elucidated for the IVD. Additionally, the contribution of this domain to the 
binding affinity to IKKβ and to the thermal stability of NEMO is described 
herein. Perhaps most significantly, the requirement of the IVD to propagate NF-
κB signaling is also revealed in this thesis. In addition to the study of this 
previously uncharacterized domain, a fluorescence-based assay was developed 
to measure the binding affinity of NEMO and IκBα. Furthermore, a number of 
organic small molecules and macrocycles have been screened against the NEMO-
IKKβ interaction, with the ultimate goal of finding the first non-peptide NEMO-
targeted inhibitor. One small-molecule hit was validated and is described in this 
thesis. These data represent the first characterization of the IVD as a region 
required for the function of the key control point in NF-κB signaling, and may 
prove to be an allosteric target for NEMO drug discovery efforts. 
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Chapter 2: The Role of the Intervening Domain in NEMO Structure and 
Dynamics 
2.1  Introduction 
Scaffold proteins function by orienting their protein binding partners so as 
to enable or modulate their function. This orientation can occur by several 
distinct mechanisms, including rigid protein binding, ligand-based activation, 
disorder-to-order transition, and dynamic processes such as phosphorylation. 
Allosteric regulation of scaffold function appears to be implicit given these 
strategies, except for rigid protein binding, but the mechanism by which allostery 
occurs has yet to be elucidated. Evidence for such a mechanism shows that 
mutations outside of scaffold protein binding sites can affect binding110,111. For 
example, researchers were able to discover and characterize an allosteric 
inhibitor that binds an intrinsically disordered region of the Protein Tyrosine 
Phosphatase 1B (PTP1B)112, and the same group showed unidentified allosteric 
sites outside of the canonical kinase interaction motif of striatal enriched protein 
tyrosine phosphatase contribute to ERK2 binding113.  
Recent work has suggested links between conformational dynamics and 
scaffold function. A pH-induced conformational change in the scaffold protein 
IscU has been suggested to play a role in iron-sulfur cluster biosynthesis37. 
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Structural and kinetic studies have shown that Kinase Suppressor of Ras (KSR) 
undergoes an allosteric transition upon B-Raf binding, thereby stimulating 
phosphorylation of Mitogen-Activated Protein-Kinase Kinase (MAPKK)35. 
Truncation mapping and a partial crystal structure of the yeast scaffold Ste5 have 
been used to generate a model of autoinhibition, in which a conformational 
change in Ste5 acts as a gate to present the binding surface for Fus3, which then 
propagates a mating-specific signal40. In fact, Ste5 has been shown to employ all 
four scaffold protein functional strategies19,41 (see Chapter 1 for discussion of 
strategies). It is possible that scaffold proteins commonly employ all or most of 
such strategies, and that we simply have not characterized them well enough to 
determine that this is the case.  
 NEMO is a good model for studying scaffold proteins because it has been 
extensively studied, but its underlying molecular mechanism of activation is 
unknown. NEMO has been shown to exist in multiple oligomeric states, 
particularly as a constitutive noncovalent dimer28,104. To date, four regions of 
NEMO have been crystallized28,94,96,98, and binding interactions with some of its 
partners have also been well characterized58,69,107,108; refer to Figure 5 in Section 1.4. 
A number of mutations of NEMO have been shown to cause genetic 
immunodeficiencies42,82,114,115. This structural and functional information provides 
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a solid framework for the work presented in this and the following Chapter of 
this dissertation.  
 The region spanning residues 44 to 111 in NEMO is annotated as the IKKβ 
binding region, and has been extensively studied28,116. A domain of NEMO C-
terminal to residue 195, referred to as CC2 for its coiled-coil structure, has also 
been extensively studied28,94,104. However, the region between these domains, 
which we term the Intervening Domain (IVD), has no known function or 
structure. This chapter discusses the IVD domain and these mutations in the 
context of sequence conservation. A high level of sequence conservation is 
generally correlated with strong evolutionary pressure to retain the same amino 
acid side chains; therefore, there likely is significant adaptive role of these 
particular side chains.  
 In addition to determining sequence conservation of NEMO, this chapter 
focuses on obtaining protein for, and subsequent structural characterization of, 
the IVD in the context of both NEMO(44-195) and full-length 7xAla NEMO. 
Protein purity is confirmed by SDS-PAGE, before secondary structure 
characterization by CD, conformational assessment by SAXS and AUC, and 
progress toward determining a high-resolution crystal structure of the construct 
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comprising the IKKβ binding domain with the previously uncharacterized IVD 
(NEMO(44-195)). 
 
2.2 Materials and Methods 
2.2.1 Multiple Sequence Alignment 
Annotated NEMO sequences were obtained using BLASTp (National 
Center for Biotechnology Information). BLASTp takes an input protein sequence 
query, in this case WT-NEMO, and compares it through local, i.e. small sections 
of, alignments to all other protein sequences in NCBI-accessible databases. Local 
alignments with the top scores are extended to improve sequence cover, and top 
final scoring sequences are returned. Redundant sequences, splice variants, and 
hypothetical sequences were removed from the resulting 100 sequences, as were 
fragment sequences with fewer than 50 residues and the similar but functionally 
unrelated protein optineurin. These sequences were imported into Unipro 
UGENE117 and exported as an MSA using the algorithm MUSCLE118 with default 
settings. Iterative rounds of trimming, pruning, and re-aligning were performed 
to represent most accurately the conservation of NEMO sequences.   
2.2.2 Vectors and Mutagenesis Strategies 
Full-length NEMO constructs, NEMO(44-111), and NEMO(1-120) were 
 
 
 
 
30 
 
cloned as described previously103,116. NEMO(44-195) and NEMO(110-195) were 
cloned from 5xAla NEMO, a codon-optimized template (GenScript)103, by PCR, 
and restriction digested and ligated into a SUMOstar vector (LifeSensors) via 
BsaI and XhoI sites and T4 DNA Ligase. These constructs were transformed into 
T7 Express competent cells (New England Biolabs) to take advantage of the 
codon optimization. The variants 9SG and L153R were generated from the 7xAla 
full-length NEMO template using the NEB Q5 Site-Directed Mutagenesis Kit 
(New England Biolabs), and transformed into Rosetta 2(DE3)pLysS competent 
cells (Novagen). This cell line allows for the expression of additional tRNAs to 
account for rare, i.e. eukaryotic-preferred, codons present in this NEMO clone. 
Point mutants E57K, L80P, D113N, and R123W were generated in a 7xAla 
template using QuickChange mutagenesis, and transformed into Rosetta 
2(DE3)pLysS competent cells (Novagen). Full-length IκBα in a mammalian 
expression vector was graciously donated by Dr. Susan Kandarian. GST-tagged 
IκBα(1-55) in a mammalian expression vector was graciously donated by Dr. 
Thomas Gilmore. For bacterial protein expression, these IκBα sequences were 
PCR amplified and cloned into a pDEST-17 vector via Gateway Cloning 
(Invitrogen). The list of primers used to generate these constructs is listed in 
Appendix I. All constructs were confirmed by DNA sequencing by Genewiz 
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(South Plainfield, NJ) using universal T7 polymerase forward and terminator 
primers. 
2.2.3 E. coli Expression and Purification 
For each NEMO variant, cells transformed with a plasmid bearing the 
gene encoding NEMO were grown in LB broth shaking at 250 rpm at 37 °C 
overnight, to seed a new expression culture at a 1:200 dilution with 50 μg/mL 
kanamycin for antibiotic selection. This new culture was grown until OD600 
reached between 0.4 and 0.6. Protein expression was induced by 1 mM isopropyl 
β-D-thiogalactoside (IPTG) and incubated for four more hours. Cells were 
pelleted by centrifugation and stored at -20 °C. The pellets were lysed using a 
microfluidizer, and incubated with 0.1 μL/mL Universal Nuclease (Pierce) and 10 
μL/mL Halt Protease Inhibitor Cocktail (ThermoFisher) for 20 m. Urea (at 8 M) 
was then added to the lysate to prevent chaperones and other contaminating 
proteins from co-purifying with NEMO, and the solution incubated for 1 h. The 
lysate was then clarified by ultracentrifugation at 38,000 rpm for 30 m, sonicated 
to shear any remaining large DNA fragments, and filtered through a 0.8 μm 
filter. 
The protein was initially purified from bacterial lysate as described 
previously, which includes a re-folding step on a nickel column to remove 
 
 
 
 
32 
 
urea103,116. Instead of the gel filtration step, NEMO(44-195) and NEMO(110-195) 
were concentrated to 1 mL and incubated with SUMOstar Protease 1 
(LifeSensors) for 2 hours at room temperature, and then 4 °C overnight. To 
isolate untagged NEMO(44-195), this mixture was then applied to a 5 mL 
HisTrap HP column (GE Healthcare) for subtractive affinity chromatography; 
the six-His-tagged SUMOstar tag and SUMOstar Protease 1 bound the column, 
while the untagged NEMO(44-195) flowed through and was collected. Purified 
proteins were pooled and concentrated to < 3 mL, typically about 2 mg/mL for 
full-length NEMO and 10 mg/mL for the shorter NEMO constructs. Full-length 
NEMO protein concentrations were calculated from the absorbance at 280 nm 
(NanoDrop, Thermo Scientific) using an extinction coefficient of 14400 M-1 cm-1 as 
predicted by ExPASY ProtParam119. NEMO(44-195) and NEMO(110-195) contain 
no tryptophan residues, so protein concentration was calculated by densitometry 
via SDS-PAGE with protein standards. Aliquots of each prep were stored at -80 
°C. 
Expression and purification of full-length IκBα was performed similarly to 
that for full-length NEMO protein, except for the omission of the gel filtration 
step. Protein concentrations were calculated from the absorbance at 280 nm 
(NanoDrop, Thermo Scientific) using an extinction coefficient of 28000 M-1 cm-1 as 
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predicted by ExPASY ProtParam119. Purity was assessed by SDS-PAGE.  
2.2.4 SDS-PAGE Analysis 
All SDS-PAGE experiments were performed using 12% polyacrylamide 
Tris-HEPES gels. Gels were stained using a solution of 40% methanol, 10% acetic 
acid, and 0.3% Coomassie R-250. To oxidize or reduce the protein, NEMO 
constructs were pre-treated with 5% H2O2 or 5 mM DTT for 1 h. After pre-
treatment, the protein was incubated in SDS sample buffer (4% [w/v] SDS, 20% 
[v/v] glycerol, 0.01% [w/v] Bromophenol Blue, 125 mM Tris, pH 6.8) for 5 m 
and/or boiled in SDS sample buffer with 100 mM DTT prior to analysis. 
2.2.5 Circular Dichroism Spectroscopy 
NEMO constructs were diluted to 0.25 mg/mL in a buffer containing 20 
mM sodium phosphate and 500 mM NaCl at pH 7.4. Spectra were obtained using 
a 1 mm 300 μL quartz cuvette in an Applied Photophysics Chirascan CD 
spectrometer. Buffer-subtracted spectra from 180 to 260 nm with a step of 1 nm 
were measured at 10 °C. Mean molar residual ellipticity (in units of degrees 
square centimeters per decimole) was calculated from the raw signal (in units of 
millidegrees) to normalize for differences in concentration and number of 
residues120. For thermal denaturation experiments121, mean molar residual 
ellipticity was calculated from the signal at 222 nm, and traced as the sample 
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temperature was ramped at 1 °C /m from 10 °C to 70 °C. Slowing the ramping 
rate to 0.5 °C /m had no effect on the TM. TM values were determined as the 
maximum of a plot of the first derivative of the thermal denaturation curve, 
(δΘ/δT). For 2,2,2-trifluoroethanol (TFE) inclusion to determine maximum level 
of α-helicity, NEMO was concentrated to 2.5 mg/mL before 10-fold dilution with 
TFE to yield a 90% TFE solution. Spectra were then obtained as described above. 
Percentage α-helix is calculated as a ratio described previously by Zhou and 
colleagues116, between Θ222 in aqueous buffer and that in TFE-containing buffer 
according to Equation 1 below: 
𝛼 ℎ𝑒𝑙𝑖𝑥 (%) = ఏమమమ(௔௤௨௘௢௨௦)
ఏమమమ(்ிா)
∗ 100          (1) 
2.2.6 Small-Angle X-ray Scattering 
5xAla-NEMO SAXS data were collected on beamline X9 of the National 
Synchrotron Light Source, and all other sample data were collected on beamline 
16-ID-LIX of the National Synchrotron Light Source II, at Brookhaven National 
Laboratories (Upton, NY). Samples were transported frozen and filtered with a 
0.22 μm filter after thawing, and centrifuged to remove any particulates. The 
protein concentrations were ~1.6 mg/mL and ~0.8 mg/mL for each component in 
20 mM sodium phosphate, 500 mM NaCl, pH 7.4. Samples were loaded into 8-
tube strips at ambient temperature and aspirated into a thin-walled 1.5-mm 
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diameter sample tube using an automated system as described previously122. At 
X9, scattered intensities were determined from q = 0.005 to 1.99 Å-1 using an X-
ray wavelength of 0.9184 Å and detected via a Mar 165 CCD detector 3.4 m from 
the sample. At LiX, scattered intensities were determined from q = 0.005 to 2.47 
Å-1 using an X-ray wavelength of 0.9184 Å and detected via a Pilatus3 1M SAXS 
detector and two Pilatus3 300K WAXS detectors. Three replicates were collected 
and data processing was performed using the X9 or LIX software packages to 
produce radially averaged intensity profiles extending over the entire scattering 
range. The data from the two concentrations were checked for consistency at low 
q and merged using PRIMUS123. For data collection and processing software 
comparison, 5XAla-NEMO datasets were obtained at both sites: the Rg for data 
collected and processed at X9 was 90 Å; at LIX Rg was 94 Å. 
X-ray scattering patterns were initially checked for aggregation using the 
ATSAS suite123. The radius of gyration (Rg) and P(r) function were calculated 
using GNOM124 with the data range indicated in Table 2. Following P(r) function 
determination by GNOM, this information was used in DAMMIN125 to generate 
10 ab initio models of the shape of each construct of NEMO using default 
parameters. The 10 models were averaged using DAMAVER126. The final output 
of DAMAVER was then re-run through DAMMIN for final refinement, using 
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default parameters. The goodness of fit of this final model was determined by 
FoXS127,128 in CHIMERA by χ-value calculation129. The volume envelope of the 
model was generated using the “Fit in Map” feature of CHIMERA129. CHIMERA 
was also used to align the NEMO(44-195) volume envelope with that of the full-
length NEMO model for direct comparison. Superposition of the envelope with 
previously solved X-ray crystal structures of individual NEMO domains IBD, 
HLX2, and CoZi was accomplished by using BUNCH130. This atomistic modeling 
fits the original scattering data well (χ = 0.74 theoretical scattering versus 
experimental), but should be considered provisional due to SAXS resolution 
limits.  
2.2.7 Analytical Ultracentrifugation 
Sedimentation velocity experiments were performed in a Beckman XL-I 
analytical ultracentrifuge131, using aluminum double-sector sapphire cells in an 
An-50 Ti rotor (located at the MIT Biophysical Instrumentation Facility, 
Cambridge, MA). The rotor speed was 3,000 rpm for temperature equilibration 
(10 °C throughout the run), and then 42,000 rpm during the sedimentation run. 
Prior to centrifugation, protein samples were buffer exchanged against the buffer 
blank (20 mM sodium phosphate, 500 mM NaCl, pH 7.4). The protein 
concentration was at 0.7 mg/mL and 0.3 mg/mL; when included, IKKβ(701-745) 
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was in 10-fold molar excess. Interference images were collected every 60 s during 
the sedimentation run. The data recorded from moving boundaries was 
automatically buffer subtracted by the Beckman XL-I software and processed 
using SedAnal132. 
Sedimentation equilibrium experiments with the same instrument and 
rotor as for equilibrium velocity experiments were performed, except using 
aluminum six-sector sapphire cells. The spin speeds were 11,200, 14,000, and 
21,000 rpm. The temperature was maintained at 10 °C. Prior to centrifugation, 
protein samples were buffer exchanged against what would be used as the buffer 
blank (20 mM sodium phosphate, 500 mM NaCl, pH 7.4). The protein 
concentration was at 0.7 mg/mL and 0.3 mg/mL; when included, IKKβ(701-745) 
was in 10-fold molar excess. 
2.2.8 Crystallography of NEMO(44-195) 
For selenomethionine (SeMet)-labeling for phase solution133, NEMO(44-
195) was expressed in T7 Express cells (New England Biolabs, Ipswich, MA) as 
was also done for the native protein. A 15 mL overnight culture was grown with 
shaking at 250 RPM at 37 °C in LB broth with 50 μg/mL kanamycin (GoldBio). A 
portion of the overnight culture (3 mL) was used to inoculate 1 L of fresh M9 
minimal media supplemented with 50 μg/mL kanamycin, glucose, vitamins, 
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MgSO4, and CaCl2. Cultures grown with shaking at 250 rpm at 37 °C until OD600 
reached 0.8-1.0. Amino acids were then added to the media to stop the natural 
methionine biosynthesis pathway: threonine, lysine, phenylalanine, leucine, 
isoleucine, valine, and selenomethionine, and were allowed to incubate for 15 m. 
IPTG was then used to induce expression of NEMO(44-195) overnight. Cells 
were pelleted at 5000 RPM and stored frozen at -20 °C until purification. 
Purification of SeMet NEMO(44-195) was identical to native protein except for 
inclusion of 5 mM DTT throughout until dialysis with the crystallization buffer 
(containing 10 mM Tris, 100 mM NaCl, 2.5 mM TCEP, at pH 7). 
Dilute protein sample at ~0.001 mg/mL in the crystallization buffer was 
incubated with equimolar NBD peptide dissolved in water at 37 °C for 30 m, and 
subsequently concentrated to <200 μL. Crystals were grown using vapor-
diffusion hanging-drop geometry at 17 °C using a 0.5:2 μL volume ratio of 
concentrated protein to crystallization solution of 100 mM HEPES pH 7.5, 5 mM 
DTT, and 19% PEG 3350. Two rounds of microseeding were accomplished by 
centrifuging crystals using Seed Beads (Hampton Research) in 100 mM HEPES 
pH 7.5, 5 mM DTT, and 25% PEG-3350, diluting the microseed solution 1:10, and 
adding 0.5 μL of this dilution to each drop that had been equilibrating for at least 
24 h. The final crystals were cryoprotected in 100 mM HEPES, 5 mM DTT, 26% 
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PEG 3350, and 30% glycerol and transferred into liquid nitrogen. The I71M 
mutant was cloned using the NEB Q5 Mutagenesis Kit (New England Biolabs, 
Ipswich, MA), and protein was expressed, purified, and crystallized identically 
to the selenomethionine-incorporated WT version of the protein. 
Multiple anomalous dispersion (MAD) data for SeMet NEMO(44-195) 
were collected at BL9-2 at Stanford Synchrotron Radiation Lightsource (Menlo 
Park, CA) at wavelengths 0.979 (peak), 0.91162 (remote), and 0.97934 (inflection). 
Data processing to 2.11 Å was performed with the HKL2000134 program package. 
The attempt to solve the structure of the NEMO/NBD peptide complex by MAD 
phasing used AutoSol135, which identified two selenium sites per asymmetric 
unit and produced phases with a figure of merit of 0.481 to 2.2 Å. AutoBuild136 
was used to attempt model building into electron density output by AutoSol, 
with several different attempts with different parameter selections, including but 
not limited to Quick Mode, simulated annealing, and a lower resolution cutoff. 
SHELX137 was also used to attempt to solve phases using a different method; 
heavy atom sites from SHELXC/D were fed into the Phenix pipeline starting with 
AutoSol for subsequent attempts at model building.  
One crystal was observed for SeMet NEMO(44-195) I71M under identical 
conditions to those that produced the above crystal, except no seeding was used. 
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This crystal was cryo-protected in 50% well solution and 50% glycerol and 
transferred into liquid nitrogen. Data collection was attempted at beamline NE 
CAT 24-ID-C at Advanced Photon Source (Lemont, IL), but no diffraction was 
observed for this crystal.  
 
2.3 Results and Discussion 
2.3.1 The IVD is Highly Conserved and Contains Human Disease-Associated 
Mutations 
The error rate for DNA replication is between 10-8 and 10-10 for eukaryotic 
DNA polymerases after repair mechanisms are taken into account138. In the entire 
human genome of over 3x109 base pairs, errors occur on average less than once 
per replication event. If an error is made in a gene that does not affect function 
significantly, it can be safely passed down to the subsequent generations. 
Mutations can be beneficial, i.e. gain of function, but they can also be 
detrimental, and can either result in disease or be lethal in utero. For residues 
directly involved in function and/or structural stability, there is little to no 
tolerance for mutation. By analyzing sequence variation for orthologs, residues 
under evolutionary pressure can be determined. Residues important for function 
are not as free to change, and are thus more highly conserved; residues 
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unimportant for function are freer to change to other residues. To analyze this 
sequence variation, a Multiple Sequence Alignment (MSA) was performed on the 
sequences obtained from BLASTp. This procedure may be performed in multiple 
ways; the most common, and the one used in this thesis, is progressive alignment 
construction as implemented by MUSCLE118. In brief, the technique aligns the 
most similar sequences first, progressively, until the most distantly related is 
aligned. 
To determine whether the sequence of the IVD is conserved across 
species, we performed an MSA using annotated NEMO sequences obtained from 
BLASTp (National Center for Biotechnology Information). Of the 38 unique 
NEMO sequences after removing redundant sequences etc., 27 were from 
mammals, 10 from fish or amphibians, and 1 from Drosophila. The results suggest 
that NEMO appeared no more than 780 million years ago139, as the most 
evolutionarily distant homolog for which sequence information is available is an 
arthropod (Drosophila melanogaster). Among all these species, NEMO is highly 
conserved (Appendix V). The alignment showed that, in the core regions of 
functionally important domains such as the IBD (IKKβ binding), the HLX2 
domain (LUBAC binding), the CC2-LZ domains (ubiquitin binding), and the zinc 
finger (IκBα binding), the NEMO sequence is highly conserved even among the 
 
 
 
 
42 
 
non-mammalian orthologs. However, conservation is significantly lower towards 
the borders of these domains, and in the segments linking them (Appendix V). 
The alignment of the central portion of IVD is shown in Figure 6. Within the IVD, 
encompassing residues 112-195, there was high sequence conservation. 
Specifically, there is a highly conserved segment (residues 134-161), which 
includes a stretch of nine amino acids (QV/ATSLLGEL; aa 145-153) that is strictly 
conserved across all mammalian and non-mammalian vertebrate species, with 
the exception of a conservative Val/Ala polymorphism at position 146 in some 
non-mammalian species (Figure 6). Several residues in or near this region of the 
IVD sequence are conserved, even in Drosophila. Thus, the core of the IVD shows 
sequence conservation that is as high as or higher than any of the other 
functional regions of NEMO (Appendix V). The high sequence conservation 
observed in this region is consistent with the hypothesis that the IVD plays an 
important role in NEMO function. This hypothesis is further strengthened by the 
observation that several mutations associated with genetic immunodeficiency 
diseases are located in or near the IVD, including D113N, R123W, L153R, R173G, 
R175P and Q183H42,82. These IVD disease mutations do not significantly reduce 
NEMO expression140–144, and thus likely exert their effects by altering NEMO 
protein function. From this information, it is interesting to note that the more 
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highly conserved center of the IVD appears to play a role in ectodermal dysplasia 
with immunodeficiency (EDA-ID), while the periphery of this domain is 
associated with incontinentia pigmenti (IP) (Table 2).  
 
 
  
Table 2: Disease-associated mutations within the IVD. 
Mutation Disease % Identity 
D113N IP 55.3 
R123W* IP 26.3 
L153R EDA-ID 97.4 
Q157P OL-EDA-ID 97.4 
A169P** EDA-ID 55.3 
L170P IP 92.1 
R173G IP 76.3 
R175P EDA-ID 78.9 
R182P IP 76.3 
Q183H IP 73.7 
*42.1% Q; **18.4% T. IP: Incontinentia Pigmenti. OL-EDA-ID: 
osteopetrosis, lymphedema, anhidrotic ectodermal dysplasia, and 
immunodeficiency. % Identity: percent conservation of noted residue 
among sequences in NEMO MSA (Appendix V). 
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2.3.2 Design and Production of IVD Constructs for Bacterial Expression 
To assess the biochemical and biophysical properties of the IVD in vitro, 
bacterial expression vectors were created for a variety of NEMO constructs. 
These are shown in Figure 7. The boundaries of the construct NEMO(44-195) 
were selected to encompass both the entire IKKβ binding site and the IVD. A 
construct NEMO(44-111), which does not include the IVD, had been crystallized 
previously bound to the IKKβ(701-745)28, and the structure determined. This 
NEMO(44-195) construct was made along with NEMO(110-195), which contains 
only the IVD. Both constructs were cloned from a previously codon-optimized 
5xAla template103 into a SUMOstar vector (LifeSensors) that contained a six-His 
tag N-terminal to a SUMOstar tag, which is N-terminal to the gene of interest. 
 
Figure 6: Multiple sequence alignment of full-length NEMO reveals a high level of sequence 
conservation in the IVD region. Shown is the region that spans residues 141-161. 9SG 
substitution is 145-QVTSLLGEL-153. Residues in blue indicate consensus. 
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This construction allowed for initial purification via nickel-NTA affinity 
chromatography, followed by proteolytic cleavage of the SUMOstar tag with 
subtractive nickel-NTA chromatography, to purify away the SUMOstar tags 
from the protein of interest. The SUMOstar tag has been optimized for increased 
bacterial expression, and additionally was included to increase solubility of 
newly expressed protein to avoid inclusion bodies which is a known obstacle in 
NEMO(1-120) purification116. 
Recombinant full-length 7xAla NEMO protein was developed previously and 
purified according to the original purification scheme103. 9SG NEMO, which 
contains a nine amino acid substitution in a core conserved region of NEMO 
 
Figure 7: Full-length NEMO, L153R, 9SG, and NEMO(44-195) indicated on NEMO domain 
map with indicated mutations and fusions. NEMO(110-195) comprises the IVD, and 1-120 
comprises residues 1 through the CC1 or IKKβ binding site. 
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(Figure 7), was constructed in the same background, and is expressed and 
purified identically. Recombinant 5xAla-, 7xAla-, and 9SG-NEMO include an 
uncleaved six-His tag at the C-terminus as a result of inclusion in the pET24b 
vector (Appendix I). NEMO variants E57K, L80P, D113N, and R123W were 
generated successfully but were not used in any of the following experiments. 
2.3.3 IVD Mutations Negatively Affect NEMO Stability 
To determine whether the IVD is a significant structural component, the 
effect of the presence or absence of the IVD on thermal stability of the IBD was 
measured using circular dichroism spectroscopy (CD) to monitor thermal 
unfolding through the associated loss of secondary structure. FL-NEMO had a 
melting temperature of  41 ± 3 °C (n = 3) (Figure 8A), while it was previously 
shown that covalently dimeric NEMO(1-120) is less stable, melting at a 
temperature of 33 ± 2 °C116. Notably, NEMO(44-195) showed a single cooperative 
melting transition, with TM = 45 ± 2 °C (n = 3), comparable to the TM of FL-NEMO 
(41 ± 3 °C, n = 3). The NEMO(1-120) and NEMO(44-195) each contain a single 
inter-chain disulfide through Cys54; therefore, the difference in thermal stability 
can be attributed directly to the effect of the presence or absence of the IVD. The 
result that inclusion of the IVD substantially stabilized the protein to form a 
single, cooperatively unfolding unit therefore indicates that the IBD and IVD are 
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intimately structurally interconnected. The 9SG-NEMO variant had reduced 
structural stability, melting with TM 34 ± 2 °C (n = 2), comparable to the value 
seen for the IBD only construct (Figure 8A). This result and the results from the 
IKKβ binding experiments show that the 9SG variant of the IVD disrupts the 
structure and function of the IBD-IVD region of NEMO. 
 
 To determine whether the 9SG mutation disrupts protein secondary 
structure, we characterized 9SG-NEMO and NEMO(44-195) by CD. Helical 
content was quantified by comparing the CD spectra measured in aqueous buffer 
with that in 90% 2,2,2-trifluoroethanol (TFE), a solvent that induces adoption of 
α-helical structure regardless of the protein primary structure145,146. Taking the 
 
Figure 8: Influence of IVD on NEMO thermal stability. A: Thermal denaturation of NEMO 
monitored by CD. An increase in signal at Θ= 222 nm corresponds to loss of secondary 
structure. Curves are normalized to each other and are representative of n≥2 experiments. 
Inset: first derivative of melting curve used to identify TM value. B: CD spectra of NEMO 
constructs determined at 10 °C and normalized. Normalization was performed, rather than 
calculating mean molar residual ellipticity, because the error in concentration determination of 
the tryptophan-less NEMO(44-195) and NEMO(44-111) may have confounded direct 
comparison. Negative peaks at 208 and 222 nm indicative of alpha-helical content. 
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spectrum obtained in 90% TFE as representative of a 100% α-helical structure, the 
ratio of the molar ellipticity at 222 nm measured in aqueous buffer to the 
corresponding value in 90% TFE gives an estimate of the α-helix content of the 
protein in aqueous conditions. The results of these measurements showed that, 
in aqueous buffer, 9SG-NEMO was 65% α-helix, approximately the same as FL-
NEMO. This finding suggests that the 9SG mutations do not cause overall 
disruption of the protein secondary structure. Using the same approach, 
NEMO(44-195) was found to be 83% α-helix. To verify that 90% TFE was 
sufficient to induce full α-helicity, NEMO(44-195) was also evaluated in 97% 
TFE, giving an result which does not differ significantly (81% α-helix). This high 
helical content suggests that the bulk of the IVD domain is folded and α-helical 
in secondary structure. 
2.3.4 Structure of the IVD in the Context of Full-Length NEMO 
 Small-angle X-ray scattering (SAXS) has been used to reveal information 
about macromolecular structure and dynamics in solution. In SAXS, the raw x-
ray scattering data are radially averaged about the beam center, and then buffer-
subtracted to obtain the specific scattering intensity of the protein as a function of 
scattering angle. This information can be analyzed to reveal features of the 
protein structure, including generating a three-dimensional shape reconstruction 
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with a resolution on the order of 10- 50 Å147. The solution structure of full-length 
NEMO in complex with MBP-tagged herpesvirus FLICE inhibitory protein 
(vFLIP) has recently been determined by SAXS63. To probe the structure of 
unliganded full-length NEMO, we analyzed 5XAla-NEMO using SAXS. The 
scattering data are shown in Figure 9A as scattering intensity (I) against inverse 
scattering angle (q, Å-1). Although the Guinier plot (ln(I) versus q2, where I is the 
scattering intensity and q is a function of the scattering angle) for this data 
(Figure 9B) is not linear below q2 = 0.0006 Å-2, extended macromolecules are not 
expected to be linear in this region147. The key SAXS results for all constructs 
discussed in this dissertation are summarized in Table 3. 
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The initial scattering curve can be used to calculate a distance-distribution 
function P(r), a histogram of all possible pairwise atom distances. The form of the 
P(r) plot is characteristic of the three-dimensional shape of the molecule and the 
maximum x-value equal to the maximum dimension of the scattering particle147. 
The P(r) plot for 5XAla-NEMO is shown in Figure 9C. The scoring function of 
GNOM is similar to χ2 analysis124; a theoretical, extended model with a SAXS 
curve calculated by FoXS resulted in a χ2 value of 0.601; 5XAla-NEMO resulted 
 
Figure 9: 5XAla-NEMO SAXS analysis. A: scattering curve for 5XAla-NEMO (blue), with 
theoretical scattering (red) calculated from model shown in panel D. B: Guinier plot. 
Nonlinearity at low q is expected for a partially flexible, extended protein. C: Distance-
distribution function generated by GNOM. D: Shape reconstruction generated by DAMMIN 
(gray envelope) with superposed NEMO model (blue) generated by BUNCH. 
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in χ2 = 0.583. This plot indicates that full-length NEMO has a highly extended 
structure, with a maximum at short interatomic distances and a long tail 
extending to the maximum particle dimension, Dmax, of 315 Å. This is similar to 
the NEMO-MBP-vFLIP complex (320 Å) reported previously63. Fragments of 
NEMO encompassing residues 44-111 (IBD)28, 197-249 (HLX2)94, and 269-336 
(CC2-LZ; unpublished PDB ID 4BWN), have been crystallized and shown to be 
dimeric coiled coils (Figure 4). The structure of the ZF of NEMO (residues 391-
419) has been determined by NMR and adopts a fold typical of CCHC zinc 
fingers (PDB ID 2JVX)98, but is not resolved in our SAXS model. The three 
ordered segments that fit in our model sum to 186 residues, corresponding to 
~280 Å of extended α-helical structure. Therefore, our value of 315 Å indicates 
that the remaining 233 residues cannot all be in an extended coiled-coil 
conformation, and must be disordered or assume more tightly folded forms. It is 
possible, but unlikely, that the subdomains adopt a different conformation in the 
context of full-length NEMO. 
The SAXS data were further analyzed to allow ab initio structure 
modeling. Specifically, the software package DAMMIN125 was used to generate 
low resolution structures of each sample based on the P(r) data, modeling the 
protein by using dummy beads on a fixed lattice125. Ten models were generated, 
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averaged, and refined; prior to averaging, their average normalized spatial 
discrepancy is 0.58 ± 0.3. This unitless value reflects variability among DAMMIN 
models, with values < 1 indicating acceptable convergence on a final structure. 
The final highest scoring model was fit into a volume map using UCSF 
CHIMERA129 revealing the shape of the average volume in solution.  
The quality of the resulting model for 5XAla-NEMO was evaluated in 
three ways. First, FoXS was used to calculate a theoretical scattering curve from 
the final DAMMIN model127,128, demonstrating how well each model represents 
the original scattering data (Figure 9A). The quality of the fit of the 5XAla-NEMO 
model was assessed using FoXS to calculate χ. The value of χ = 0.6 indicates that 
the model fit well to the original experimental scattering data. As a further test of 
robustness, a NEMO model was generated using AllosMOD-FoXS127,128 (χ = 0.6), 
which calculates a model differently than DAMMIN. There is a high degree of 
similarity between the DAMMIN and AllosMOD-FoXS; Rg is 94 Å from the 
ATSAS suite, and 88 Å from AllosMOD-FoXS.  
The structural model for 5XAla-NEMO (Figure 9D), reveals an extended 
structure containing several kinks. Superposing the extended, coil-coil segments 
of the published X-ray crystal structures of the IBD, HLX2 and CC2-LZ 
fragments of NEMO were modeled together using BUNCH130. The results also 
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indicate that the C-terminal ZF domains of NEMO are not visible in the SAXS 
structure, suggesting that the ZF domains are not fixed in position relative to the 
remainder of NEMO. Similarly, N-terminal residues 1-43 are absent from the 
SAXS surface envelope, consistent with previous results indicating that this 
region is structurally disordered28,116. It is notable that this disordered region is 
well conserved among mammalian sequences of NEMO, but not in more 
evolutionarily distant species, suggesting a recently evolved function, perhaps 
related to phosphorylation events57. The small projection visible at the center of 
the extended structure likely reflects residual electron density resulting from a 
small fraction of dimer-dimer contacts involving this region of the molecule, as 
has been proposed79,104, but may also be an artifact from DAMMIN. The apparent 
compact, globular, nature of the residues between the IBD and HLX2 (i.e. the 
region containing the IVD) is notable given the extended nature of the individual 
NEMO X-ray crystal structures and previous lack of characterization of this 
region. Further evidence supporting the observation that this region is folded 
and compact include the circular dichroism experiments in Section 2.3.3. 
To probe the structure of NEMO(44-195) in solution, SAXS was employed 
as for 5XAla-NEMO (vide supra). The experimental scattering was overlaid with 
theoretical scattering from the shape reconstruction model (Figure 10A), showing 
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a reasonable fit with χ = 0.7. The Guinier plot (Figure 10B) indicates no 
significant aggregation, as it is linear up to q2 = 0.0006 Å-2. The P(r) function for 
NEMO(44-195) is shown in Figure 10C (χ2 = 0.507), and the shape reconstruction 
in Figure 10D. The notable consistency between the shape reconstruction of the 
fragment and that of FL-NEMO is shown by superposition in Figure 10E. This is 
direct evidence that the conformation and oligomerization state of the IBD plus 
IVD within FL-NEMO is to that of the shorter construct NEMO(44-195).  
Therefore, NEMO(44-195) is a good surrogate for FL-NEMO for probing NEMO 
functionality. 
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2.3.5 Structural Dynamics of NEMO in Response to IKKβ Binding 
To further probe the impact of the 9SG substitution, we analyzed the 
structural dynamics of 5XAla-NEMO and NEMO(44-195) versus 9SG-NEMO in 
response to IKKβ(701-745) binding. This IKKβ peptide, and all IKKβ peptides 
used throughout this thesis, contain a mutation of the only endogenous cysteine 
 
Figure 10: Solution structure of full length 5XAla-NEMO and NEMO(44-195). A: Scattering 
curves for 5XAla-NEMO and NEMO(44-195). Theoretical scattering for curve fits of models 
overlaid in red. B: Guinier plots. C: Distance-distribution functions generated by GNOM. D: 
Shape reconstruction for NEMO(44-195) generated by DAMMIN. E: Shape reconstruction 
for NEMO(44-195) in orange superposed on shape reconstruction for full length 5XAla-
NEMO (gray). 
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to an alanine to prevent disulfide-mediated aggregation. The scattering curves, 
Guinier plots, and P(r) plots for these conditions are shown in Figure 11A-C. 
Notably, the P(r) functions for both NEMO(44-195) (with IKKβ, χ2 = 0.843) and 
5XAla-NEMO (with IKKβ, χ2 = 0.580) indicate that, upon IKKβ binding, NEMO 
appears to fold in on itself. Specifically, Dmax for 5XAla-NEMO decreases from 
315 to 255 Å, and for NEMO(44-195) Dmax decreases from 138 to 93 Å. It is 
important to note why we have chosen to discuss Dmax here, as opposed to Rg. 
Because Dmax is the maximum distance present in the scattering mass, it will not 
change upon addition of a smaller peptide. On the other hand, Rg is the square 
root of the average squared distance of each scatterer to its center, so it would be 
expected to change with addition of a smaller species such as a peptide as that 
average distance shrinks147. These solution scattering results indicate that binding 
of IKKβ peptide causes NEMO to adopt a conformation that is more compact 
than that seen for unbound NEMO as demonstrated by a reduction in the length 
of the maximum distance vector in the scattering mass. Unlike the case for wild-
type IVD-containing NEMO constructs 5XAla-NEMO and NEMO(44-195), 9SG-
NEMO solution scattering is not consistent with a more compact form upon 
IKKβ binding as illustrated by the P(r) functions (χ2 = 0.529 and 0.620, 
respectively). In fact, 9SG-NEMO appears to elongate upon IKKβ binding, from 
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250 to 280 Å. This may be due to an overall rigidification of 9SG-NEMO upon 
IKKβ binding. Key SAXS results are summarized in Table 3. Taken together, 
these results suggest that the wild-type IVD sequence is required for ligand-
induced conformational change to occur in NEMO, and that this change is 
required for downstream signal-induced activation of IKKβ. 
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Figure 11: SAXS analysis of each NEMO construct with and without IKKβ(701-745). A: scattering 
curves with (red) and without (blue) IKKβ(701-745) in 10-fold molar excess. Error bars are SEM of 
three independent measurements. Protein concentrations were ~1.6 mg/mL and ~0.8 mg/mL for 
each component in 20 mM sodium phosphate, 500 mM NaCl, pH 7.4. Data are merged scattering 
intensities from the two concentrations after data quality confirmation in PRIMUS. B: Guinier plots 
calculated from squaring x-axis in scattering curves in panel A. Data range from scattering plots in 
panel A used to generate Guinier plots (in Å-1): 44-195, 0.015-0.325; 44-195 with IKKβ(701-745), 
0.012-0.3128; 5xAla, 0.008-0.26; 5xAla with IKKβ(701-745), 0.013-0.56; 9SG, 0.011-0.79; 9SG with 
IKKβ(701-745), 0.009-0.255. C: Normalized distance-distribution functions generated by GNOM 
calculated from scattering curves in panel A, where x-intercept indicates maximum dimension of 
the scattering mass (Dmax). 
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To corroborate these findings, we performed analytical ultracentrifugation 
(AUC). AUC works on the principle that proteins sediment along a centrifuge 
cell ultimately according to their size and shape131. Sedimentation velocity 
experiments were performed with NEMO(44-195) in the presence and absence of 
IKKβ(701-745). Results can be shown by a distribution function, G(s), versus 
sedimentation coefficient (s) plot. It is therefore related directly to the 
distribution of macromolecules as a function of signal intensity131. This plot for 
Table 3: Summary of key SAXS parameters. 
Protein Rg (Å)a Dmax  (Å)a 
Max Dmax 
(Å)b 
Data Range 
(Å-1) 
GNOM 
χ2 c 
Model χ 
valued 
DAMMIN 
Models NSDe 
44-195 38.8 ± 1.8 138 226.5 0.015 – 0.325 0.507 0.6 0.55 ± 0.2 
44-195 plus 
IKKβ 
31.6 ± 
0.33 
100 226.5 
0.012 – 
0.3128 
0.843 n.d. N/A 
5xAla 94.2 ± 1.5 315 628.5 0.008 – 0.26 0.583 0.3 0.58 ± 0.3 
5xAla plus 
IKKβ 
79.6 ± 9.0 255 628.5 0.013 – 0.56 0.580 n.d. N/A 
9SG 
77.4 ± 
17.6 
250 628.5 0.011 – 0.79 0.529 n.d. N/A 
9SG plus 
IKKβ 
89.9 ± 
10.5 
280 628.5 0.009 – 0.255 0.620 n.d. N/A 
Theoretical 
Extended 
76.2 270 270 0.000 – 0.499 0.601 n.d. N/A 
Theoretical 
Bent 
46.7 129 270 0.000 – 0.499 0.754 n.d. N/A 
aRg and Dmax values calculated by GNOM. Standard deviation for Dmax not reported because it is 
a user input; Dmax is best fit by optimizing GNOM χ2. bMax Dmax refers to the maximum possible 
dimension if the same number of residues adopted a purely extended α-helix (1.5 Å x n 
residues). cGNOM χ2 refers to scoring function from P(r) calculation; above 0.5 is reasonable. 
dModel χ-value calculated by FoXS. eNSD (unitless) is normalized spatial discrepancy average ± 
standard deviation for each DAMMIN model during averaging; n.d. not determined; N/A not 
applicable.  
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unliganded NEMO(44-195) shows two peaks, corresponding to two different 
species in solution, likely monomer and dimer (Figure 12). Note the presence of 
2.5 mM TCEP may be sufficient for some measurable fraction of NEMO to be 
reduced and monomeric. The plot for NEMO(44-195) in the presence of 10-fold 
molar excess of IKKβ(701-745), on the other hand, displays a single peak that is 
right-shifted, indicating an increase in mass (Figure 12). Peaks correspond to s = 
1.1 and 1.7 for NEMO(44-195), and s = 2.2 for NEMO(44-195) in complex with 
IKKβ(701-745). The data are not of sufficient quality to draw more meaningful 
conclusions, but we can conclude the basic facts that the presence of IKKβ 
induces a homogenous population in solution, where each particle is larger by 
mass than any particle in the unliganded sample. Further analysis is required 
with 7XAla-NEMO and NEMO(44-111) to establish the direct relationship 
between the IVD and IKKβ-induced hydrodynamic changes. 
 Sedimentation equilibrium experiments were also performed with 
NEMO(44-195) in the presence and absence of IKKβ(701-745). However, unlike 
SV experiments, protein aggregation was sufficient to prevent processing of the 
SE data. Future attempts at running SE experiments will require optimization of 
sample prep. Fresh protein, purified within one week of experimentation, may 
be required. 
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2.3.6 Crystallography of NEMO(44-195) 
Attempts to crystallize NEMO were based on success with NEMO(44-111) 
construct28 and previous positive results from Dr. Andrew Lynch. Briefly, 
crystallization conditions were optimized to co-crystallization with equimolar 
NBD peptide, 0.1 M HEPES pH 7.5 and 17-22% PEG-3350, following three 
rounds of microseeding using quasi-crystals. Additional attempts to refine 
crystallization conditions for the NEMO(44-195) construct included use of the 
Silver Bullet additive screen (Hampton), finer grid screening, seeding in dioxane 
to poison new nucleation, and replacing the NBD peptide with a longer 45mer 
 
Figure 12: IKKβ promotes NEMO hydrodynamic changes. This preliminary data screenshot 
from SedAnal showing G(s) versus s indicates a clear difference in the hydrodynamic 
behavior of NEMO(44-195) before (left) versus after (right) addition of IKKβ(701-745). Further 
analysis is required with 7XAla-NEMO and NEMO(44-111) to establish the direct relationship 
between the IVD and IKKβ-induced hydrodynamic changes. G(s) is distribution of s values. 
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peptide, IKKβ(701-745), to attempt to increase rigidity. None of these additional 
attempts produced crystals. 
One crystal, shown in Figure 13A, diffracted, and its diffraction pattern is 
shown in Figure 13B. Basic structure solution was attempted as described in 
section 2.2.8 above. Data were collected to 2.11Å, and the unit cell was observed 
with the following dimensions: a=41.659Å, b=40.059Å, c=58.01Å, α=90°, 
β=98.446°, γ=90°. Additionally, attempts to solve the structure were performed 
using the CCP4 suite, specifically the SHELXC/D/E pipeline. Output from these 
programs yielded some contiguous electron density, but attempts to build 
protein models within the density consistently failed as before in Phenix. 
 
 
Figure 13: Crystallography of NEMO(44-195). A: Crystal that diffracted to 2.11 Å grown in 0.1 
M HEPES pH 7.5 and 20% PEG-3350 after three rounds of microseeding. B: Resulting 
diffraction pattern. 
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To attempt to manually add information to aid structure solution, 
molecular replacement and manual model building were attempted. For 
molecular replacement, Phaser-MR148 was used with various model inputs: PDB 
3BRV, 3BRV modified to truncate IKKβ to NBD peptide, 3BRV with truncated 
IKKβ with symmetry data trimmed from the file, 3BRV with truncated IKKβ 
with symmetry mates generated by Coot149, and 3BRV with truncated IKKβ 
docked into best electron density map from AutoSol using Coot. When molecular 
replacement would not generate a reasonable model, sulfur sites from the 
molecular replacement solutions were used as heavy atom sites for selenium in 
subsequent AutoSol runs for phasing attempts. These were unsuccessful as well. 
Manual model building was attempted using Coot in two different ways. 
First, results from AutoBuild that were poor solutions were altered with 1) 
correct amino acid side chains based on heavy atom sites assuming there are 
selenomethionine residues, and 2) rotamer selection and fitting to best occupy 
the electron density. Subsequent refinement in AutoBuild using these models 
never generated results with R free better than 0.5. The second model building 
procedure involved using Coot to generate de novo an extended alpha-helix of the 
N-terminus of the IVD (LKRAQQQMAEDKASV) to be used in addition to 
modified 3BRV described above. This procedure also failed to generate models 
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with R free better than 0.5. 
 
2.4 Conclusions and Future Directions 
Scaffold proteins have been shown to employ a small variety of strategies 
to perform their function; however, the underlying molecular mechanisms by 
which these functions are accomplished are unknown. Herein, we have shown 
that the central IVD region of NEMO is highly conserved, has a defined 
structure, confers thermal stability, and is required for IKKβ-induced 
conformational change to occur. We hypothesize that the IVD is highly 
conserved because it plays a role in conformational change that is required for 
downstream signaling to NF-κB. This would indicate that NEMO is an 
allosterically regulated scaffold protein. The functional importance of this region 
is further explored in Chapter 3. Of note, the last residue of the targeted region in 
the 9SG variant (i.e., L153) is the site of an EDA-ID-associated mutant (L153R), 
which is defective for NF-κB signaling141. This hypothesis is further tested in the 
following chapter of this dissertation. 
In addition to L153R, there are several disease-associated mutations 
within this highly conserved region, between residues 110-195. D113N, R123W, 
L170P, R173G, R182P and Q183H are associated with IP, Q157P with anhidrotic 
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ectodermal dysplasia with immunodeficiency, osteopetrosis, and lymphedema 
(OL-EDA-ID), and A169P and R175P with EDA-ID82. From this information, it is 
interesting that the more highly conserved central segment of the IVD appears to 
play a role in EDA-ID, whereas the periphery of this domain is associated with IP 
(Table 2).  
The 9SG substitution in the IVD impacts thermal stability. Despite the 
lower thermal stability in the 9SG variant, the IVD is structured, given that the 
9SG and 7XAla NEMO variants both have 65% α-helix, as measured by TFE 
experiments using CD. The 9SG substitution therefore does not disrupt the 
overall fold of NEMO. It is notable that NEMO(44-195) has a higher percent α-
helix than FL-NEMO at 82%; this is likely due to substantially disordered regions 
of NEMO, including the first 43 residues and perhaps residues 336-38728,95. With 
higher quality data, Kratky plots from SAXS data may be useful to further probe 
the folded-ness of each of these NEMO constructs in solution. Additionally, AUC 
experiments would be ideal to corroborate SAXS findings, especially with respect 
to molecular shape. 
A recent study106 demonstrated, by both intrinsic tryptophan fluorescence 
and ANS fluorescence in the presence of either the IKKβ(735-745) NBD peptide 
or a 13mer peptide of IκBα, that NEMO undergoes a ligand-induced 
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conformational change. Importantly, this established that NEMO alters its 
structure once bound to its canonical NF-κB signaling binding partners. In view 
of our SAXS data on molecular dimensions and previous evidence of 
conformational change, we favor a model where the IVD is required for a 
conformational change in NEMO that is necessary for directed phosphorylation 
of IκBα by IKKβ. We propose that other scaffold proteins may function similarly, 
and a similar approach to the one taken herein may be useful to determine their 
major regulatory regions. The study of undruggable targets may benefit from 
this approach, in identifying regions that may be targeted with small molecules 
to modulate function by impacting the target’s ability to undergo an essential 
conformational change. SAXS is a powerful tool to probe these ligand-induced 
conformational changes. A high-throughput application of SAXS would be 
useful in identifying potential therapeutics that alter either apo- or liganded-
conformational states of a target protein. Scaffold proteins are a specific class that 
would benefit most directly from this approach, as functional assays are more 
difficult to develop due to the lack of intrinsic catalytic activity. 
We have attempted to crystallize NEMO(44-195) in complex with 
IKKβ(701-745). Previously, the structure of NEMO(44-111) was solved28, leaving 
the IVD structurally uncharacterized. Despite obtaining high resolution (2.21 Å) 
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data sets for a selenomethionine-incorporated version of NEMO(44-195), with 
phase figure of merit of 0.481, we were unable to solve the structure. This may be 
due to the difficulty placing α-helices along long, tube-like electron density; 
rotation and translation functions likely cannot distinguish productive from 
nonproductive helix placement. To attempt to address this, an I71M variant of 
NEMO(44-195) was cloned and used to increase the phasing power by 
incorporation of an additional methionine. Unfortunately, diffracting crystals 
were not produced from the variant. Future experiments include additional 
crystallization conditions for this variant to obtain diffracting crystals, co-
crystallization with IKKβ(701-745) for increased rigidity, and optimization of 
cryo-protection conditions, as the introduced mutation may have altered the 
requirements for stable freezing, resulting in a loss of diffraction. 
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Chapter 3: The Intervening Domain is Required for NEMO Function in 
Canonical NF-κB Signaling 
3.1 Introduction 
NEMO function has been extensively studied: protein binding interactions 
have been mapped, individual domains have been crystallized, a number of 
disease-associated mutations have been annotated, and its oligomerization state 
has been debated28,42,58,69,82,94,96,98,104,107,108,114,115. Additions to this endeavor are 
described above in Chapter 2. However, beyond rigid-protein binding28,58, the 
mechanism of action of NEMO is poorly understood. In the previous chapter, the 
structural, thermal stability, and dynamical contributions of the IVD to NEMO 
overall were described. Given this dynamic nature, it is unlikely that NEMO only 
serves as a rigid docking site for protein binding. In this chapter, the functional 
attributes of the IVD will be explored, to determine a link between biophysical 
traits and biologically relevant functionality. 
To probe IVD function, WT-NEMO activity is compared to that of 9SG-
NEMO, where the central site of highest conservation in the IVD has been 
mutated to serines and glycines. Given the lack of ability to undergo IKKβ-
induced conformational change as determined by SAXS, we expect the 9SG 
mutant to be less capable of propagating NF-κB signaling. This idea is not 
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unprecedented: it has been shown that mutations outside of binding sites can 
affect function. In one example, two mutant versions of mouse transcription 
factor c-Rel were generated: R266H and SPW (insertion of proline and 
tryptophan between aa 266 and 267). These mutations occur outside of the dimer 
interface, yet prevent dimerization and thus efficient transcriptional activity from 
occurring110. In another example, the most common mutation (A149P) in aldolase 
B associated with hereditary fructose intolerance (HFI) was generated in 
recombinantly expressed protein. The crystal structure was solved, and it was 
determined that the proline substitution disrupts quaternary structure and 
thermal stability. Interestingly, this disruption is propagated to a loop region 
comprising residues 110-129, which is the subunit-subunit interface, and explains 
the loss of quaternary structure and enzymatic activity resulting in HFI111.  
NEMO(1-120) is a fragment of NEMO containing the disordered N-
terminal tail and the entire IKKβ-binding site, yet binds to IKKβ with an affinity 
approximately 10-fold lower than full-length NEMO116. Therefore, there must 
exist some allosteric contribution from another domain of NEMO. This might be 
accomplished by either of two mechanisms: pre-ordering, where the entropic 
cost of the formation of the final protein-protein complex is lowered by 
rigidification of the binding site; or by additional physical interactions, where 
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another part of NEMO folds around or onto the IKKβ protein to make additional 
contacts, increasing affinity. The rod-like, extended nature of all existing crystal 
structures of NEMO domains and the crystal structure of NEMO(44-111) in 
complex with IKKβ(701-745) suggest that additional NEMO contacts to IKKβ 
would be limited at best due to the "seal" of residues around the hydrophobic 
binding interface28. It is therefore more likely that the IVD allosterically regulates 
NEMO by pre-ordering rather than additional physical interactions with IKKβ. 
Another part of NEMO likely pre-orders the IKKβ binding site for a lower 
entropic cost upon binding. This hypothesis is also supported by the 
contributions of the IVD to thermal stability and conformational rigidity 
described above in Chapter 2. A recent paper introduces the hypothesis that 
additional physical interactions drive negative regulation63. The CC1 of NEMO 
(residues 120-150) is postulated to interact with the UBAN domain to block the 
ability of NEMO to adopt an active conformation, until poly-ubiquitin (at least 
Ub4) disrupts the CC1-UBAN interaction, opening up NEMO. The plausibility of 
this model is discussed later in this chapter. 
In this chapter, the development of a NEMO-IκBα FA assay is described 
to establish the first quantitative analysis of this interaction. The zinc 
requirement and kinetics of the interaction are also described. Using a peptide 
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similar to that in the FA assay as a substrate, an in vitro assay to measure the 
contribution of NEMO to IKK activity will be discussed. This assay is also used 
to explore the effect of linear tetra-ubiquitin on NEMO-mediated IKK activity, 
which has been postulated to be required for activation of NEMO63. The IVD is 
the most logical domain to investigate for allosteric control due to the findings in 
Chapter 2, especially the high level of sequence conservation that must be due to 
evolutionarily important function. Simply put, the IVD confers pre-ordering, 
stability, and contributes to the conformational dynamics of NEMO, so it likely 
plays a key role in the function of the protein. To this end, this chapter also 
explores the contribution of the IVD in NEMO binding to IKKβ by use of a FA 
assay developed previously103. To relate all of the above findings to a biologically 
relevant context, cellular studies conducted by the Gilmore group at Boston 
University are also described. Specifically, the ability of 9SG-NEMO and L153R-
NEMO to propagate NF-κB signaling and co-immunoprecipitate IKKβ and IκBα 
are tested. One way NEMO may signal is in trans, where a head-to-tail dimer 
brings the terminally-bound ligands into close proximity, negating the 
requirement for a conformational change in function. This hypothesis was tested 
and is described using co-transfected ΔN and ΔC truncated versions of NEMO.  
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3.2 Materials and Methods 
3.2.1 Materials 
All NEMO constructs used in this chapter were generated and prepared 
as described in Sections 2.2.2 and 2.2.3. NEMO cDNAs used in mammalian cell-
based experiments were cloned identically, except into mammalian vectors 
pBABE and/or pcDNA-FLAG, and are described below. FITC-IKKβ(701-
PAKKSEELVAEAHNLCTLLENAIQDTVREQDSFTALDWSWLQTE-745), 
unlabeled IKKβ(701-745), FITC-IκBα(20-LKKERLLDDRHDSGLDSMKDEEY-42), 
and unlabeled IκBα(20-42) were purchased from Genscript (Piscataway, NJ). The 
IKKβ sequence has been highly characterized in terms of its structure and 
interactions with NEMO28,102,103,108,150, and the IκBα sequences is based on the site 
shown to interact with NEMO58,106. Each FITC conjugation was at the N-terminus 
of the peptide via a flexible aminohexanoic acid moiety. Unlabeled peptides 
contain an N-terminal acetylation and a C-terminal amidation. The Sox-based151 
kinase assay described herein was developed by AssayQuant (Marlborough, 
MA), and reagents specific to that assay were graciously provided by the 
company.  
GST-tagged IκBα(1-55) was provided by the Gilmore group at Boston 
University. Transformed BL21 DE3 cells were grown in LB broth shaking at 250 
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rpm at 37 °C overnight, to seed a new expression culture at a 1:200 dilution with 
ampicillin antibiotic selection. This new culture was grown until OD600 reached 
between 0.4 and 0.6. Protein expression was induced by 1 mM IPTG and 
incubated at 37 °C for 4 more hours. Cells were pelleted by centrifugation and 
stored at -20 °C. The pellets were lysed by microfluidizer, and incubated with 0.1 
μL/mL Universal Nuclease (Pierce) and 10 μL/mL Halt Protease Inhibitor 
Cocktail (Thermo) for 20 m. 8 M urea was then added to the lysate to prevent 
chaperones and other contaminating proteins from co-purifying with the protein, 
and incubated for 1 h. The lysate was then clarified by ultracentrifugation at 
38,000 rpm for 30 m, sonicated to shear any remaining large DNA fragments, and 
filtered through a 0.8 μm filter. This lysate was then incubated with GST resin 
overnight at 4 °C. The resin-lysate solution was then centrifuged to collect non-
bound flow-through, washed twice with 20 mM sodium phosphate, 500 mM 
NaCl, pH 7.4 buffer, and GST-tagged IκBα(1-55) was eluted with 20 mM sodium 
phosphate, 500 mM NaCl, 10 mM reduced glutathione at pH 7.4 following a 30 m 
incubation. 
3.2.2 Fluorescence Anisotropy Binding Studies 
The NEMO-IKKβ FA assay used herein has been described previously103; 
the NEMO-IκBα FA assay is based on that protocol. Briefly, assays were run in 
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black 96-well polypropylene plates with a total assay volume of 200 μL. The 
assay buffer contained 50 mM Tris, 200 mM NaCl, and 0.01% Triton X-100, at pH 
7.4. Assays with FITC-IκBα included 1 mM ZnCl2 and no DTT, unless otherwise 
indicated. NEMO concentrations were varied from 10 pM to 1 μM while keeping 
FITC-IKKβ(701-745) peptide or FITC-IκBα(20-42) peptide (tracer probe) constant 
at 15 nM. Plates were incubated at 25 °C for 1 h prior to reading for FITC-IKKβ 
experiments, or 15 m for FITC-IκBα experiments. Fluorescence anisotropy was 
read using a SpectraMax M5 plate reader using λ = 488/520 ex/em and 100 reads 
per well. Anisotropy was calculated as described previously according to 
Equation 2 below, where r is anisotropy and I is the measured intensity in either 
the parallel (∥) or perpendicular directions (⊥)103.  
𝑟 = 1000 ∗ ( ூ∥ିூ఼
ூ∥ାଶூ఼
)    (2) 
Briefly, raw anisotropy was calculated using the SpectraMax plate reader 
software and multiplied by 1000 as in Equation 2. These values were then 
exported to Microsoft Excel for averaging and calculation of standard deviation. 
These results were then plotted and fitted to a relevant binding equation in 
GraphPad Prism. Data were either plotted as averages ± standard deviation with 
no background subtraction or were normalized to high (NEMO + tracer probe) or 
low (tracer probe alone) controls. 
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3.2.3 Dynamic Light Scattering 
Size distribution experiments using dynamic light scattering were 
performed with a DynaPro NanoStar DLS instrument (Wyatt Technology 
Corporation, Santa Barbara, CA, US) in the presence of 15 nM FITC-IκBα, 10 mM 
Tris, 500 mM NaCl, 5 mM DTT, at pH 7.4. Exogenous addition of metal ion (Mg2+ 
or Zn2+) was accomplished by additional inclusion of buffer containing 50 mM 
Tris, 200 mM NaCl, and 0.02% Triton X-100 at pH 7.4 containing metal and 
concentration as indicated in Section 3.2.2. Tris was included in the buffer as a 
weak zinc chelator to improve its solubility at such high concentrations. DTT was 
included to minimize disulfide-mediated protein aggregation. The presence of 
both Tris and DTT likely lowered the free zinc concentration available to NEMO, 
but did not prevent a zinc-specific effect from being observed. Final volumes 
were 10 μL. Measurements were taken with a 100 mW He-Ne laser with λ = 633 
nm at a scattering angle of Θ = 90° at ambient room temperature in a 
microcuvette. For data analysis, particle type was assumed to be globular (as 
opposed to a type of large polymer), and 10 acquisitions were collected and 
averaged for final scattering determination. 
3.2.4 Surface Plasmon Resonance Binding Studies 
7xAla NEMO was immobilized on a GLH sensor chip in a Bio-Rad 
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ProteOn XPR36 SPR system (Hercules, CA) using either amine coupling 
(resulting in 12,880 RU) or thiol coupling (6,600 RU) as indicated. Amine 
coupling was accomplished through N-hydroxysuccinimide 
ethyl(dimethylaminopropyl) carbodiimide (NHS-EDC) chemistry, where an EDC 
cross-linker forms an amine-reactive sulfo-NHS ester on the chip. The primary 
amine (from lysine) can then attack the original carbonyl from the chip to form 
an amide bond. Thiol coupling was accomplished using NHS-EDC reagents also, 
but with subsequent addition of 2-(pyridinyldithio)ethane amine (PDEA) prior to 
protein addition. PDEA generates a disulfide bonded leaving group, which once 
dissociated allows protein to come in and link through a free cysteine. Blocking 
was performed with water for amine-coupled lanes, and L-cysteine for thiol-
coupled lanes. Binding to FITC-IκBα(20-42) or GST-tagged IκBα(1-55) was 
performed twice: once in 50 mM Tris, 200 mM NaCl, 0.01% Triton X-100, pH 7.4 
buffer, and again in the same buffer but with 1 mM ZnCl2. 200 nM each IκBα 
protein was serially diluted 2-fold for a concentration series. The flow rate was 50 
μL/min, contact time 120 s, and dissociation time 300 s. Sensor data were 
processed using the Bio-Rad ProteOn Manager software and plotted in 
GraphPad Prism. 
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3.2.5 Microscale Thermophoresis 
To determine the affinity of NEMO binding to zinc by MST, all 
measurements were performed on a NanoTemper Monolith NT.115 instrument 
(Munich, Germany) according to previously published protocols152. 7xAla NEMO 
was kept unlabeled at 500 μM, and therefore heat-induced diffusion was 
monitored by absorbance at 280 nm. ZnCl2 was serially diluted 2-fold from an 
initial concentration of 1 mM. Data were processed using the NanoTemper 
Software, and plotted and fit to a quadratic binding equation in GraphPad Prism. 
3.2.6 Atomic Emission Spectroscopy 
To determine the metal content of NEMO (i.e., what metal is bound and in 
what concentration relative to protein), all measurements were performed on an 
Agilent 4200 MP-AES instrument with an SPS 4 Autosampler (Santa Clara, 
California, US). ZnAc and/or NiCl2 standards were prepared at 5, 10, and 15 μM 
concentrations. NEMO samples were either desalted or not, and diluted to 5 μM 
in dH2O. The system was equilibrated with nitrogen gas prior to and during data 
collection. Autosampler uptake time was set to 75 s, and stabilization time set to 
10 s. Zinc concentration was measured at 213.857 nm, and nickel concentration 
was measured at 352.454 nm, both by averaging three readings and subtracting 
averaged background reading from water-only blank. Data were processed using 
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the Agilent software, and a linear fit of the standard data was performed with 
GraphPad Prism to interpret sample concentration. 
3.2.7 Development of an in vitro Assay to Measure IKKβ Phosphorylation of IκBα 
An assay to determine Michaelis-Menton parameters for IKK complex 
function, and effect of mutation of NEMO thereof, was developed by Assay 
Quant Technologies Inc. (Marlborough, MA, US) and is based on Sox peptide 
phosphorylation detection151. Reactions include 50 mM HEPES pH 7.5, 1 mM 
ATP, 1 mM DTT, 0.01% Brij-35, 1% glycerol, 0.2 mg/mL BSA, 0.5 mM EGTA, 10 
mM MgCl2, 10 μM IκB-based Sox substrate (AQT0220, Assay Quant 
Technologies), 5 nM or varied full-length IKKβ, 100 nM or varied NEMO, and 30 
μM or varied zinc. To allow sufficient equilibration time for NEMO to bind 
IKKβ, all assay components including NEMO and IKKβ were incubated for 10 m 
at 30 °C prior to addition of ATP to begin the reaction. Note the NEMO-IKKβ FA 
assay equilibrates for 1 h, which implies a t1/2 of at most 3.75 m. Reactions are run 
at 30 °C for 120 m, with ex/em 360/485 nm readings taken every 2 m in Corning 
half-area 96-well, white flat-bottom polystyrene NBS microplates (Corning, NY). 
Background signal from IKKβ(-) wells is subtracted from IKKβ(+) wells.  
3.2.8 Design and Cloning of IVD Constructs for Mammalian Expression 
WT NEMO, 5xAla, 7xAla, and R123W were previously prepared for 
 
 
 
 
79 
 
mammalian expression by the Gilmore group103,153,154. 9SG and L153R NEMO 
were cloned into both pBABE-7xAla and pcDNA-FLAG-7xAla vectors by Q5 
Mutagenesis Kit (New England Biolabs, Ipswich, MA) or standard QuickChange 
mutagenesis, respectively. Primers used in this regard are listed in Appendix I. 
The decision for use of these constructs is explained above in section 2.2.2.  
3.2.9 In Cellulo Characterization of Disease-Associated Mutations within the IVD 
The following procedure was performed by Professor Thomas Gilmore 
and members of his lab; it is briefly described here for convenience. NEMO-
deficient mouse fibroblasts (NIH3T3), 293 cells and NEMO-deficient 293T cells 
were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Fisher, 
Waltham, MA) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS) (Biologos, Montgomery, IL) as described previously103,153,154. NEMO-
deficient 293T-cells were generated by CRISPR/Cas9 disruption of a short 
sequence in the 5’-UTR of the NEMO gene. The creation of pcDNA-FLAG and 
pBABE-puro vectors for the expression of WT NEMO and 7XAlaNEMO have 
been described previously103,153. The 9SG mutation in NEMO was created using 
the NEB Q5 Site-Directed Mutagenesis Kit (New England Biolabs). The pDNA-
FLAG and pBABE vectors for the 9SG mutant were created by standard 
recombinant DNA techniques. Transfections of 293 cells and retroviral 
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transduction of mouse NEMO knockout cells were performed as described 
previously103. Virally transduced NEMO-knockout fibroblasts were selected 
using 2.5 μg/mL puromycin (Sigma, St. Louis, MO) for approximately 1−2 
weeks110. 
Western blotting was performed as described previously153. For analyzing 
phosphorylation of IκBα, cells were first treated with 20 ng/mL TNFα (R&D 
Systems, Minneapolis, MN) for 10 m, 2 ng/mL of IL-1 for 6 m, or 100 ng/mL of 
LPS for 12 m.  Cells were then lysed directly in 2X SDS sample buffer. In all 
cases, samples containing approximately equal amounts of protein were 
separated on SDS−polyacrylamide gels, proteins were transferred to 
nitrocellulose membranes, and filters were incubated overnight at 4 °C with anti-
NEMO antiserum (catalog no. 2685, Cell Signaling Technology, Danvers, MA; 
1:1000 dilution) or anti-phospho-IκBα (catalog no. 9246, Cell Signaling 
Technology; 1:1000 dilution). Horseradish peroxidase-labeled secondary 
antiserum was added, and immunoreactive proteins were detected by 
Supersignal Dura West chemiluminescence (Thermo Scientific). For co-
immunoprecipitation experiments, transfected 293 cells in subconfluent 100-mm 
tissue culture dishes were lysed in 500 μL of AT buffer [20 mM HEPES (pH 7.9), 
1 mM EDTA, 1 mM EGTA, 20 mM Na4P2O7, 1 mM DTT, 1% (v/v) Triton X-100, 
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20% (w/v) glycerol, 1 mM Na3VO4, 1 μg/mL PMSF, 1 μg/mL leupeptin, and 1 
μg/mL pepstatin]. An aliquot (20 μL) was saved as the input sample. To the 
remainder of the lysate was added 30 μL of anti-FLAG agarose beads (Sigma cat 
#A2220; Sigma, St. Louis, MO), and samples were incubated overnight with 
rocking at 4 °C. The beads were washed several times with AT buffer, and then 
bound proteins were removed by heating the samples at 90 °C in SDS sample 
buffer containing β-mercaptoethanol. Samples (input or immunoprecipitates) 
were then analyzed by reducing SDS−PAGE followed by Western bloĴing with 
the anti-IKKβ antibody (sc-7607, Santa Cruz Biotechnology), anti-NEMO 
antiserum (catalog no. 2685, Cell Signaling Technology), or anti-FLAG antiserum 
(Cell Signaling Technology car #2368; Cell Signaling Technology, Danvers, MA) 
as described previously103. 
 
3.3 Results and Discussion 
3.3.1 Development of a NEMO-IκBα Fluorescence Anisotropy Assay 
An FA assay was developed to measure the binding affinity of the NEMO-
IκBα interaction. This interaction has been qualitatively demonstrated in vitro to 
require the ZF of NEMO by gel filtration chromatography58 and by inducing 
change in ANS binding to NEMO106. Therefore, the exact binding affinity, zinc 
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requirements, and kinetics remain unknown. The assay was designed based on 
the FA assay for measuring NEMO-IKKβ binding, developed previously103. The 
fluorescein moiety for fluorescence detection was used due to its fluorescence 
lifetime of 4 ns, near the ideal 10 ns calculated previously for the NEMO-IKKβ 
interaction155. The region of IκBα that was selected encompasses residues 20-42. 
This selection is based on the IκB responsive region highlighted by Schröfelbauer 
and colleagues (2012)58 plus additional residues C-terminal to S36 including Y42 
for quantitation purposes using UV spectroscopy. Of note, the IκB responsive 
region contains two Asp residues that are important for co-immunorecipitation 
with NEMO, as compared to a construct with substitution of the aspartates for 
argininies. 
Holding FITC-IκBα constant at 15 nM, 5XAla-NEMO was titrated from 10 
μM down to 0.78 nM in the presence of 1 mM ZnCl2 and equilibrated for 15 m. 
Zinc was included because 1) preliminary experiments showed no measurable 
binding in the absence of zinc (for example, see results from inclusion of EDTA 
in Figure 14), 2) it has previously been shown that the ZF is required for 
interaction with IκBα, and 3) it was unknown whether the ZF was occupied with 
zinc. It was observed that the signal remains constant over the first 15 m. The 
kinetics are further explored below in Section 3.3.2. The data were fit to the 
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quadratic binding equation and the apparent binding affinity was measured to 
be 2.0 μM (1.5 and 2.5 μM, n = 2). A control experiment with no Zn2+ and 100 μM 
EDTA showed that no binding is measured in the absence of zinc. The results 
from both experiments are shown in Figure 14. To determine if the interaction 
between NEMO-Zn and FITC-IκBα(20-42) had reached equilibrium after 15 m, 
the binding was measured after assay incubation for times of 1, 5, 15, 30, or 60 m. 
The data remained unchanged over the first 15 m after reading, indicating that 
the complex reaches equilibrium rather quickly. Notably, the signal appears to 
degrade at high [NEMO] after 15 m; this is likely due to NEMO instability in 
such high concentrations of zinc, as such signal decreases are not seen in 
experiments without added zinc. A binding curve measured after 15, 30, and 60 
m is shown in Figure 15. 
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Figure 14: Fluorescence anisotropy binding assay to determine affinity of NEMO binding to 
FITC-IκBα, either with 1 mM Zn2+ (blue) or 100 μM EDTA (red). Error bars are standard 
deviation of three technical replicates. The dashed horizontal lines indicate IκBα controls in 
either zinc or EDTA. The solid line is the best fit of the data to a quadratic binding equation, 
showing that NEMO binds FITC-IκBα with an apparent affinity of 2 μM in the presence of 1 
mM zinc. In the presence of 100 μM EDTA, no binding was observed. 
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An unlabeled IκBα(20-42) peptide was used as a positive control 
competitive inhibitor of the interaction of NEMO-Zn with FITC-IκBα(20-42) 
(Figure 16). The primary motivation for this assay was to 1) determine the 
affinity of the IκBα-derived peptide without a fluorescein label, and 2) ensure 
that the increase in anisotropy signal from NEMO titration is due to specific 
binding, and is not nonspecific or otherwise artefactual. Holding FITC-IκBα 
constant at 15 nM and NEMO constant at 500 nM, the unlabeled peptide was 
 
Figure 15: NEMO-IκBα binding curve measured after 15 (blue), 30 (red), or 60 minutes 
(green) in the presence of 1 mM zinc. Signal degrades at high NEMO concentration after 15 
minutes. Error bars are standard deviation of three technical replicates. The dashed 
horizontal line indicates the IκBα alone control. The solid line is the fit of the data to a 
quadratic binding equation. 
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titrated from 250 μM in the presence of 1 or 10 mM ZnCl2 and equilibrated for 15 
m. An inhibition curve was observed, indicating that the unlabeled peptide was 
able to compete off the FITC-labeled peptide. IC50 values were determined to be 
33.7 ± 5.6 μM (n = 2) for the 1 mM zinc condition, and 45.5 μM for the 10 mM zinc 
condition. Because the IC50 values are materially similar for the two zinc 
conditions, they were averaged for determination of the binding affinity of the 
unlabeled peptide. The Cheng-Prusoff relationship allows for this calculation, 
when the labeled peptide is in competition with a titrated and otherwise 
identical unlabeled species. The apparent binding constant of the unlabeled 
IκBα(20-42) peptide was thus determined to be 50 ± 40 μM (n = 3). This affinity is 
an order of magnitude above that of the labeled peptide. There are two potential 
explanations for the large difference. The unlabeled peptide has an additional 
tryptophan at the N-terminus for quantification purposes, and the labeled 
peptide has a large fluorescein moiety; it is possible that one or both have a 
detrimental effect on binding affinity, and explains this order of magnitude 
difference. 
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A previous study reported a significant effect of polyubiquitin on the rate 
of ligand-induced conformational change in NEMO. To determine whether 
linear di-ubiquitin, previously shown to bind directly to NEMO with an affinity 
in the low single-digit μM range83, affects the binding affinity of NEMO for IκBα, 
linear di-ubiquitin was titrated in the FA assay from 1 μM down to 7.8 nM. 1 μM 
was the highest concentration possible given the stock from Enzo Life Sciences, 
which is equivalent to the affinity of NEMO for linear di-ubiquitin83. No 
 
Figure 16: Unlabeled IκBα competition assay. FITC-IκBα at 15 nM was competed off 500 nM 
NEMO by an unlabeled version of the peptide in the indicated concentration of zinc acetate. 
Error bars are standard error of the mean of two technical replicates. Anisotropy was 
normalized to high (NEMO + FITC-IκBα) and low (IκBα alone) controls. The solid line is the 
best fit of the data to the four-parameter inhibition equation. 
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measurable effect on the assay was observed. Therefore, at these concentrations 
the presence of linear di-ubiquitin likely does not impact the binding affinity of 
NEMO for IκBα. Similar experiments were performed with FITC-IKKβ and are 
shown in Appendix III. No effect was observed for the presence of linear di-
ubiquitin on IKKβ binding to NEMO either. 
3.3.2 Validation of Zinc Addition Requirement for NEMO to bind IκBα 
To corroborate the finding that zinc must be added exogenously for 
NEMO to bind IκBα, SPR experiments were performed. Two protocols for 
coupling of NEMO to the surface of a chip were developed by Dan Petrescu. 
First, homogenous coupling of 7XAla-NEMO was achieved via thiol coupling of 
its single solvent exposed cysteine at the C-terminus. The second strategy was 
through random amine coupling. For these experiments, both strategies were 
used, but because IκBα is thought to bind to the NEMO C-terminus, which is 
precluded by thiol coupling, only the data from the random amine coupling 
strategy was chosen for subsequent analysis. A total of 12,880 response units 
(RUs) of NEMO were immobilized on a GLH chip (BioRad). These chips are 
better suited for amine coupling of protein than others. NEMO was chosen for 
immobilization due to potential avidity effects, because NEMO is known to 
dimerize, and it is unlikely that IκBα peptide dimerizes. The mass ratio of 
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NEMO and IκBα is 50 kDa to 2.5 kDa, or approximately 20x. Given this mass 
ratio we can estimate that, given the RUs of immobilized NEMO, saturated 
binding should yield 644 RU. FITC-IκBα(20-42), the same ligand as that used in 
the FA assays, was flowed over as the analyte in a concentration series from 200 
nM diluted two-fold down to 6.25 nM. In the running buffer, zinc was either not 
included, or included at 1 mM. As the analyte is injected, the signal (RU) 
increases when binding occurs, until an equilibrium point where the on-rate is 
equal to the off-rate. Once the analyte injection is terminated, the signal decreases 
as the analytes dissociate from the immobilized protein. As shown in Figure 17A, 
there is no measurable binding in the absence of zinc. In Figure 17B, in the 
presence of 1 mM zinc, a binding signal is seen. This is less than the 613 RU 
estimated for saturation of binding, indicating saturation has not been reached, 
but direct binding to NEMO had occurred. A sub-saturating signal is not 
surprising, given the concentrations of IκBα were limited to those below the 
apparent affinity from FA experiments. These data are informative about the zinc 
requirement for NEMO binding to IκBα.  
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All previous experiments with FITC-IκBα were performed with a single 
concentration of zinc at 1 mM. However, it is unknown if this concentration of 
zinc is saturating, or if it is only enough to just detect NEMO binding to IκBα. To 
determine a full titration curve for zinc in the FA assay, NEMO was kept 
constant at 500 nM, zinc was titrated from 1 mM down to 7.8 μM, and 
magnesium was counter-titrated to maintain a constant concentration of divalent 
cation. Despite this high concentration of zinc, the anisotropy signal does not 
plateau at 1 mM, but rather appears to be increasing substantially. In order to 
achieve saturation, the titration was repeated starting with zinc at 10 mM. As 
shown in Figure 18, this higher concentration of zinc allowed for saturation at 
375 mP (milli-polarization units). The largest anisotropy value possible is 400 
mP, which would indicate a complex large enough that the absorption and 
 
Figure 17: SPR results for IκBα(20-42) flowed over random-amine coupled NEMO. In panel A 
analyte is flowed without zinc in the running buffer; in panel B analyte is flowed in presence of 
1 mM zinc in buffer. Vertical lines indicate time of analyte injection (left line) and switch back 
to running buffer (right line). Analyte concentrations are listed in the legend. 
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emission dipoles are collinear, so there is no re-orientation resulting in 
depolarization156. Therefore, the NEMO-IκBα-zinc complex must be rather large. 
An EC50 for the zinc requirement in the FA assay was calculated to be 4 mM. If 
this large signal were due to simple protein aggregation, there would be a 
substantial increase in the absorbance at 600 nm, as proteins do not absorb at 
such long wavelengths unless there are large particulates blocking the 
transmission of light. These experiments appeared to be unaffected by large 
amounts of zinc, decreasing the likelihood of large-scale aggregation. To 
determine whether the signal from this large zinc addition is nonspecific, the 
experiment was repeated with a FITC-IL-2 peptide, which is not expected to bind 
to NEMO. Figure 18 shows that these anisotropy levels are unaffected by 
titration of zinc, indicating that the zinc effect seen before was specific to the 
NEMO-IκBα interaction and is not due to nonspecific effects such as protein 
aggregation. The NEMO-IKKβ interaction was probed similarly; constant 500 nM 
NEMO and 15 nM FITC-IKKβ were included in the same zinc titration. FITC-
IKKβ alone was not affected by increasing concentrations of zinc, but the signal 
in the presence of NEMO increases by about 70 units with an EC50 near 1 mM. 
This is potentially due to large complexes of NEMO formed in high 
concentrations of zinc. 
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To provide evidence that the large anisotropy signal in the presence of a large 
excess of zinc was in fact due to large complex formation and nonspecific 
aggregation, dynamic light scattering was used. This technique determines the 
size of particles in solution in a nondestructive manner. It is sensitive to transient 
and low affinity interactions, and allows for higher-throughput optimization. 
First, 5XAla-NEMO was analyzed on its own to establish a baseline (top plot 
 
Figure 18: NEMO-IκBα FA assay control experiments in saturating concentrations of 
zinc. “Denatured” and “nondenatured” refer to denaturation, or not, of NEMO during 
purification procedure, and are further discussed in Section 3.3.3. All FITC-tagged 
peptides kept constant at 15 nM, NEMO at 500 nM. Zinc titrated from 10 mM down to 
78 μM. Solid lines connect points. 
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Figure 19: NEMO-IκBα-Zn complex size determination by DLS. From top to bottom: 5XAla-
NEMO at 10 μM; with FA assay buffer; with 1 mM Mg; with 1 mM Zn; and with 10 mM Zn. 
Blue bars indicate signal intensity for a given particle radius in nm. Clusters of blue bars are 
indicative of a single species relative to instrument precision. 
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Figure 19). Then, a series of samples were prepared identically as in the FA assay 
shown in Figure 15, except 5XAla-NEMO was at 10 μM, and the concentration of 
metal additive varied: no metal, 1 mM magnesium, 1 mM zinc, and 10 mM zinc. 
This experiment was done to analyze the NEMO-IκBα-zinc complex in a manner 
as close as possible to the anisotropy assay for direct comparison. The 
concentration of NEMO was increased to 10 μM to ensure enough signal. Tris 
was included in the buffer as a weak zinc chelator to improve its solubility at 
such high concentrations. DTT was included to minimize disulfide-mediated 
protein aggregation. The presence of both Tris and DTT likely lowered the free 
zinc concentration available to NEMO, but did not prevent a zinc-specific effect 
from being observed. Figure 19 shows the distribution of the intensity of light 
scatter as a function of particle diameter for each condition. For 5XAla-NEMO 
alone, the major species particle radius of 38.6 nm, or 386 Å, is slightly larger 
than that seen by SAXS (315 Å), but is important to note the difference in buffers 
used (sodium phosphate for SAXS, Tris with DTT for DLS). For 5XAla-NEMO as 
in the FA assay with either no metal additives or the addition of 1 mM 
magnesium, this peak broadens, but as expected, no noteworthy size increase is 
observed. In the FA assay, the addition of 1 mM zinc is where the sigmoidal 
curve starts its exponential phase; this is corroborated by a right shift in particle 
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radius to 1605 nm as measured by DLS and is shown in Figure 19. Finally, the 
curve from the FA assay has plateaued around 10 mM zinc, the magnitude of 
which indicates the presence of very large complexes. In DLS, this condition 
shows a sharpening of the radius distribution around the right-shifted peak, with 
the addition of an even larger peak at 12560 nm. Therefore, these DLS 
experiments provide key evidence corroborating the large complex formation 
seen in the zinc titration in the FA assay. 
To attempt to determine kinetics of IκBα binding to NEMO-Zn, the 
NEMO-IκBα FA assay was used as previously. The binding was initially 
measured at t = -1 m, to determine the starting, equilibrium anisotropy level. At t 
= 0 m, EDTA was spiked in a stoichiometric excess (5 mM) and the plate was 
read immediately to attempt to measure an off rate. As is shown in Figure 20, 
binding was no longer detected within the time it took to spike EDTA and read 
the plate, likely indicating zinc was no longer available in sufficient amount to 
activate the ZF of NEMO. The quickness of the apparent koff corroborates the 
previous finding that the NEMO-IκBα binding affinity is rather weak, and 
indicates that the NEMO-Zn binding affinity is rather weak as it can be displaced 
by EDTA rapidly. 
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 The NEMO-IκBα complex is dependent on the presence of exogenously 
added zinc and dissociates rapidly. If zinc binds to NEMO prior to IκBα, then the 
EC50 of zinc titration will be independent of IκBα concentration. However, if the 
EC50 of zinc titration varies with IκBα concentration, then IκBα may bind to 
NEMO first. To determine the order of binding, zinc titrations were performed 
from 1 mM down to 7.8 μM in the presence of varying concentrations of IκBα. As 
shown in Figure 21, there is no effect on the EC50 of zinc titration for IκBα 
 
Figure 20: NEMO-IκBα complex dissociates rapidly following addition of to the assay at 
indicated times, and anisotropy was measured within 15 seconds. Error bars (SD) 
representative of three technical replicates. Anisotropy normalized to high (NEMO with IκBα 
and 1 mM zinc) and low (IκBα alone with 1 mM zinc) controls. 
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concentrations up to 135 nM. The highest concentration of IκBα, 135 nM, was 
chosen because of solubility issues of the peptide at concentrations above this 
level. Because the zinc titration EC50 was not affected my increasing 
concentrations of IκBα, zinc binding to NEMO is independent of IκBα 
concentration, so zinc must bind to NEMO before IκBα can. 
 
3.3.3 NEMO Binds Zinc with Low Affinity 
To explore this potentially weak interaction between NEMO and zinc, the 
affinity was determined by Microscale Thermophoresis (MST). Briefly, MST 
 
Figure 21: NEMO-IκBα FA assay zinc titration in the presence of varying concentrations of 
FITC-IκBα. NEMO kept constant at 500 nM. Zinc titrated from 1 mM down to 7.8 μM. Data 
fit to a quadratic binding equation. 15 nM FITC-IκBα experiments are independent 
replicates. 
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works on the principle that proteins or complexes of different sizes or hydration 
shells diffuse at different rates away from a heat source. If a protein is bound to a 
ligand, its diffusion characteristics change, which can be determined by 
monitoring the intensity of protein fluorescence in a specific location as a result 
of heating at that location152. Holding NEMO constant at 500 nM, and titrating 
zinc from 1 mM down to 0.78 μM, the affinity of zinc binding was determined to 
be 14 μM (Figure 22). Previous studies have determined the NEMO ZF affinity 
for zinc to be 0.3 ± 0.1 μM98, or approximately 50 times higher than determined 
here. The discrepancy may be due to several factors discussed below in this 
Section. The affinity of various zinc finger peptides for Zn2+ ranges over nearly 7 
orders of magnitude (6.3 nM to 2 fM) at pH 7.0. The NEMO ZF is type CCHC; for 
these specifically, Kapp at pH 7.0 was reported to be around 1 fM157. Regardless of 
this large range, according to our results and previous results from Cordier and 
colleagues98, the NEMO ZF affinity for zinc ion appears to be substantially 
weaker than expected. 
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One potential explanation for the weak binding of zinc to NEMO is that 
there is another metal bound, that must be competed away for zinc to occupy its 
binding site. The most likely other metal is nickel. Because NEMO is purified on 
a nickel column, an unoccupied ZF may pull nickel off the column as it is 
refolded (see purification protocol in section 2.2.2). To test for the presence of 
nickel, we used atomic emission spectroscopy (AES). AES works on the principle 
that incinerated metal will emit at a precise wavelength. The comparison of this 
emission to standards of known concentration allows for determination of 
concentration of that metal. The results for AES metal determination in NEMO 
are shown in Figure 23: the plot above shows the standard curve, and table 
 
Figure 22: Determination of the binding affinity of zinc to NEMO using MST. Fnorm (%) is 
change in signal, F, normalized out of 1000, using the NanoTemper software. Solid line is 
curve fit to quadratic equation to determine EC50. 
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below is a table of results. Nickel concentrations were below the limit of 
detection, so nickel is not bound in the ZF of NEMO. Important buffer controls 
are listed in the table of results. In two separate experiments, it was determined 
that WT-NEMO is zinc-occupied. In the first, 5 μM of protein was shown to 
contain 5.5 μM zinc; in the second, 10 μM protein contains 8 μM zinc. 
Interestingly, 5xAla-NEMO only contains 1 μM of zinc for 5 μM of protein. This 
was not an equilibrium experiment, so it is not possible to determine from these 
data whether WT-NEMO has a higher affinity for zinc than 5xAla-NEMO. 
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Another potential explanation for weak zinc binding is that during 
purification, the ZF is irreparably misfolded during the denaturation step and 
therefore only a small fraction of NEMO ZF’s can bind zinc following this harsh 
treatment. To test this hypothesis, 5xAla-NEMO was purified without 
denaturation and subjected to AES. Two peaks were collected from the nickel 
affinity purification, whereas inclusion of urea earlier in the purification process 
 
Figure 23: Atomic Emission Spectroscopy results for WT-NEMO. Above plot is the standard 
curve to determine zinc concentration. Table at bottom displays concentrations of zinc 
interpolated from standard curve. Each concentration is the average of three technical 
replicates. 
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yields a single peak. The first peak contained zinc in a roughly 1:1 ratio to NEMO 
protein, while the second did not contain zinc. Notably, this zinc-containing 
protein behaved identically in requiring zinc to bind to IκBα as its purification-
denatured counterpart.  
In summary, WT-NEMO appears to co-purify with zinc, whereas 5XAla-
NEMO co-purifies with zinc only when purified under non-denaturing 
conditions. 5XAla-NEMO is therefore not zinc-loaded when purified under 
denaturing conditions. In the IκBα FA assay, 5XAla-NEMO that was not 
denatured during purification behaved identically to that which was denatured 
during purification, and only the former co-purifies with zinc. The requirement 
of addition of a large amount of zinc suggests either the presence of a secondary 
binding site for zinc, or that zinc in some way induces multimerization of 
NEMO. It is unlikely that there exists a second zinc-binding site required for 
binding to IκBα, as concentrations of zinc used in these assays are far above the 
μM concentrations seen in living cells.  Therefore, it is likely that there is a large 
complex formation induced by the presence of large quantities of zinc that is 
competent and required to bind IκBα, irrespective of the zinc occupancy of the 
ZF. 
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3.3.4 Development of an in vitro assay to measure IKKβ phosphorylation of IκBα 
At this point, the interactions of NEMO with IκBα, zinc, IKKβ103, and 
linear di-ubiquitin83 have been characterized. To study how these individual 
components contribute to an active IKK signaling complex, a fluorescence-based 
assay using Sox peptide technology was developed in collaboration with Assay 
Quant Technologies (Marlborough, MA)151. Briefly, the assay requires a peptide 
with four modules: a phosphorylation site, a β-turn sequence, a recognition site 
for the kinase, and a Sox amino acid. The side chain of the Sox amino acid is a 
fluorophore that, once the peptide is phosphorylated, forms a complex with a 
magnesium ion and the phosphorylated residue. The complex is diagramed in 
Figure 24. This complex is excited at 360 nm and emits at 485 nm, with an 
intensity 3-5 fold brighter following phosphorylation. This complex is then stable 
on the scale of hours, allowing for low concentrations of enzyme for easily 
observable rates. Results will be shown as plots of time versus RFU (relative 
fluorescence units), where an increase in RFU is proportional to an increase in 
amount of phosphorylated peptide. 
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First, a fluorescence anisotropy competition assay was performed to 
demonstrate that the Sox peptide used here is capable of binding to NEMO 
similarly to the IκBα peptide used previously (see Figure 16). As shown in the 
top panel of Figure 25, the Sox peptide binds almost identically to NEMO as the 
unlabeled IκBα peptide. That is, the IC50 values are 1.5 ± 0.4 and 2.3 ± 0.4 μM for 
the unlabeled IκBα peptide and Sox peptide, respectively. This was expected, 
given the high degree of sequence overlap as shown at the bottom of Figure 25. It 
should be noted that the arrangement of the Sox peptide modules is crucial. The 
Sox amino acid is best located in the middle of the IKKβ recognition sequence of 
IκBα (31-DSGLDSMKD-38) in terms of the most IKKβ phosphorylation as 
screened by Assay Quant. The Sox amino acid replaces L34. It is unclear which 
 
Figure 24: Scheme representing Sox peptide fluorescent probe construction. Sox amino acid 
side chain chemical structure shown in box in lower right. Upon phosphorylation of S/T/Y, a 
magnesium ion is chelated by the phosphate and the Sox peptide, which emits at 485 nm after 
excitation at 360 nm. Figure adapted from Shults and colleagues (2003)151. 
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phosphorylation site is responsible for the Sox signal. 
First, a titration of the enzyme, IKKβ, was performed to demonstrate linearity in 
rate versus enzyme concentration. Figure 26A-B show the course of the reaction 
(change in RFU) over time. Initial rates were determined by calculating the slope 
over the first 20 m. Plots of rate versus enzyme concentration are shown on the 
right side in Figure 26. 
 
Figure 25: FA competition assay comparing the affinity of the Sox peptide (red) used in this 
section to the unlabeled IκBα peptide (blue) used in Section 3.3.2. Phosphorylation sites are 
S32 and S36 and are underlined above; C(Sx) replaces L34. IC50 values are 2.3 and 1.5 μM for 
the unlabeled IκBα peptide and Sox peptide, respectively. Error bars represent standard 
deviation. Dotted lines indicate anisotropy level of high (NEMO plus IκBα) control and low 
(IκBα alone) control. Concentrations were NEMO at 500 nM, FITC-IκBα at 15 nM, and zinc 
at 1 mM. 
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Overall, the reaction rate appears to be linear with respect to enzyme 
concentration. Additional tests of the assay were designed to determine whether 
the equilibrium reached with higher concentrations of IKKβ is due to inactive 
enzyme or exhaustion of substrate. In Figure 26A, the peptide substrate was 
spiked at 4 h. In the 50 nM IKKβ case, the signal that had plateaued began 
increasing again, indicating that the enzyme was still active prior to substrate 
spiking and an equilibrium was reached for maximal phosphorylation of the 
Sox-IκBα peptide.  
 
Figure 26: IKKβ titrations. A, left: Titration of IKKβ from 50 nM with additional substrate 
spike at 4 h. Right: Plot of initial rate of reaction versus enzyme concentration. Solid line is 
linear fit. B, left: Titration of IKKβ from 50 nM. Right: Plot of initial rate of reaction versus 
enzyme concentration. Solid line is linear fit. 
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To determine the IκBα peptide substrate KM value and a saturable Vmax, a 
substrate titration was performed. Here, IKKβ was kept constant at 25 nM, 
NEMO at 100 nM, and zinc at 62.5 μM. As shown in Figure 27, the plot of rate 
versus substrate concentration is hyperbolic and shows saturation. A Michaelis-
Menten fit of this curve together with an independent replicate yields a KM value 
of 29 μM (22.8 – 35.2 μM, n = 2). This KM value is approximately 29 times the 
reported value by Kishore et al. (2002) of 1 μM using a similar peptide of IκBα158. 
The difference may be caused by the presence of the Sox amino acid, reducing 
the affinity of the peptide for IKKβ. 
 
Next, the effect on IKKβ phosphorylation rate from the titration of zinc, 
NEMO, and/or linear poly-ubiquitin was assessed. Zinc addition was shown to 
be required for IκBα binding to NEMO, so it was included. Linear poly-ubiquitin 
 
Figure 27: Substrate titration shows saturable Vmax with KM = 29 ± 6.2 μM. Substrate AQT0220 
titrated from 100 μM down to 78 nM, and IKKβ at 25 nM. A: Timecourse from which initial 
slopes were determined. B: Plot of initial slopes of the reactions versus substrate (AQT0220) 
concentration. Blue line is fit to Michaelis-Menten equation to determine KM and Vmax. 
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has been shown to be required for IKK activation50,105 and was hypothesized to be 
required to activate NEMO63, so it is hypothesized to enhance or be required for 
NEMO-mediated IKK activity. In these experiments, IKKβ was kept at 6.25 nM, 
substrate at 10 μM, and additive was titrated from 125 μM, 1 μM, and 1 μM, for 
zinc, NEMO, and linear poly-ubiquitin, respectively. From FA results in Figure 
24, the addition of zinc is required for NEMO to bind IκBα; therefore, it is 
hypothesized that NEMO would not have an effect on the Sox assay without the 
addition of zinc. To determine the concentration of zinc to use, two independent 
zinc titration replicates indicated that IKK activity is steady at concentrations 
lower than 125 μM (Figure 28A). Zinc is known to compete with magnesium for 
binding to the Sox peptide for fluorescence emission to occur151, so it is important 
to show concentrations of zinc in excess of NEMO do not adversely affect the 
reaction. Moving forward, the concentration 62.5 μM zinc was used, which is in 
great excess over NEMO. For NEMO addition (Figure 28B), it appears that 
higher concentrations of NEMO have little, if any, effect on IKKβ activity. The 
magnitude of change from highest to lowest concentration of NEMO is no more 
than 4 RFU/min, which is a rather modest change and more replicates would be 
needed to establish if the minor apparent inhibition is of statistical significance. 
To compare the effect of M1-2Ub and M1-4Ub on IKKβ phosphorylation 
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rate in the presence of 100 nM NEMO, these ubiquitin proteins were titrated 
while keeping other assay conditions identical. Results are shown in Figure 28C. 
The only difference was that for the M1-2Ub experiment, the IKKβ used was 
older and had been kept frozen for approximately two months longer than the 
IKKβ used in the M1-4Ub experiment. Therefore, it is difficult to compare 
directly the magnitude of the rates for each experiment, as the older IKKβ may 
not have been as active. There is no dose-dependent effect for M1-2Ub on IKK 
activity. There appears to be a peak for M1-4Ub at lower concentrations (91.25 
and 45.6 nM). However, it is unlikely that this is mechanistically relevant given 
that this is not dose-dependent. An additional replicate for M1-4Ub titration is 
shown in Figure 28D; again, there is no dose-dependence, supporting the 
conclusion that M1-4Ub has no effect on NEMO-mediated IKKβ activity. 
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To validate the result that NEMO plus M1-4Ub has no effect on IKKβ 
phosphorylation rate, which is surprising given recent findings63, substrate 
titrations were performed with the addition of one or more of these components. 
First, the effect of NEMO on IKKβ activity was determined and is shown in 
Figure 29A. Notably, NEMO appears to inhibit the reaction, as the observed rates 
 
Figure 28: Effect of addition of  various relevant signaling components on IKKβ 
phosphorylation of IκBα. A: Representative zinc titration from 250 μM down to 38 nM. 
Dashed horizontal line indicates activity in the absence of zinc. B: Two independent 
replicates of NEMO titration from 1000 nM down to 7.8 nM. Inset: curves were normalized 
to show reproducible behavior. C: Titration of either M1-2Ub or M1-4Ub with 100 nM 
NEMO and 62.5 μM zinc present. D: Replicate of M1-4Ub titration at 1500, 300, and 60 nM. 
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are slower in the presence of 100 nM NEMO. Specifically, the KM roughly 
doubles in the presence of NEMO from 18 ± 1.5 to 37 ± 5.9 μM, while Vmax 
remains unchanged.  
To determine whether M1-4Ub can overcome this NEMO-dependent 
inhibition, a similar substrate titration was performed in the presence of 100 nM 
NEMO and 1 μM M1-4Ub. In this experiment, shown in Figure 29B, there was no 
difference in observed rate between the conditions with M1-4Ub versus without. 
KM values are similar to previous findings, at 21 ± 2.6 and 25 ± 6.3 μM, while Vmax 
remains unchanged, indicating again no substantial effect of NEMO with M1-
4Ub on IKKβ activity. An expanded experiment was performed to add in a key 
control, M1-4Ub without NEMO, to determine whether M1-4Ub inhibits IKKβ 
activity on its own. Results are shown in Figure 29C. There is no substantial 
difference in activity in the presence of NEMO and M1-4Ub together versus each 
component added individually. A further expanded experiment with an 
additional key control, IKKβ alone, was then performed. Results are shown in 
Figure 29D. As had been seen in most previous experiments, there appeared to 
be no effect of any combination of added component in this experiment, as all 
observed rates were comparable to that seen in the IKKβ alone case. 
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The above results show that the Sox amino acid-based phosphorylation 
assay to measure the rate of IKKβ phosphorylation of IκBα appears to be 
working, in that the rate versus enzyme concentration is linear, and the rate 
versus substrate concentration is hyperbolic. These results are reproducible. A 
dose-dependent slowing of reaction rate in two independent NEMO titration 
experiments (Figure 28A), and a comparison of the presence versus absence of 
 
Figure 29: Substrate titration results. A: The presence of NEMO at 100 nM appears 
to slow IKKβ activity. B: 1 μM M1-4Ub with 100 nM NEMO has no effect on IKKβ 
activity except at the highest concentration of substrate, which is difficult to 
explain mechanistically. C: Substrate titration to determine the activity of the 
indicated combinations of components. D: Same experiment as in C except 
additional condition, IKKβ alone. All curve fits performed using Michaelis-
Menten fit. 
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NEMO in a substrate titration (Figure 29A), indicates that rather than increasing 
the reaction rate between IKKβ and IκBα, NEMO appears to slightly inhibit 
IKKβ activity under the conditions used. At the indicated concentrations of 
NEMO (100 nM) and IKKβ (25 nM), which are above KD, it is possible that two 
NEMO molecules may bind to one IKKβ, preventing IKKβ dimerization which 
has been shown in solution and may be important for activity159. Based on a 
hypothesis from Hauenstein et al.63 and discussed above in Section 3.1, the 
addition of M1-4Ub was thought to increase NEMO-mediated IKKβ activity. 
However, NEMO and M1-4Ub together appear to have no effect on the rate of 
IKKβ phosphorylation of the IκBα peptide; there is a lack of a dose-response in 2 
independent M1-4Ub titrations (one is shown in Figure 28C, the two are 
averaged in Figure 29D), and no effect in a substrate titration (Figure 29B).  
There are at least five ways to explain these results. First, the affinity of 
M1-4Ub for NEMO has not been reported, so it is unknown if we were using 
concentrations below KD which would lead to fewer than 50% of NEMO 
molecules bound to M1-4Ub. Additionally, it is not known whether M1-4Ub does 
anything other than facilitate ligand-induced conformational changes by IKKβ 
and IκBα106. These conformational changes may or may not contribute 
significantly to activity. Second, it has been shown previously57 that NEMO is 
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phosphorylated on N-terminal residues, which may be important for enhancing 
IKKβ activity. Without phosphorylation, as is the case in these experiments, 
NEMO may not be competent to enhance IKKβ activity. Third, previous assays58 
that showed NEMO can enhance IKKβ activity were performed with full-length 
IκBα; perhaps the peptide we are using is missing important residues for 
interactions with NEMO. Fourth, it has been shown that 5xAla-NEMO can 
restore canonical NF-κB signaling in NEMO knockout cells; though unlikely, 
perhaps it is through a manner other than enhancing IKKβ activity that this 
construct accomplishes this task. It would therefore be interesting to test WT-
NEMO in this Sox assay to answer this question. Fifth, it has been demonstrated 
above using fluorescence anisotropy that NEMO requires a large excess of zinc, 
at least 1 mM, to show measurable binding to almost the same IκBα peptide. In 
these assays, concentrations of zinc above 62.5 μM inhibited the reaction, so this 
was the concentration used. According to the FA assay results, this concentration 
of zinc is insufficient to observe binding of NEMO to IκBα, and perhaps NEMO 
is not binding to IκBα in these assays. However, it is possible that the NEMO-
IκBα interaction only need to be transient for efficient directed phosphorylation 
by IKKβ to occur, whereas stable binding is required for observation by FA. 
Finally, IKKβ may need to be phosphorylated by another protein such as TAK1, 
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to become fully active.  
A fluorescence-based assay has been developed to quantitatively 
characterize the phosphorylation of IκBα by IKKβ. Given results from a previous 
study58, NEMO was thought to enhance IKKβ activity; however, it was shown 
here to not affect it, possibly due to one or more of the reasons stated above. 
Hauenstein and colleagues63 hypothesized that NEMO exists in an auto-
inhibitory state prior to poly-ubiquitin binding. Therefore, we assessed the 
ability of tetra-ubiquitin to activate NEMO by means of enhancing IKKβ activity. 
Tetra-ubiquitin was shown to have no effect on this activity, discounting this 
hypothesis. 
 
3.3.5 The Intervening Domain Confers Full Binding Affinity to NEMO for IKKβ 
Previously, an FA assay to characterize the NEMO-IKKβ interaction was 
published by our group103; here, we used that assay to assess the contribution of 
the IVD to the interaction of NEMO and IKKβ. First, the ability of NEMO(44-195) 
to bind to a 45-mer peptide derived from the C-terminal sequence of IKKβ61 was 
explored. Previous studies have shown that covalently dimeric NEMO(1-120) 
and NEMO(44-111) constructs, which contain the IBD but not the IVD, bind 
IKKβ with an affinity of 70-310 nM and 210-560 nM, respectively116. Similarly, 
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IBD constructs comprising residues 44-111, rendered dimeric by fusion at the N- 
and/or C-terminus to a constitutively dimeric α-helical coiled-coil, binds the 
same IKKβ peptide with an affinity of 100-1000 nM, and likewise, when 
expressed as a dimeric fusion protein with glutathione-S-transferase (GST) binds 
with KD = 170 nM160. Full-length NEMO, on the other hand, binds this IKKβ 
peptide with the substantially higher affinity of 2.2 ± 0.8 nM103. These differences 
in affinity for IKKβ between fragments of NEMO up to residue 120 and full-
length NEMO have previously been assumed to derive from subtle differences in 
the structure or flexibility of constructs containing the IBD alone compared to 
full-length NEMO116. To determine whether the IVD affects the binding affinity 
of the IBD for IKKβ, we tested the binding of NEMO(44-195) and 9SG-NEMO to 
the same IKKβ-derived peptide using a FA binding assay described 
previously103,108. Figure 30 shows that, consistent with previous results, FL-
NEMO bound the IKKβ peptide with KD = 4.9 ± 0.6 nM (n = 3), although the IBD-
only NEMO(1-120) construct displayed a lower affinity of KD = 95 ± 25 nM (n = 
3)116 (inset table). NEMO(44-195), which contains both the IBD and IVD region, 
bound the IKKβ peptide with an affinity of 7.4 ± 2.2 nM (n = 4). This result shows 
that the presence of the IVD affords IKKβ binding affinity to truncated NEMO 
similar to that of full-length NEMO. Notably, 9SG-NEMO bound the IKKβ 
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peptide with KD = 67 ± 17 nM (n = 3) (Figure 30), i.e., 10-fold more weakly than 
FL-NEMO, and similar to the value obtained for NEMO(1-120) (inset table). The 
NEMO(110-195) construct comprising the IVD alone showed no detectable 
binding to the IKKβ peptide (Figure 30), ruling out the possibility that the 
peptide could be binding directly to a site in the IVD itself. Thus, mutation of the 
nine highly conserved residues at the core of the IVD abolishes the ability of the 
IVD to confer high IKKβ binding affinity to the adjacent IBD.  
 
 
Figure 30: Fluorescence anisotropy binding assay results for various NEMO constructs. 
Results are representative of three independent experiments. Inset: table of mean affinities of 
each NEMO construct for FITC-IKKβ(701-745) after three independent replicates. Refer to text 
for standard deviations.  
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3.3.6 Mutation of Highly Conserved Residues in the IVD Abolishes Canonical NF-κB 
Signaling 
All cellular assays were performed by members of the Gilmore group. As 
a first test of whether the IVD plays a role in the ability of NEMO ability to 
mediate NF-κB pathway signaling, the ability of 9SG-NEMO to restore TNFα-
induced phosphorylation of IκBα was tested in a 293T cell line in which NEMO 
expression had been disrupted by CRISPR/Cas9 targeting (Figure 31, left). These 
NEMO-deficient cells displayed TNFα-dependent phosphorylation of IκBα after 
transfection with FLAG-NEMO, but expression of equivalent levels of 9SG-
NEMO gave a substantially weaker response (Figure 31, right). 
 
 As a more extensive test of 9SG-NEMO function, retroviral transduction 
 
Figure 31: 7XAla-NEMO rescues IKK function in NEMO knockout cells, but 9SG-NEMO does 
not. Left, Whole cell extracts from WT- and NEMO-knockout 293T cells were analyzed by 
anti-NEMO Western blotting (top) or Ponceau staining for total protein (bottom). Right, 293T 
NEMO knockout cells were transfected with plasmids for the expression of 7XAla- or 9SG-
NEMO. Cells that were either untreated (-) or treated with TNFα (+) were analyzed by 
Western blotting for phospho-IκBα or NEMO or by Ponceau staining. These experiments 
were performed by Yuekun Liu of the Gilmore group. 
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was used to reconstitute mouse NEMO knockout cells with FL-NEMO or the 9SG 
mutant. Previously, this method has been shown to express biologically relevant 
levels of NEMO protein and can be used to test NEMO activity103,153. Mouse 
knockout cells reconstituted with FL-NEMO showed phosphorylation of IκBα 
upon treatment with the known NF-κB pathway activators TNFα, LPS or IL-1β 
(Figure 32). In contrast, there was little to no induction of IκBα phosphorylation 
in cells reconstituted with 9SG-NEMO or the empty vector control. Similar levels 
of NEMO protein were expressed in all cells. To ensure that the lack of activity of 
the 9SG mutant was not due to the 7X-Ala background, we also created the 9SG 
mutation in the wild-type NEMO background. The 9SG variant in the wild-type 
NEMO background was also defective for TNFα-induced phosphorylation of 
IκBα when expressed in mouse NEMO knockout cells, whereas expression of 
WT NEMO restored TNFα-induced phosphorylation of IκBα in these cells. 
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Taken together, these results show that disruption of the highly conserved 
core IVD sequence by the 9SG mutation disrupts the ability of NEMO to support 
activation of IKK in human and mouse cells in response to a variety of upstream 
inducers of NF κB activity. 
 
3.3.7 IVD Mutations do not Affect NEMO Ability to Co-Immunoprecipitate IKKβ or 
IκBα 
To determine whether this loss of signaling ability is due to a loss of 
 
Figure 32: 7XAla-NEMO can propagate TNF-mediated signaling but 9SG-NEMO cannot. 
Mouse NEMO knockout fibroblasts were stably transduced with retroviral vectors for the 
indicated NEMO proteins. Stable cell lines were then untreated (-) or treated (+) with the 
indicated compounds. Extracts were then analyzed by Western blotting for the indicated 
proteins. These experiments were performed by Larisa Kagermazova of the Gilmore group. 
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interaction with IKKβ, the ability of wild-type and 9SG-NEMO to co-
immunoprecipitate IKKβ in cells was compared. Human 293 cells were 
transfected with overexpression vectors for FLAG-NEMO or FLAG-9SG-NEMO, 
and binding to endogenous IKKβ was evaluated in anti-FLAG co-
immunoprecipitation assays. As shown in Figure 33, similar amounts of IKKβ 
were co-precipitated with FLAG-NEMO and FLAG-9SG. No IKKβ was co-
precipitated in extracts from cells transfected with the empty vector control. The 
ability of 9SG-NEMO to pull down IKKβ similarly to wild-type NEMO suggests 
that a 10-fold loss of NEMO binding affinity to the 45-mer IKKβ peptide as 
measured in vitro may not be apparent by Western blotting of co-
immunoprecipitates from cells for two reasons: full-length IKKβ dimerizes159 
whereas the IKKβ peptide used in vitro does not, and likely imparts an avidity 
effect, and NEMO was highly overexpressed in the 293T cells used for the co-
immunoprecipitation experiments. 
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3.3.8 NEMO Cannot Undergo in Trans Signaling  
A crucial test for the hypothesis that a ligand-induced conformational 
change is required for signal propagation, is that NEMO must not be able to 
propagate signaling in trans. In other words, if head-to-tail signaling is possible 
and NEMO can associate in an anti-parallel fashion, then there is no reason to 
expect conformational change to be necessary to actively bring protein ligands 
together for signaling to occur. To determine whether NEMO is capable of such 
in trans signaling, ΔN- and ΔC-NEMO were cloned into pcDNA-FLAG vectors 
by deletion using standard subcloning with primers listed in Appendix I. In vivo 
experiments were performed by the Gilmore group and results are shown in 
Figure 34. Human 293 cells with disrupted NEMO gene (see Figure 31) were 
 
Figure 33: The indicated FLAG-tagged NEMO constructs were transfected into 293T cells, and 
extracts were immunoprecipitated (IP) with anti-FLAG beads. Immunoprecipitates were then 
analyzed by anti-FLAG (bottom) and anti-IKKβ (top) Western blotting. In the Input lanes, 4% 
of the extract used in the immunoprecipitations was analyzed by Western blotting. These 
experiments were performed by Larisa Kagermazova of the Gilmore group. 
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transfected with indicated NEMO constructs. Upon 10 m of TNF stimulation, 
WT-NEMO allows phosphorylation of IκBα as has been demonstrated 
previously103. Notably, co-transfection of ΔN- and ΔC-NEMO does not increase 
the phosphorylation of IκBα seen with ΔC-NEMO alone. Interestingly, 
transfection of only the ΔC-NEMO construct did allow some TNF-induced 
phosphorylation of IκBα, as was seen previously161.  
 
From these results, a hypothesis may be formed to explain the pairwise 
roles within the IKK complex. NEMO may sequester either IKKβ (ΔC-NEMO, 
IKKβ bound at N-terminus) or  IκBα (ΔN-NEMO, IκBα bound at C-terminus) as 
has been postulated previously58; binding of NEMO to IKKβ activates IKKβ,  
 
Figure 34: ΔN- and ΔC-NEMO cannot reconstitute TNF-induced 
phosphorylation of IκBα, whereas ΔC-NEMO on its own shows partial 
activity. Note NEMO truncation constructs FLAG-tagged. These 
experiments were performed by Yuekun Liu of the Gilmore group. 
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whereas IκBα binding to NEMO contributes to signaling but is not required for 
propagation to occur. 
 
3.4 Conclusions and Future Directions 
In this chapter, the protein-protein interaction between NEMO and IκBα 
was quantitatively characterized for the first time. This interaction has been 
shown previously to be direct by co-elution from size exclusion chromatography 
and to require the ZF of NEMO58, and that a short peptide of IκBα induces a 
conformational change in NEMO106. However, the binding affinity and zinc 
requirement of the NEMO-IκBα interaction was previously unknown. Here, we 
showed that the NEMO-IκBα interaction is fast on/off, and requires a large 
amount of zinc to achieve a stable complex for such equilibrium measurements. 
A binding scheme for the formation of the NEMO-zinc-IκBα complex is 
shown in Figure 35. As shown in Figure 21, zinc binding to NEMO is 
independent of IκBα concentration, so the first step in complex formation must 
be the association of NEMO and zinc. From MST experiments, the NEMO-zinc 
binding affinity, denoted as K1 in the scheme below, was determined to be 14 μM 
in Section 3.3.3. However, even zinc concentrations ~ 8-fold above this KD at 100 
μM were not sufficient to achieve measurable binding of NEMO to IκBα. 
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Therefore, there must be an additional zinc-dependent event to induce an IκBα-
binding competent form of NEMO, denoted here as N*, upon the addition of 
even more zinc. This event may either be zinc binding to a secondary site, or zinc 
inducing multimerization of NEMO in some other fashion. It is unlikely that 
there exists a second zinc-binding site on NEMO required for binding to IκBα, as 
concentrations of zinc used in these assays are far above the μM concentrations 
of zinc seen in living cells. However, it is also unlikely that this zinc affinity 
represents the binding of zinc ion to the ZF because NEMO can co-purify with 
zinc under non-denaturing conditions and this is substantially weaker than other 
reported ZF-zinc binding162.  
 
The EC50 for the formation of N*:Zn from zinc titration in the FA assay in 
Section 3.3.2, or K1*K2, is 2.5 ± 0.3 mM (n = 2). Once these competent complexes 
are formed, IκBα can then bind with dissociation constant K3.  This was shown to 
be 2.0 ± 0.5 μM (n = 2) in Section 3.3.1. This complex formation is substantially 
weaker than that of the NEMO-IKKβ interaction. This can be rationalized by 
 
Figure 35: Binding scheme for the NEMO-zinc-IκBα interaction. N denotes NEMO; N* 
denotes the large complex formed in the presence of excess zinc; Zn denotes zinc; I denotes 
IκBα. Zinc binding to NEMO is independent of IκBα concentration, so zinc must bind to 
NEMO before IκBα. 
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thinking about possible IKK signaling mechanisms. There are two such possible 
mechanisms: single turnover, where the complex forms, one IκBα molecule is 
phosphorylated, and the complex dissociates; or multiple turnover, where 
NEMO and IKKβ form a stable complex, turning over multiple IκBα 
phosphorylation events. The 1000-fold difference in binding affinity between 
IKKβ and IκBα binding to NEMO favors the latter scenario, of a stable IKK 
complex turning over many IκBα substrates. If NEMO had identical affinity for 
both IKKβ and IκBα, it would suggest that the two ligands bind NEMO an equal 
number of times per activation event. A key test of this hypothesis would be to 
perform SPR experiments to determine the on/off rates of IKKβ and IκBα 
binding to NEMO to calculate residence time. Additionally, relation of these in 
vitro findings to a more biologically relevant situation, tracking IKKβ and IκBα 
localization within the cell during NF-κB activation would be strong evidence for 
or against this hypothesis. We do not know for a fact that the binding affinity 
measured with the IκBα peptide is representative of that that would be seen with 
full-length IκBα. It is also possible that a NEMO-IKKβ complex binds IκBα more 
tightly than NEMO alone does. In any event, NEMO-IκBα peptide complex 
formation requires exogenous zinc, is substantially weaker than that of NEMO-
IKKβ, and NEMO-zinc-IκBα peptide complexes are large as demonstrated by 
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DLS experiments. 
In collaboration with Assay Quant Technologies, Inc. (Marlborough, MA), 
we developed an in vitro kinase assay based on Sox peptide technology151 to 
quantitatively characterize IKK activity towards an IκBα peptide, and 
specifically the contribution of NEMO thereof. We demonstrated that the IκBα-
derived peptide substrate binds to NEMO similarly to an unmodified version of 
IκBα peptide discussed above in the presence of large molar excess of zinc. Given 
previous results from Schröfelbauer et al., we expected NEMO to increase IKKβ 
phosphorylation activity towards IκBα. However, this was not the case, and in 
fact NEMO appeared to inhibit the IKK activity in our assays. Notably, we have 
also demonstrated that linear tetra-ubiquitin does not enhance NEMO-mediated 
IKK activity in this context, contrary to the hypothesis from Hauenstein and 
colleagues63. Many possible explanations exist as discussed above, including the 
possibility that NEMO requires an additional modification to be competent to 
function with these binding partners in this context. In summary, there must be 
some additional required aspect to NEMO-mediated IKK activity, or full-length 
IκBα is required for NEMO to elicit an effect on activity. Establishment of 
conditions where NEMO enhances the rate of IKKβ activity in the Sox assay is 
perhaps most important to quantitatively assess the effect on activity of disease-
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associated mutations and other components such as TAK1. 
Additionally, we analyzed the contribution of the IVD to NEMO binding 
of IKKβ. 5xAla-NEMO binds IKKβ(701-745) with an affinity of 4.9 ± 0.6 nM, 
whereas 9SG-NEMO binds with an affinity of 67 ± 17 nM. Clearly, the SG 
substitution at the sequence of highest conservation in the IVD impacts IKKβ 
binding, despite being outside of the interaction site. To further support this 
conclusion, NEMO(44-195), which includes the IBD and the IVD, binds similarly 
to FL-NEMO (7.4 ± 2.2 nM), whereas a construct without the IVD, NEMO(1-120), 
binds similarly to 9SG-NEMO (95 ± 25 nM). NEMO(110-195) showed no 
measureable binding, suggesting that IKKβ makes no contacts with the IVD. We 
previously showed that an IKKβ-induced conformational change occurs in 
5xAla-NEMO and NEMO(44-195) but not in 9SG-NEMO. It is possible that this 
conformational change effectively “locks” IKKβ in to NEMO, raising the 
apparent binding affinity by slowing the off rate. If this mechanism were to be 
true, it would have to be distinct from the stabilization demonstrated by Zhou 
and colleagues116 achieved via disulfide bonds, because the binding affinity of 
disulfide-stabilized, IVD-less NEMO constructs to IKKβ is lower than that of 
IVD-included constructs. Another possibility is that the IVD pre-orders the IBD 
for IKKβ binding, lowering the entropic cost of binding. Either way, at the very 
 
 
 
 
129 
 
least, the IVD allosterically regulates NEMO interactions. 
Previous studies have tested the ability of NEMO bearing various disease-
associated mutations to propagate NF-κB signaling114,115,163. However, disease-
associated NEMO mutants are typically still functional in response to at least one 
stimulus of canonical NF-κB signaling. For instance, in patients with an E315A 
mutation in NEMO, LPS induction of NF-κB was diminished, while TNF and IL-
1β were able to stimulate NF-κB as normal163. Additional evidence for differential 
signaling effects of NEMO mutations lies in the distinct ubiquitin requirements 
for activating the IKK complex by TNFα and IL-1β as demonstrated by IKK 
complex formation seen by confocal microcopy of GFP-tagged NEMO83,164, and a 
differential signaling response to LPS compared to IL-1β and TNFα as 
demonstrated by mutagenesis of ubiquitination sites on the NEMO UBAN 
domain165. In this thesis, we have shown that the 9SG substitution abolishes the 
ability of NEMO to function in canonical signaling in response to TNF, LPS or IL-
1β. It is almost certainly not due to diminished affinity for IKKβ, as a 10-fold loss 
of binding affinity is modest, and it was measured using a 45-mer peptide 
surrogate for the full-length protein that may or may not retain full binding 
affinity. Therefore, it is likely that the SG mutation disrupts the ability of NEMO 
to perform some other required function for downstream signaling, aside from 
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binding IKKβ. This could be explained by several scenarios. Given the results of 
Chapter 2, we hypothesize that this loss of function with 9SG-NEMO is due to a 
loss of ability to undergo a productive ligand-induced conformational change. If 
NEMO does require a conformational change to occur to activate IKKβ, then 
efficiently signaling in trans would be dispensable. This idea can be tested by 
disrupting the ability of NEMO to undergo a conformational change. If in trans 
signaling can occur, then abolishing the conformational change would allow 
some level of signaling to continue by the in trans mechanism. Indeed, co-
transfection of ΔN- and ΔC-NEMO does not reconstitute WT-NEMO activity, 
providing crucial evidence for the requirement of conformational change in 
signal propagation. 
From these data, we can learn a great deal more about the mechanism by 
which the IKK complex propagates NF-κB signaling. An expanded model of 
these signaling events is shown in Figure 36. 
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The pathway can be turned on by multiple external stimuli including LPS, 
TNF, and IL-1β. Their respective receptors are subsequently activated, which 
associate with effector proteins such as RIP. RIP is then poly-ubiquitinated by 
E2/E3 ligases. This poly-ubiquitin chain is then attached to NEMO, localizing it 
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The pathway can be turned on by multiple external stimuli including LPS, 
TNF, and IL-1β. Their respective receptors are subsequently activated, which 
associate with effector proteins such as RIP. RIP is then poly-ubiquitinated by 
E2/E3 ligases. This poly-ubiquitin chain is then attached to NEMO, localizing it 
 
Figure 36: Schematic of NF-κB expanded with findings from this dissertation. 1: The pathway can be 
turned on by several extracellular stimuli including LPS, TNF, and IL-1β. 2: An activated receptor 
associates with effector proteins such as RIP that become poly-ubiquitinated. NEMO is then attached to 
these poly-ubiquitin chains and localized to the membrane. 3: IKKβ binds to NEMO and induces a 
conformational change as determined by SAXS that we believe is required for subsequent signal 
propagation. The IVD is required for this change to occur, and for full binding affinity to IKKβ. 4: 
NEMO-bound IKKβ phosphorylates multiple IκBα molecules, as suggested by the 1000-fold weaker 
apparent affinity of NEMO-Zn for IκBα than IKKβ. IκBα is then degraded in the proteasome, which 
releases the previously sequestered NF-κB subunits (here, p50 and p65) to 5: translocate into the 
nucleus and upregulate NF-κB target gene transcription. 
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to the cell membrane. IKKβ then binds to NEMO and induces a conformational 
change that requires an intact IVD region, as determined by SAXS (see Section 
2.3.5). The IVD is highly conserved, as shown in the MSA in Section 2.3.1, which 
highlights its importance in NEMO function. The IVD also contributes to the 
thermal stability of NEMO (Section 2.3.4), and the binding affinity of NEMO to 
IKKβ (Section 3.3.5), but neither is sufficient to substantially impact binding to 
IKKβ or signaling capability in cells (Sections 3.3.6 and 3.3.7). Therefore, a deficit 
in conformational change is likely the reason for the inability of the IVD mutant 
9SG-NEMO to propagate NF-κB signaling. Additional evidence for this is shown 
by the inability of co-transfected ΔN- and ΔC-NEMO constructs to activate IKKβ 
(Section 3.3.8): if NEMO can signal in trans, conformational change would be 
dispensable for NF-κB signaling. We have shown that this is not the case. It is 
important to note that because the addition of NEMO to the Sox assay did not 
enhance the rate of IKKβ phosphorylation of IκBα, despite IKKβ inducing a 
conformational change in NEMO under somewhat similar conditions, this 
conformational change may not be sufficient for signal propagation to occur. 
More likely, there are additional co-factors such as poly-ubiquitin that are 
required for signaling to be activated.  
For instance, a study by Catici and colleagues106 provided evidence that 
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poly-ubiquitin allosterically drives molecular interactions of NEMO with IKKβ 
and IκBα. The presence of IKKβ and IκBα on their own or in concert induced a 
conformational change in NEMO as measured by ANS fluorescence changes and 
the change in intrinsic fluorescence of W6. This ligand-induced conformational 
change concept is illustrated in Figure 37C. A conformational change in NEMO 
upon IKKβ binding was also demonstrated in Section 2.3.5 of this dissertation. 
The addition of deca-ubiquitin changed the kinetics of these conformational 
changes from zero-order with respect to the concentration of IKKβ and IκBα, to 
first-order. Therefore, ubiquitin binding is likely eliminating a rate-limiting step 
to make NEMO more competent to either bind IKKβ and IκBα or undergo a 
conformational change. Using SAXS to probe the effect of poly-ubiquitin on 
NEMO conformational change, as has been demonstrated in this dissertation, 
would allow more detailed exploration of this allosteric mechanism by which 
ubiquitin drives NEMO interactions. While the evidence of Catici et al. is clear 
that IκBα induces a conformational change in NEMO, it is unlikely that this 
relatively slow event is a mechanistically important occurrence because NEMO-
IKKβ likely phosphorylate multiple IκBα molecules per complex formation, as 
discussed above and is diagrammed in Figure 37D.  
An alternative model was recently proposed by Hauenstein and 
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colleagues63 where NEMO is in an auto-inhibited state prior to binding of 
ubiquitin chains longer than four units. The region spanning amino acids 120-150 
in NEMO was hypothesized to be required for maintenance of this auto-inhibited 
state, as its presence precludes binding of a more C-terminal region of NEMO to 
linear di-ubiquitin, but not linear tetra-ubiquitin. This model is illustrated in 
Figure 37B. If it were true, mutation of highly conserved residues 145-153 as in 
the 9SG-NEMO construct, as well as the disease-associated mutation R123W, 
would likely prevent auto-inhibition from occurring, resulting in a constitutively 
active NEMO. Section 3.3.6 and a study by Fusco and colleagues140 provide 
evidence contrary to the Hauenstein et al. hypothesis, as 9SG-NEMO is inactive 
in propagating signaling and R123W behaves as WT. Additionally, these authors 
argue, based on SAXS analysis, that vFLIP activates NEMO by opening it up, 
overcoming auto-inhibition. vFLIP has been previously shown to induce NF-κB 
signal activation by binding to NEMO68. This MBP-vFLIP-NEMO SAXS model is 
highly similar to that shown above in Section 2.3.3 which is unliganded (Dmax 320 
versus 315 Å, respectively), despite the perhaps misinterpreted presence of MBP-
vFLIP. Therefore, it is unlikely that their SAXS model reflects a vFLIP-induced 
"opening" of NEMO, but rather reflects the "open" natural conformation of 
NEMO on its own. Given all of the above, the opposite of the Hauenstein et al. 
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hypothesis is more likely to be true: NEMO is extended and inactive prior to 
IKKβ binding (Section 2.3.5) and poly-ubiquitin binding106, rather than folded 
inward and inactive prior to poly-ubiquitin binding "opening up" NEMO.  
Once a stable ubiquitin-NEMO-IKKβ complex is formed at the membrane, 
it is likely that this complex phosphorylates many IκBα molecules, as opposed to 
the complex turning over one molecule per complex formation. Evidence for this 
is from the apparent affinity of NEMO-zinc for IκBα, which is approximately 
1000-fold weaker than the binding affinity of NEMO for IKKβ as discussed in 
Section 3.3.3. A single turnover for the formed complex would likely require an 
affinity of NEMO for IκBα similar to that of IKKβ, and would likely be 
energetically costly to assemble such a complex for a single phosphorylation 
event. Figure 37D illustrates the hypothesis that a stable NEMO-IKKβ complex 
turns over multiple IκBα molecules. It should be noted that this inference from in 
vitro experiments might or might not be true in vivo for a few possible reasons, 
rendering single turnover IKK complex formation to be more energetically 
efficient and plausible: perhaps other binding partners enhance IKK complex 
formation; the IKK complex members are localized to the membrane so 
dissociated complexes may reform much more rapidly than in vitro; and there 
may be additional post-translational modifications that alter complex formation 
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and turnover. Once phosphorylation is complete, IκBα is subsequently degraded 
in the proteasome, releasing the previously sequestered NF-κB subunits to 
translocate into the nucleus and upregulate NF-κB gene transcription. 
 
 
Figure 37: Possible mechanisms of NEMO activation. A: IKKβ and IκBα bind to NEMO 
through simple rigid protein binding. IKKβ and IκBα are close enough to produce a 
phosphorylation event. B: Model proposed by Hauenstein and colleagues63, where NEMO 
exists in an auto-inhibitory state with binding sites inaccessible or occluded prior to linear 
tetra-ubiquitin (M1-4Ub) binding. Subsequent steps occur in some fashion, perhaps 
according to schemes A, C, or D, in which phosphorylated IκBα is produced. C: IKKβ and 
IκBα each induce a conformational change in NEMO that leads to a final productive complex 
formation. This model, combined with linear poly-ubiquitin binding, is consistent with 
findings from Catici and colleagues106. D: IKKβ binds to NEMO and induces a 
conformational change to a catalytically competent complex, where the stable complex can 
phosphorylate multiple sequential IκBα molecules. 
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Chapter 4: Screening for NEMO-IKKβ Interaction Inhibitors 
4.1 Introduction 
Scaffold proteins typically do not have so-called active sites for chemistry 
to occur; instead, they function by binding their target protein(s), which in turn 
elicits a response. These protein-protein interaction sites, or PPIs, are often 
lacking concavities with binding energy hot spots more dispersed than typically 
seen in a small binding pocket, and are often considered undruggable. This is 
because small molecule libraries have been refined based on likeness to existing 
drugs166, most of which may have difficulty selectively bridging multiple binding 
hot spots on a potentially featureless surface167. Also, many PPIs share common 
binding interface characteristics, such as similar electrostatics and shape. This 
greatly increases the challenge in finding a selective PPI inhibitor. It is estimated 
that of the approximately 30,000 proteins in the human proteome, there are 
between 40,000 and 200,000 PPIs in the human interactome168,169. To rationally 
exploit this large number of potential drug targets and overcome the challenge of 
“undruggability,” we need to better understand PPIs beyond simple protein 
binding. Because of this current limited knowledge and other technical 
difficulties, investment of resources in PPI targets by pharmaceutical companies 
is rare. Despite this, some progress has been made regarding types of PPIs that 
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can be inhibited109,170 and individual PPIs have been successfully targeted with 
drug-like compounds171–178. Notably and conversely, progress has also been 
shown using small molecules that promote stabilization of PPIs179. 
Binding energy hot spots are sites on a protein where specific interatomic 
interactions contribute significantly to ΔΔG of a binding event. Docking 
algorithms such as FTMap180 have been designed to robustly identify such hot 
spots, and have been validated experimentally108. Because PPIs typically have 
larger, flatter binding surfaces, the identification of hot spots may help facilitate 
the design of inhibitors that, while substantially smaller than their protein 
competitors, bind efficiently to these sites, competing for surface. On one hand, 
classical small molecules may be screened for inhibition, with structure-activity 
relationship studies performed on hits to improve potency and other relevant 
parameters. However, they are less likely to occupy multiple hot spots to provide 
sufficient potency181. Additionally, there is the issue of macromolecular crowding 
in cells that can lead to reduction in inhibitory activity in vivo. For example 1), the 
observation of reduction of inhibition activity of a capsid-binding peptide and a 
small capsid protein domain that interfere with assembly of the human 
immunodeficiency virus capsid in cellulo versus ex cellulo, and 2), similarly that of 
a RGD-containing peptide blocking the interaction between foot-and-mouth 
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disease virus and receptor molecules on the host cell membrane182,183. Therefore, 
for an inhibitor to elicit a therapeutically relevant response in cells, it must be 
highly potent to overcome these potential crowding issues. 
A potentially advantageous strategy is to screen molecules more likely to 
occupy multiple hot spots to begin with, thus increasing potency. Macrocycles 
are such molecules, which are large organic molecules often above 500 Da that 
frequently bind to proteins to modulate their function184. Additionally, 
stabilization of the molecule by having a rigid ring structure lowers the entropic 
cost of binding, and may enhance cell permeability185,186. Because of these 
potential advantages, macrocycles are a good class of potential inhibitors to 
screen for PPI inhibition. Importantly, there have been successes with non-
classical drug-like, FDA-approved macrocycles for treatment of disease, 
primarily from natural product analogs such as Torisel (temsirolimus, mTOR 
inhibitor)187, Ixempra (ixabepilone, a microtubule stabilizer)188, and 17-
allylamino-geldanamycin (Hsp90 inhibitor)189. 
Because NEMO is an essential component of a major signaling pathway in 
human biology, there exists a strong therapeutic motive in studying and 
targeting this protein. A small-molecule inhibitor of the NEMO-Ubiquitin 
interaction was developed that selectively inhibits NF-κB activation in response 
 
 
 
 
140 
 
to TNFα, but not IL-1β, stimulation. This small molecule was shown to 
selectively kill lymphoma cells that were addicted to NF-κB signaling, providing 
strong evidence that NEMO is a potentially useful therapeutic target83. A 
different small-molecule inhibitor of the NEMO-IKKβ interaction was shown to 
inhibit cellular NF-κB signaling, and was computationally docked into the X-ray 
crystal structure of the NEMO-IKKβ binding interface84. However, no 
mechanistic studies were performed, so the precise target of the small molecule is 
unknown. A cell-permeant version of the NBD 11-mer peptide has been shown 
to disrupt the NEMO/IKKβ complex in vivo, and causes a specific biological 
outcome that attenuates activation of NF-κB but does not affect basal NF-κB 
function85,86. Quite surprisingly, the NBD peptide has been shown to prevent 
memory loss in a mouse model of Alzheimer’s disease, a function with which 
NF-κB had not previously been directly linked87. The NBD peptide has also been 
shown to attenuate tumor proliferation and prolonged mouse survival in a 
malignant glioma mouse line88. A synthetic loop replacement version of the NBD, 
in which a conserved hydrogen bond was replaced with a covalent hydrocarbon 
bridge to enhance rigidity, has been shown to be 10-fold more potent in blocking 
NEMO-mediated NF-κB signaling than wild-type NBD peptide89, and may prove 
to be a worthwhile strategy for further optimizing the NBD peptide for 
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Figure 38: Inhibitor discovery work flow. Pyramid indicates that each step 
should narrow down the number of compounds by eliminating those with no 
activity or that were false hits. 
 
Single-point inhibition screen
Single-point solubility test
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SPR Validation
Cell-based 
assays
therapeutic use. IKKβ knockout in a mouse model mimicked NEMO-knockout, 
but the fatal liver damage occurred at a later stage in embryonic development90. 
Notably, IKKβ inhibition through salicylate and its derivatives has been 
established but studied in models of vascular disorders and metabolic 
syndrome91 in addition to immunomodulatory capacities92,93. These attempts to 
inhibit NF-κB signaling through IKKβ have not been shown to modulate NEMO-
based NF-κB disease states. 
This chapter describes attempts to develop a non-peptide small molecule 
or macrocycle inhibitor of NEMO. The work flow is illustrated as a funnel in 
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Figure 38 in order to draw attention to the fact that each step in the process is 
designed to eliminate false hits from previous steps and verify true NEMO 
inhibitors. First, compounds were screened for inhibition and solubility in an 
aqueous environment at a single concentration. Determining solubility at this 
step is important to reduce the likelihood of false positives; additionally, organic 
small molecules tend to have poor solubility in an aqueous environment; these 
are less likely to become therapeutically relevant given the aqueous nature of 
cells. Second, the concentration dependence of inhibition of the initial hits is 
measured to eliminate false positives due to, for example, microaggregates 
nonspecifically segregating or inactivating one or both of the binding partners190. 
A true inhibitor should go from 10% inhibition to 90% inhibition over two log 
units of concentration; microaggregates typically have a steeper slope over this 
inhibition range, corresponding to its solubility190. Third, fluorescence-based 
assays are prone to inhibition for a number of reasons156,190,191, so a secondary 
validation assay is important. Here, SPR is employed to show that the compound 
binds to NEMO in a simple stoichiometric fashion, with an affinity relatable to 
that measured in a dose-response FA assay. Finally, the ability of the compound 
to inhibit NEMO in a cellular context is evaluated by two means: stimulating NF-
κB signaling and measuring the ability of NEMO to direct IκBα phosphorylation; 
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and determining whether NEMO can co-immunoprecipitate with IKKβ. This 
demonstrates whether the compound is cell permeable and whether it may be 
potent enough for further studies as a therapeutic.  
In silico analysis can strengthen or weaken the case for a compound to 
inhibit its target. This is accomplished by docking the molecule into the 3D 
structure of the target; this often illuminates possible binding modes, which can 
yield invaluable information for subsequent SAR work to improve potency 
and/or PK/PD profiles. Occasionally, however, docking identifies no meaningful 
binding pose. If no meaningful binding pose is found despite clear in vitro 
inhibition, either the molecule is inhibiting by some allosteric mechanism, i.e. 
binding to a region outside of the 3D structure used for docking, or the molecule 
is likely to be a false positive. Because these two possibilities are often extremely 
difficult to distinguish, computational docking is not considered a “filtering” 
step. Nevertheless, docking analysis for a small-molecule hit is presented here, 
and shows an interesting binding pose that may be valuable for SAR follow-up 
work. 
In this chapter, the described discovery pipeline is presented for inhibitor 
discovery for the NEMO-IKKβ interaction. Both classical drug-like small-
molecule and non-classical macrocycle libraries were screened. One hit from the 
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CMD collection is described in terms of its physicochemical properties, and 
validated by an orthogonal FA assay, SPR, and in a cell lysate Co-IP. However, 
no macrocycles passed the first validation step.  
 
4.2 Materials and Methods  
4.2.1 Materials  
All small-molecule compounds and Set 5 macrocycles were provided by 
the Boston University Center for Molecular Discovery (BU-CMD) from their 
library of compounds. From an initial library of 80,000 macrocycles from Asinex 
Corporation (Winston-Salem, NC), the BU-CMD selected 800 of which had 
predicted good aqueous solubility and structural diversity. The remaining 
reagents were identical to those used in Chapter 3 (Section 3.2.2). A list of the 
screened compound sets is provided in Table 4, and the structures for all hits are 
shown in Appendix VI. 
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4.2.2 Initial Screen using Fluorescence Anisotropy and UV/Vis Spectroscopy 
Screened compounds were provided either as a stock solution in 100% 
DMSO at 20 mM, 100% DMSO at 0.3 mM, or 200 nmol dry powder. Compounds 
were provided dried in 96-well plate format, and were re-dissolved with 10 μL of 
100% DMSO to achieve a concentration of 20 mM. For initial screening of 
compounds provided at 20 mM, the compounds were diluted to 400 μM in 50 μL 
of 10% (v/v) DMSO, so that addition of this solution into the 200 μL final assay 
volume results in a final concentration of 100 μM compound and 2.5% (v/v) 
DMSO. For initial screening of compounds provided at 0.3 mM, the compounds 
were diluted to 120 μM in 25 μL in 60% (v/v) DMSO, so that addition into the 100 
μL final assay volume results in a final concentration of 30 μM in 15% (v/v) 
DMSO. Prior to screening, the UV spectra from 220-750 nm of the compounds in 
final assay solution was measured in a 96-well UV-transparent microtiter plate. 
Table 4: List of screened compound sets. 
 Type Origin # screened # initial hits 
# validated 
by D-Ra 
# for further 
study 
Set 1 Small-molecule CMLD 869 26 4 1 
Set 2 Small-molecule CMLD 12 5 2 2 
Set 3 Small-molecule CMLD 45 2 1 0 
Set 4 Diverse CMLD 2457 35 -- -- 
Set 5 Macrocycle CMLD 28 0 -- -- 
Set 6 Macrocycle Asinex 800 7 0 -- 
aD-R: dose-response 
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The turbidity at 700 nm relative to a blank containing all assay components 
except compound was used to determine solubility; small organic molecules, 
which are not green in color, should not absorb at long wavelengths such as 700 
nm, so any "absorbance" is due to optical interference by insoluble particles. 
Compounds with absorbance values > 20% above the baseline were deemed 
insoluble. 
Regardless of solubility at this stage, compounds were then transferred to 
black opaque 96-well plates for performance of the FA assay. These assays were 
performed as described previously (Section 3.2.2). Briefly, 50 μL assay buffer (200 
mM Tris, pH 7.4, 800 mM NaCl, 0.04% (v/v) Triton X-100, 4 mM DTT, stock 
concentration) was added to each well. Both NEMO and FITC-IKKβ were diluted 
from a concentrated stock to 60 nM in water and then added to the wells at 50 μL 
each. Columns 1 and 12 of each assay plate were reserved for controls: wells A, 
B, and C contained the high control, NEMO plus FITC-IKKβ; wells D, E, and F 
contained the low control, FITC-IKKβ alone; and wells G and H contained only 
buffer. The assay plate was then covered with opaque adhesive to prevent 
fluorophore bleaching and incubated at 25 °C for 1 h before the fluorescence was 
measured. 
The anisotropy signals were calculated based on the method used in 
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Section 3.2.2 and converted to % Max FA signal using Equation 3: 
% 𝑀𝑎𝑥 𝐹𝐴 = ቀ ௌିௌ೘೔೙
ௌ೘ೌೣିௌ೘೔೙
ቁ ∗ 100    (3) 
For each well, the assay signal (S) was normalized to the assay range of each 
plate (Smax and Smin determined by high [NEMO plus FITC-IKKβ] and low [FITC-
IKKβ alone] controls, respectively), and multiplied by 100 to give the percentage 
of tracer probe binding at the indicated compound concentration. Normalization 
corrects for plate-to-plate variability. Compounds that showed both (a) < 50% 
Max FA Signal, i.e. > 50% inhibition, and (b) an absorbance at 700 nm less than 
20% above baseline were deemed hits from this initial screen. These strict cutoffs 
were chosen to achieve < 5% hit rate for follow-up. 
4.2.3 Dose-Response Fluorescence Anisotropy Assay 
Hits from the initial single-point screen were then further characterized 
using the FA assay in a dose-response format. The assay was identical to the 
initial screen with one difference: working concentrations were 400 μM in 50 μL 
(for 200 μL assay volume) or 120 μM in 25 μL (for 100 μL assay volume) prior to 
two-fold serial dilution in 10% or 40% (v/v) DMSO respectively. The assay was 
performed and data were normalized as in Section 4.2.2. If dose-dependent 
inhibition was observed for a compound, the data were fit to the four-parameter 
Equation 4 below to determine the IC50, where L is IC50, and F is a scaling factor:  
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𝑌 = (𝑌௠௔௫ − 𝑌௠௜௡) ∗ ൭
ଵ
ଵାቀಽೣቁ
ಷ൱ + 𝑌௠௜௡    (4) 
Occasionally compounds may pass initial screening tests despite being 
false positives190. For compounds showing any unusual signs, such as a steep 
slope (typically defined as greater than 1.5) between 10% and 90% inhibition, 
total fluorescence intensity was examined to confirm dose-dependent inhibition 
in this assay. Aggregation of the compounds would be a primary cause of 
inconsistency in total fluorescence. The fluorescence intensity of each compound 
was determined by examining the raw fluorescence data from the plate reader. 
None of the validated hits showed dose-dependent fluorescence intensity 
changes above or below the minus-compound controls. 
4.2.4 Hit Validation 
Compounds that passed the follow-up dose-response assay with an IC50 < 
50 μM and no unusual features in solubility or dose-response were then 
subjected to three validation tests to rule out false positive inhibition as a result 
of an assay artifact. The first test was an orthogonal dose-response inhibition 
screen against the Keap1-Nrf2 interaction developed by Mengqi Zhong of the 
Whitty group (M. Zhong, unpublished). A specific inhibitor should not inhibit an 
unrelated PPI. Compounds were tested identically as in the NEMO/IKKβ assay, 
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except the final concentration of Keap1 was 10 nM and FITC-Nrf2 was 5 nM. 
The second validation test was surface plasmon resonance (SPR) to 
measure direct binding and signs of compound aggregation. SPR was run 
identically as described in Section 3.2.3, except the 7xAla-NEMO protein coupled 
to the surface was only thiol-coupled, with NEMO(44-195) and BSA as negative 
controls random amine coupled to the chip. Compounds were initially tested at 
200 μM and serially diluted from 100 μM to 12.5 μM for a dose-response format. 
A true hit should show reversible binding (i.e. signal decreases to baseline after 
stoppage of compound injection) and a signal in response units (RU) 
proportional to that expected for its mass. 
The third validation test was co-immunoprecipitation (Co-IP), performed 
by the Gilmore group, to test for inhibition in a more biologically-relevant 
environment. Briefly, Mouse Embryonic Fibroblasts (MEFs) that express FLAG-
NEMO and IKKβ were harvested and lysed. Varying concentrations of the 
inhibitor were then added to the lysate, or DMSO alone as a negative control. 
Agarose beads displaying anti-FLAG antibodies were then used to 
immunoprecipitate the FLAG-NEMO from the cell lysate. These samples were 
analyzed by Western blot to determine whether the compound blocked the co-
immunoprecipitation of IKKβ with the NEMO.  
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4.3 Results and Discussion  
4.3.1 Small-Molecule Library Screening and Validation 
A set of 869 small organic compounds (Set 1) were provided by the BU-
CMD for screening. These compounds were screened for solubility and 
inhibition of the NEMO- IKKβ peptide interaction at a single concentration, 100 
μM in 10% DMSO v/v. Out of this set, 26 compounds emerged as hits (Appendix 
VI), having better than 50% inhibition and absorbance at 700 nm below 0.1. This 
corresponds to a hit rate of 3% (Figure 39). 
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 Each of the 26 hits was then analyzed in an eight-point dose-response 
assay titrated from a concentration of 100 μM to 0.78 μM. Eight of the 26 hits 
showed a dose-response. Of these, four were deemed too weak (IC50 > 100 μM) to 
continue, and four were then subjected to a repeat dose-response assay 
performed in triplicate. The final results of initial % max FA signal at 100 μM, 
Abs at 700 nm, and IC50 are shown in Table 5, and the selected dose-response 
profiles of the top two hits are shown in Figure 40. The compound that showed 
the best inhibition was 10190, which gave IC50 values in the two independent 
Figure 39: Results of inhibition and solubility screens of Set 1. Compounds that showed better 
than 50% inhibition (lower than 50% max FA signal) and an absorbance at 700 nm < 0.1 were 
selected for dose-response analysis and are within the box delineated by red dashed lines. 
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experiments of 17 ± 1.8 μM and 32 ± 1.6 μM. 
 
Additional analogs of 10190, designed for improved solubility, were obtained 
from the CMD-BU and were tested in the NEMO FA assay in a dose-response 
format. These compounds are referred to as Set 2. Of the twelve compounds in 
Table 5: Statistics for 8 hits from Set 1 that passed dose-response validation. 
CMD Code % Max FA Signal Abs700 IC50 
9571 34 0.04 ≥100 μM 
9574 21 0.05 ≥100 μM 
9576 19 0.05 ≥100 μM 
9578 37 0.04 ≥100 μM 
9725 30 0.03 ≥100 μM 
9744 46 0.04 ≥100 μM 
10190 -18 0.05 16 μM 
10197 7.5 0.04 70 μM  
 
Figure 40: Dose-response data for top two compound hits from Set 1. Assay was 
normalized to high (NEMO+IKKβ) and low controls (IKKβ alone). Data were fit to 
the four-parameter equation shown in Equation 2. 
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Set 2, five showed IC50 values < 50 μM, but only two showed acceptable solubility 
as well (Abs700 nm < 0.1) (Figure 41). These compounds were 10487 and 10557; both 
showed IC50 values of 8 μM, and were selected for further validation as described 
below in Section 4.3.3. 
 
Next, 45 structurally similar analogs of 10190 were screened (Set 3) as an 
expanded version of Set 2. In this set, two compounds showed significant 
inhibition following screening at 30 μM in 10% (v/v) DMSO: 10197 (previously 
identified as a weak hit in Set 1) was the only one to also show acceptable 
 
Figure 41: Dose-response of top two hits from Set 2, soluble analogs of initial hit 10190. 10189 
is a free base form of 10190; its IC50 is comparable. Assay normalized to high (NEMO+IKKβ) 
and low controls (IKKβ alone). Data were fitted to the four-parameter equation shown in 
Equation 4. 
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solubility, below the typical Abs700 cutoff of 0.1 (Figure 42). Compounds 10557 
(from Set 2) and 10190 (from Set 1) were included in this screen but, 
unexpectedly, did not show significant inhibition, despite multiple previous 
demonstrations of inhibition. Nevertheless, it was notable that 10197 showed 
signs of inhibition, because it was not pursued following weak inhibition from 
the screen in Set 1. These discrepancies may be a result of screening at a four-fold 
higher concentration of DMSO than previously, despite previous evidence 
suggesting that the assay can tolerate such concentrations (Shaun Cote, 
unpublished). 
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The availability of an updated and greatly-expanded CMD library yielded an 
opportunity to screen a larger and more diverse set of 2457 compounds (Set 4). 
These compounds were screened at 30 μM in 10% DMSO v/v, and 35 hits were 
selected that showed better than 50% inhibition and an Abs700 below 0.042 
(Figure 43). The resulting hit rate of this set meeting these criteria is 1.4%.  
 
Figure 42: Results from initial inhibition and solubility screen for Set 3. Compound 10197 was 
the only compound to show acceptable inhibition (<50% max FA signal) and solubility (Abs700  
below 0.042, baseline).  
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4.3.2 Macrocyclic Compound Screening 
In addition to the small molecules assayed above, synthetic macrocycles 
were explored as potential NEMO inhibitors. First, a set of 18 compounds (Set 5) 
was provided by the CMD. Fifteen were macrocycles, and three were multimeric 
analogs of a previous compound of interest, 9644. The three multimeric analogs 
of 9644 were include here because they are similar to macrocycles in that they are 
not considered classically drug-like. Each of these compounds was screened in a 
dose-response format, starting at 500 μM, and serially diluted to 3.9 μM in 2.5% 
 
Figure 43: Results from initial inhibition and solubility screen for Set 4. A total of 35 
compounds out of 2457 showed acceptable inhibition (<50% max FA signal) and solubility 
(Abs700 nm < 0.042, baseline).  
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v/v DMSO. The resulting anisotropy values for each compound were normalized 
to the controls as above. The data from this assay are shown in Figure 44. None 
of these compounds showed signs of inhibition, even at concentrations up  to 500 
μM. In fact, some of the compounds showed an increase in anisotropy at these 
high concentrations; this is likely due to nonspecific hydrophobic interactions 
between fluorescein and aggregated compound, resulting in a slower tumbling 
rate for the FITC-IKKβ tracer probe than when bound to NEMO. 
In addition to this set, the natural product version of 9644, Calafianin, as well as a 
 
Figure 44: Dose response results for Set 5. None of the compounds exhibited significant 
inhibition. Some showed an increase in anisotropy signal at high concentrations; this is 
likely due to insolubility artifacts. Dashed lines indicate high (NEMO + IKKβ) and low 
(IKKβ alone) controls. 
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mono-ketal protected version, were analyzed in a dose-response format. Only 
the mono-ketal protected version showed significant inhibition, at 20 μM (Figure 
45). 
 
A set of 800 macrocycles from Asinex Corporation were selected by the CMD out 
of 80,000 for structural diversity and predicted aqueous solubility, and were 
screened in the NEMO-IKKβ FA assay (Set 6) at 30 μM in 10% v/v DMSO. Seven 
hits showed greater than 50% inhibition with acceptable solubility, but none 
replicated in a dose-response assay at concentrations up to 100 μM (Figure 46). 
 
Figure 45: Dose response results for 9644 and precursors. The natural product precursor to 
9644, Calafianin, as well as a mono-ketal protected version, showed dose-dependent 
inhibition of NEMO-IKKβ binding, whereas 9644 showed an increase in anisotropy that is 
likely the result of insolubility. Dashed lines indicate high (NEMO + IKKβ) and low (IKKβ 
alone) controls. 
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4.3.3 Secondary Validation of Small-Molecule Hits  
Attempts were made to validate 10190 first because of its promising IC50 
and solubility. To determine inhibition specificity, the Keap1-Nrf2 FA assay was 
used in a dose-response format. No significant inhibition was observed at 
concentrations of 10190 up to 100 μM. However, 10190 then failed the next two 
validation tests. SPR was used to test for direct binding of 10190 to NEMO (assay 
performed by Dan Petrescu). However, superstoichiometric binding was 
 
Figure 46: Dose response results of Asinex macrocycle hits. None showed significant 
inhibition up to 100 μM. Dashed lines indicate high (NEMO + IKKβ) and low (IKKβ alone) 
controls. 
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observed, indicating large nonspecific aggregates of the compound bound to the 
surface of the chip, causing a large increase in signal disproportionate to the 
mass of the protein and compound. The second test was a co-
immunoprecipitation assay performed by the Gilmore group. The goal was to 
determine whether 10190 could block Co-IP of NEMO and IKKβ from 293 cells 
following treatment with DMSO or varying concentrations of 10190. Not only 
was there no sign of inhibition of binding, but there were seemingly no effects on 
the cells; this led to the conclusion that 10190 is likely not cell permeable. It is 
also possible that 10190 has insufficient affinity for NEMO to overcome 
macromolecular crowding effects, which would be manifested in a lack of 
activity in cells. 
To seek a variant of this chemotype that has activity in the cellular assays, 
the focus turned to the more-potent compounds 10487 and 10557 described 
above from Set 2. First, the compounds were analyzed for direct binding to 
NEMO in SPR. Compound 10557 shows direct binding to NEMO as determined 
by reversible binding and signal (RU) proportional to the mass of the compound 
(10557 shown in Figure 47). However, 10487 appeared to have a higher than 
expected signal, with signs of possible reversible covalent binding or otherwise 
unexpectedly slow dissociation kinetics. This is evident by linear binding 
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behavior with a sharp slope during the association phase and shallow slope 
during the dissociation phase. Because of these potential complications, and the 
fact that 10557 showed reversible stoichiometric binding, 10557 alone was 
continued for further validation.  
 
The second validation test for 10557 was for inhibition of the NEMO-IKKβ 
interaction in cell lysate, performed by the Gilmore group. Here, cells were 
treated with either 10557 or DMSO, and lysed. NEMO was then 
immunoprecipitated from the lysate, and a Western blot was used to probe for 
 
Figure 47: SPR results for 10557 binding to 7xAla-NEMO. 7xAla was thiol-coupled to the 
surface of the chip and two-fold serial dilutions of 10557 were flowed over the surface. 
Vertical lines indicate start (left) and end (right) of 10557 injection. Concentration of 10557 
shown in legend in upper left corner of plot. 
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co-immunoprecipitated IKKβ. As shown in Figure 48, the resultant Western blot 
appears to show decreasing IKKβ pull down with increasing concentrations of 
10557, a sign of inhibition. However, there is a faint band detected by the anti-
IKKβ antibody at a higher-than-expected molecular weight that appears in the 
presence of 10557. The faint band is not high enough to indicate an oligomer, but 
may instead be indicative of formation of a covalent adduct between 10557 and 
IKKβ. However, the formation of a covalent adduct is inconsistent with the SPR 
data that showed reversible noncovalent interaction between 10557 and NEMO. 
Thus, the only plausible mechanism for covalent adduct formation is through a 
specific interaction between 10557 and IKKβ, which seems unlikely. 
 
 
 
Figure 48: Cells that express IKKβ and FLAG-NEMO were lysed and treated with indicated 
concentrations of 10557. Beads were then added that were coated with an anti-FLAG 
antibody, and were pelleted by centrifugation. The pellets were resuspended and denatured 
with SDS running buffer to dissociate bound protein, and run on SDS-PAGE before Western 
blotting. Detection was with an anti-IKKβ antibody (IKKβ) or anti-FLAG antibody (NEMO). 
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4.3.4 Properties of Hit: CMLD10557 
To determine a theoretical binding pose, 10557 was computationally 
docked into the crystal structure of NEMO(44-111)28 using AutoDock Vina192. The 
resulting pose is displayed in Figure 49, which was created using UCSF 
Chimera129. In the docking procedure, the IKKβ chains in the structure were 
removed, leaving the IKKβ-binding site in the NEMO dimer open for ligand 
binding. The binding pose shown suggests that the bulk of the compound 
occupies a hydrophobic pocket that, in the liganded complex, accommodates hot 
spot residues W739 and W741 of IKKβ. Therefore, 10557 is likely a competitive 
inhibitor of IKKβ, competing for the same binding site. Notably, and perhaps 
predictably, AutoDock Vina docked 10557 into the top binding energy hot spot 
as determined by FTMap and alanine-scanning mutagenesis104. 
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Drug-like properties were determined for 10557 for further 
 
Figure 49: Compound 10557 was computationally docked into the NEMO(44-111) 
structure with ligand removed using AutoDock Vina and displayed in UCSF Chimera. 
The surface of NEMO is colored as an electrostatic map; red indicates negatively 
charged surface, blue positively charged surface. White indicates neutral or 
hydrophobic patches.  
Table 6: Key properties of compound 10557. 
Property Value 
cLogPa 3.67 
TPSAb 76.74 
MWc 430.5 
H-bondd acceptors 5 
H-bond donors 1 
# rotatable bonds 10 
acLogP, octanol-water partition coefficient; bTPSA, topological polar surface area; cMW, 
molecular weight; dH-bond, hydrogen bond.  
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characterization. Solubility has been addressed in Section 4.3.2; in an aqueous 
environment, an inhibitor should be soluble at > 100 μM, > 10-times above IC50. 
Physicochemical properties have classically been indicative of drug-likeness, 
despite numerous exceptions and extensions to this idea166,193–196. These key 
properties are outlined in Table 6 and were calculated using 
Molinspiration193,195,197.  
Compound 10557 falls within each tenet of Lipinski’s Rule of 5193, which 
would be remarkable for a therapeutic PPI inhibitor given the aforementioned 
difficulties in blocking a large interaction interface. Notably, the ligand efficiency 
(LE), or binding energy contribution from each heavy atom, is 0.23 kcal/mol. A 
typical Lipinski-compliant193 small molecule target for LE is 0.3 kcal/mol168; it is 
expected that 10557 is below this target value with μM affinity, versus drug-like 
affinities typically in the lower, single-digit nM range. Additionally, 10557 is 
predicted to have good oral bioavailability due to the number of rotatable bonds 
being <10 and the polar surface area being <140 Å2 195. Due to the theoretical 
binding pose at the major IKKβ binding energy hot spot and the acceptable 
physicochemical properties, 10557 appears to be a practical candidate for further 
study as a NEMO-IKKβ interaction inhibitor. 
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4.4 Conclusions and Future Directions 
A previous study showed that small-molecule inhibitor of the NEMO-
IKKβ interaction inhibits cellular NF-κB signaling, and was computationally 
docked into the X-ray crystal structure of the NEMO-IKKβ binding interface84. 
However, no mechanistic studies were performed, so the precise target of the 
small molecule is unknown. A cell-permeant version of the NBD 11-mer peptide 
has been shown to disrupt the NEMO/IKKβ complex in vivo, and causes a 
specific biological outcome that attenuates activation of NF-κB but does not 
affect basal NF-κB function85,86. The NBD peptide has also been shown to 
attenuate tumor proliferation and prolonged mouse survival in a malignant 
glioma mouse line88. A synthetic loop replacement version of the NBD, in which 
a conserved hydrogen bond was replaced with a covalent hydrocarbon bridge to 
enhance rigidity, has been shown to be 10-fold more potent in blocking NEMO-
mediated NF-κB signaling than wild-type NBD peptide89, and may prove to be a 
worthwhile strategy for further optimizing the NBD peptide for therapeutic use. 
Other than the synthetic loop replacement strategy for utilization of the NBD 
peptide for NEMO inhibition, the literature has not shown any mechanistic 
studies of a small molecule or stable (i.e., non-peptide) potential therapeutic to 
treat NEMO-related human disease. The work performed in this chapter was 
 
 
 
 
167 
 
aimed at addressing this shortcoming. 
A small number of the macrocyclic compounds tested showed initial 
activity as inhibitors of NEMO-IKKβ binding. The initial hit rate was similar to 
that of typical small molecule inhibitor screens, <5%, but none were validated in 
a dose-response assay. Improvements in computational screening will allow for 
selection of macrocycles with a higher chance of success in the future. This, 
coupled with improvements in macrocycle synthesis methods, will allow for 
better rational macrocycle library design for inhibition of protein-protein 
interactions. Additionally, an increased knowledge of how macrocycles bind in 
grooves, such as the groove in NEMO to which IKKβ binds, will afford a better 
chance of success in these endeavors. 
Compound 10190 was identified as a hit from an initial screen of the CMD 
collection after it passed dose-response validation and an initial solubility screen. 
The compound failed in an SPR orthogonal assay, however, that clearly showed 
signs of superstoichiometric binding typically observed with aggregation-prone 
compounds. Additionally, it did not show any signs of inhibition or toxicity in 
cells, so it may not have been cell-permeable. It is also possible that the 
compound has insufficient affinity for NEMO to overcome the effects of 
macromolecular crowding that decreases the apparent inhibition activity in a 
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crowded environment, which would also explain the lack of activity in cells. 
More soluble analogs of 10190 were subsequently assayed for dose 
response, and one compound emerged as both highly soluble and displayed a 
better IC50 than its parent compound. This compound, 10557, was verified by 
SPR to bind directly to NEMO in a stoichiometric manner, and appeared to block 
NEMO-IKKβ co-IP in cell lysate, though there are some technical concerns with 
that result due to the faint bands at slightly higher molecular weight that cannot 
be due to oligomerization. Physicochemical properties of this compound fall 
within Lipinski's Rule of 5, and a reasonable docked pose on the NEMO 44-111 
structure are shown above in section 4.3.4.  
Further tests are necessary to determine whether the molecule 10557 
represents a useful starting point for a potential therapeutic NEMO inhibitor. 
Orthogonal FA assays would be useful to determine inhibition specificity. Cell 
permeability assays, such as PAMPA198 or Caco-2199, would determine whether 
this compound is able to cross the cell membrane to block NF-κB signaling in the 
cytoplasm. In parallel artificial membrane permeability (PAMPA) assays, mass 
spectroscopy is used to determine whether the analyte has crossed from a donor 
compartment to an acceptor compartment through an artificial membrane that 
simulates a cell membrane. The Caco-2 cell line is a contiguous layer of 
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heterogenous human epithelial colorectal adenocarcinoma cells commonly used 
as an in vitro model to predict absorption of oral drugs. It is becoming less 
commonly used than PAMPA due to divergent characteristics of the cells 
following different passage protocols. Signaling assays in vivo such as whether 
the compound can block propagation of NF-κB signaling as discussed above 
would be the most direct way of assessing the potential of this hit for disrupting 
biological function. Similar assays have been performed by the Gilmore group 
(i.e. for 10190). Direct binding has been shown by SPR, but 2D NMR experiments 
would allow mapping of the binding site on NEMO. Such an approach could be 
useful to elucidate the structural determinants for binding, which would aid SAR 
studies to improve the potency of the compound. 
From these results and previous work in the lab155, the NEMO-IKKβ 
binding site can likely be targeted with small molecule inhibitors. One group 
reported a NEMO-IKKβ inhibitor, but did not provide evidence that the 
molecule actually targeted this interaction. It remains to be seen whether 
macrocycles can be used as well, but there exists a starting point for rational 
inhibitor design that has strong therapeutic potential. 
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Appendices 
Appendix I) Primers Used for Cloning 
Construct Use Direction Sequence 
9SG NEMO Mutation Forward TGGGTCTGGGTCTCAGGAGAGCCAGAGTCGC 
pET24b(+) Reverse GACCCAGACCCAGAGGCTTTCACAGAGGCCTTG 
L153R NEMO Mutation Forward CTCGGGGAGCGGCAGGAGAGC 
  pET24b(+) Reverse CAAGGACGTCACCTGGGC 
44-195 NEMO Cloning Forward TATACATATGCAGGGTGCACCGG 
  SUMOstar Reverse GTGCTCGAGATGCTGCTGCTG 
44-195 I71M Mutation Forward GTAATCAGATGCTGCGTGAAC 
 SUMOstar Reverse TCTGGCGAATCGCATCAC 
110-195 NEMO Cloning Forward TATACATATGGAAAAACTGGATCTGAAAC 
  SUMOstar Reverse GTGCTCGAGATGCTGCTGCTG 
ΔN NEMO Cloning Forward ATGGCCAAGTTCCAGGAG 
  Del 1-100 Reverse ATGTATATCTCCTTCTTAAAGTTAAAC 
ΔC NEMO Cloning Forward CACCACCACCACCACCACTG 
  Del 384-419 Reverse AGGTGGCTCCTCGGG 
E57K NEMO Mutation Forward CAGCGCGCCCTGGAGAAAAATCAAGAGCTCCGA 
  E57K Reverse TCGGAGCTCTTGATTTTTCTCCAGGGCGCGCTG 
L80P NEMO Mutation Forward GCCGAGGAGCTTCCGCATTTCCAAGCCA 
  L80P Reverse TGGCTTGGAAATGCGGAAGCTCCTCGGC 
D113N NEMO Mutation Forward GGGTCTGGAAAAACTGAATCTGAAACGTCAG 
  D113N Reverse CTGACGTTTCAGATTCAGTTTTTCCAGACCC 
R123W NEMO Mutation Forward AGCAGGCTCTGTGGGAGGTGGAGCA 
  R123W Reverse TGCTCCACCTCCCACAGAGCCTGCT 
IκBα Cloning Forward GAGAACCTGTACTTTCAGGGTAGCGGTATGTTCCAGGCGGCCGAG 
  pDEST-42 Reverse CTCTTGGACATGAAAGCCCACGCCTTATCATAACGTCAGACGCTGGCC 
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Appendix II) Protein Sequences of NEMO Constructs 
CLUSTAL W 2.0 multiple sequence alignment 
 
WT_NEMO        MNRHLWKSQLCEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRCLEENQE 60 
7xAla          MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60 
5xAla          MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRCLEENQE 60 
9SG            MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60 
E57K           MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEKNQE 60 
L80P           MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60 
D113N          MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60 
R123W          MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60 
L153R          MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60 
dC25           MNRHLWKSQLAEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRALEENQE 60 
dN100          ------------------------------------------------------------ 60 
44-195         --------------------------------------------QGAPETLQRCLEENQE 60 
44-195_I71M    --------------------------------------------QGAPETLQRCLEENQE 60 
44-111         --------------------------------------------QGAPETLQRCLEENQE 60 
                                                                            
 
WT_NEMO        LRDAIRQSNQILRERCEELLHFQASQREEKEFLMCKFQEARKLVERLGLEKLDLKRQKEQ 120 
7xAla          LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120 
5xAla          LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120 
9SG            LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120 
E57K           LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120 
L80P           LRDAIRQSNQILRERAEELPHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120 
D113N          LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLNLKRQKEQ 120 
R123W          LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120 
L153R          LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120 
dC25           LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120 
dN100          ---------------------------------------ARKLVERLGLEKLDLKRQKEQ 120 
44-195         LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120 
44-195_I71M    LRDAIRQSNQMLRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLEKLDLKRQKEQ 120 
44-111         LRDAIRQSNQILRERAEELLHFQASQREEKEFLMAKFQEARKLVERLGLE---------- 120 
                                                      ***********           
 
WT_NEMO        ALREVEHLKRCQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKECQALEGRARAASEQ 180 
7xAla          ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180 
5xAla          ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180 
9SG            ALREVEHLKRAQQQMAEDKASVKASGSGSGSGSQESQSRLEAATKEAQALEGRARAASEQ 180 
E57K           ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180 
L80P           ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180 
D113N          ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180 
R123W          ALWEVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180 
L153R          ALREVEHLKRAQQQMAEDKASVKAQVTSLLGERQESQSRLEAATKEAQALEGRARAASEQ 180 
dC25           ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180 
dN100          ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180 
44-195         ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180 
44-195_I71M    ALREVEHLKRAQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKEAQALEGRARAASEQ 180 
44-111         ------------------------------------------------------------ 180 
                                                                            
 
WT_NEMO        ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240 
7xAla          ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240 
5xAla          ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240 
9SG            ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240 
E57K           ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240 
L80P           ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240 
D113N          ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240 
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R123W          ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240 
L153R          ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240 
dC25           ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240 
dN100          ARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQE 240 
44-195         ARQLESEREALQQQH--------------------------------------------- 240 
44-195_I71M    ARQLESEREALQQQH--------------------------------------------- 240 
44-111         ------------------------------------------------------------ 240 
                                                                            
 
WT_NEMO        YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300 
7xAla          YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300 
5xAla          YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300 
9SG            YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300 
E57K           YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300 
L80P           YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300 
D113N          YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300 
R123W          YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300 
L153R          YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300 
dC25           YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300 
dN100          YDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPV 300 
44-195         ------------------------------------------------------------ 300 
44-195_I71M    ------------------------------------------------------------ 300 
44-111         ------------------------------------------------------------ 300 
                                                                            
 
WT_NEMO        LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASCQESARIEDMRKRH 360 
7xAla          LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360 
5xAla          LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASCQESARIEDMRKRH 360 
9SG            LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360 
E57K           LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360 
L80P           LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360 
D113N          LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360 
R123W          LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360 
L153R          LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360 
dC25           LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360 
dN100          LKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASAQESARIEDMRKRH 360 
44-195         ------------------------------------------------------------ 360 
44-195_I71M    ------------------------------------------------------------ 360 
44-111         ------------------------------------------------------------ 360 
                                                                            
 
WT_NEMO        VEVSQAPLPPAPAYLSSPLALPSQRRSPPEESSDFCCPKCQYQAPDMDTLQIHVMECIE 419 
7xAla          VEVSQAPLPPAPAYLSSPLALPSQRRSPPEESSDFCCPKCQYQAPDMDTLQIHVMECIE 419 
5xAla          VEVSQAPLPPAPAYLSSPLALPSQRRSPPEESSDFCCPKCQYQAPDMDTLQIHVMECIE 419 
9SG            VEVSQAPLPPAPAYLSSPLALPSQRRSPPEESSDFCCPKCQYQAPDMDTLQIHVMECIE 419 
E57K           VEVSQAPLPPAPAYLSSPLALPSQRRSPPEESSDFCCPKCQYQAPDMDTLQIHVMECIE 419 
L80P           VEVSQAPLPPAPAYLSSPLALPSQRRSPPEESSDFCCPKCQYQAPDMDTLQIHVMECIE 419 
D113N          VEVSQAPLPPAPAYLSSPLALPSQRRSPPEESSDFCCPKCQYQAPDMDTLQIHVMECIE 419 
R123W          VEVSQAPLPPAPAYLSSPLALPSQRRSPPEESSDFCCPKCQYQAPDMDTLQIHVMECIE 419 
L153R          VEVSQAPLPPAPAYLSSPLALPSQRRSPPEESSDFCCPKCQYQAPDMDTLQIHVMECIE 419 
dC25           VEVSQAPLPPAPAYLSSPLALPSQRRSPPEESSD------------------------- 419 
dN100          VEVSQAPLPPAPAYLSSPLALPSQRRSPPEESSDFCCPKCQYQAPDMDTLQIHVMECIE 419 
44-195         ----------------------------------------------------------- 419 
44-195_I71M    ----------------------------------------------------------- 419 
44-111         ----------------------------------------------------------- 419 
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Appendix III) Linear Di-Ubiquitin has no Effect on 5xAla-IKKβ Binding in 
Fluorescence Anisotropy 
 
  
 
 
 
 
 
Appendix Figure 1: Titration of 5xAla and 10-fold molar excess of M1-linked di-ubiquitin 
with constant 15 nM FITC-IKKβ has no significant effect on fluorescence anisotropy 
compared to 5xAla alone with FITC-IKKβ (n=3 each). 
 
Appendix Figure 2: Titration of M1-linked di-ubiquitin with constant 15 nM each 5xAla 
and FITC-IKKβ has no significant effect on fluorescence anisotropy (n=3 each). 
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Appendix IV) Redox CD and SDS-PAGE Experiments with 5xAla, 7xAla, 
and WT NEMO 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 3: Comparison of CD spectra for 5xAla oxidized, reduced, and 7xAla to 
compare effect of disulfide bond formation on secondary structure. 
 
 
 
Appendix Figure 4: SDS-PAGE of oxidized (0.5% H2O2) versus reduced (10 mM TCEP) 
5xAla protein. MW standards on left side are in units of kDa.
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Appendix V) NEMO MSA and IκBα MSA 
NEMO MSA: 
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IκBα MSA: 
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Appendix VI) Structures of NEMO-IKKβ Interaction Inhibitor Hits 
CMLD10190 
 
CMLD10487 
 
CMLD10557 
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Appendix VII) Flow synthesis of IκBα 13mer Peptide 
 
Appendix Figure 5: Synthesis schematic for base-activating amino acids, amide coupling 
to the resin or growing polypeptide chain on resin, and deprotecting the coupled amino acid by 
removing Fmoc (Simon 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 6: liquid chromatography result for WT IκBα(27-DDRHDSGLDSMKD-
39). Major peak shows purity of desired peptide. Inset: ESI-MS confirmation of peptide mass 
(daughter ion peaks at 497 [3+] and 745 [2+]). LC-MS performed on Waters qTOF Premier 
instrument using reverse phase column.
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